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ABSTRACT 
Background 
Most of the chemotherapeutic agents are characterized by a low therapeutic index and significant 
variability in therapeutic and toxic effects. 
For this reason, many efforts have been made to optimize the dosage and the administration of 
antiblastic drugs in order to obtain a maximal anti-tumor effect with acceptable levels of toxicity. 
The recent progresses in the cancer field introduced the concept of personalized therapy with the 
aim of tailoring medical treatment to the individual characteristics and needs of the single patient. 
The personalization of the dosage could be obtained with different approaches depending on the 
molecular peculiarities of each drug and on the genetic characteristics of the patients. 
In particular, in this thesis two different strategies were applied to optimize the chemotherapeutic 
treatment with fluoropirimidines, irinotecan, and sunitinib. 
The first strategy concerns a pharmacogenetics approach with the purpose of optimizing the 
fluoropirimidines and the irinotecan dosage based on genetic biomarkers predictive of severe 
toxicities.  
Regarding the fluoropyrimidines, the aim of the study was to introduce, in the clinical practice, a 
pre-treatment test for polymorphisms (SNPs) within the DPYD gene, able to predict the 
development of severe toxicities related to these drugs. 
Furthermore, a genotype-driven phase Ib study was designed to optimize the irinotecan dosage: 
according to UGT1A1*28 genotype, the dosage of irinotecan was chosen for metastatic colorectal 
cancer (mCRC) patients treated with FOLFIRI (fluorouracil in association with irinotecan) plus 
cetuximab regimen. 
In addition to this, another treatment tailoring strategy was applied, that is the therapeutic drug 
monitoring (TDM) of sunitinib. This approach aimed to monitor the plasmatic drug concentration 
in order to maintain it within the therapeutic window. 
  
Aims 
 Fluoropyrimidines project: a retrospective study was designed with the aim of validating 
the speciﬁcity of three DPYD SNPs in predicting the occurrence of severe toxicity events in a large 
set of oncological patients. The secondary aim of this study was to evaluate whether the 
additional testing of other investigational DPYD variants could increase the pharmacogenetic test 
sensitivity. 
 Irinotecan project: a phase 1b study was designed with three principal aims: 1) to define 
the Maximum Tolerated Dose (MTD), administered in the FOLFIRI regimen plus cetuximab in 
mCRC patients treated as first-line chemotherapy according to UGT1A1*28 genotype; 2) to 
evaluate the variability of irinotecan pharmacokinetics (PK), in combination with cetuximab, in 
patients with *1/*1 and *1/*28 genotype and the effect of the PK profile on toxicity and response 
rate; 3) to evaluate a possible effect of cetuximab on the PK of irinotecan. 
 Sunitinib project: the project aimed to develop and validate, according to the FDA 
guidelines, an analytical method for the quantification of sunitinib and its main metabolite, N-
desethyl sunitinib.  
 
Methods 
Each project of this thesis considered the application of different methodologies depending on the 
characteristic of the study. 
The methods for SNPs genotyping performed for the pharmacogenetic analysis were set up and 
developed using three different methodologies: Pyrosequencing, TaqMan® Allelic Discrimination 
Assay, and automated direct sequencing. 
Regarding the PK analyses and the TDM approach, two HPLC-MS/MS methods were applied.  
 
Results 
 Fluoropyrimidines project: data from this study demonstrated the clinical validity and 
specificity of the three DPYD SNPs genotyping test to prevent FL-related Grade ≥3 toxicity and to 
preserve treatment compliance, and support its introduction in the clinical practice. 
 Irinotecan project: at the moment, one patient was enrolled in this study. The PK of the 
enrolled patient was followed during the days 1-3 and the days 15-17. The main PK parameters of 
CPT-11 and its metabolites of the first patient enrolled were calculated trough a non-
compartmental analysis. 
 Sunitinib project: the method was setup and validated for the quantification of sunitinib 
and its main metabolite with a diagnostic perspective. The obtained method resulted easy, rapid 
and feasible for the clinical routine. 
 
 
Conclusions: 
The different approaches described in this PhD thesis shared the same final aim: to translate the 
research results in the clinical practice and, consequently, to ameliorate cancer patients’ life. In 
this perspective, the results of this thesis strongly encourage the introduction of the personalized 
therapy in the cancer field, where the optimization of the chemotherapy dosing is a compelling 
need. 
  
RIASSUNTO 
 
Introduzione 
La maggior parte degli agenti chemioterapici è caratterizzata da un basso indice terapeutico e da 
una elevata variabilità interpaziente sia nella risposta alla terapia che nello sviluppo di tossicità. 
Per questo motivo, la comunità scientifica ha investito molto nell’ottimizzazione del dosaggio dei 
chemioterapici con il fine ultimo di ottenerne la massima efficacia con accettabili livelli di tossicità. 
A tal proposito, i recenti progressi nel campo della medicina oncologica hanno portato 
all’introduzione del concetto di terapia personalizzata. Tale approccio propone di individuare il 
giusto trattamento per ogni singolo individuo, basandosi sulle sue caratteristiche e necessità. 
La personalizzazione della terapia chemioterapica può essere ottenuta tramite diversi approcci che 
dipendono sia dalle proprietà e caratteristiche molecolari del farmaco sia dalle peculiarità del 
singolo paziente. Questo lavoro di tesi si inserisce in questo filone di ricerca. In particolar modo, 
sono stati perseguiti due diversi approcci al fine di ottimizzare il trattamento con fluoropirimidine, 
irinotecano e sunitinib. 
Il primo approccio selezionato si basa sull’applicazione delle conoscenze ottenute dalla 
farmacogenetica, disciplina che ha lo scopo di identificare il ruolo di varianti genetiche, 
polimorfismi (SNP), nella risposta al trattamento in termini sia di efficacia che di rischio di sviluppo 
di tossicità. In tale fase, la potenzialità dell’utilizzo di SNP predittivi di tossicità grave è stata 
studiata per migliorare il dosaggio di fluoropirimidine ed irinotecano. 
Nel caso delle fluoropirimidine è stato disegnato uno studio retrospettico con lo scopo di definire 
la validità clinica di un test genetico pre-trattamento per alcuni SNP nel gene della DPYD al fine di 
valutare la capacità di questo test di predire lo sviluppo di tossicità gravi correlate a tale tipo di 
trattamento. Lo scopo di questo studio è di introdurre nella pratica clinica tale test al fine di 
migliorare la qualità di vita dei pazienti cui vengono somministrati questi farmaci. 
Un’ altra applicazione delle conoscenze della farmacogenetica analizzata in questa tesi è 
rappresentata dagli studi di fase Ib basati sul genotipo, strategia che è stata perseguita per 
ottimizzare il dosaggio dell’irinotecano. Più in dettaglio, la massima dose tollerata (MTD) di tale 
farmaco è stata valutata in base al polimorfismo UGT1A1*28 in pazienti con cancro metastatico al 
colon retto trattati con il regime FOLFIRI (5-fluorouracile associato con irinotecano) e cetuximab. 
Infine, un’altra strategia che riguarda la personalizzazione della terapia è rappresentata dal 
monitoraggio terapeutico del farmaco (TDM). Questo approccio è stato applicato per il sunitinib in 
modo da monitorarne le  concentrazioni plasmatiche e mantenerle all’interno di una finestra 
terapeutica. 
 
Scopo 
 Fluoropirimidine: è stato disegnato uno studio retrospettico con il fine ultimo di validare la 
specificità di tre SNP della DPYD nel predire l’insorgenza di tossicità grave in un’ampia 
casistica di pazienti oncologici. Scopo secondario di questo studio è stata quello di valutare se 
l’analisi di altre varianti del gene della DPYD possano migliorare la sensibilità del test 
farmacogenetico. 
 Irinotecano: è stato disegnato uno studio di fase 1b con i seguenti scopi: 1) definire la MTD, 
in base al genotipo UGT1A1*28, in pazienti metastatici con tumore al colon retto trattati con 
regime FOLFIRI associato a cetuximab; 2) valutare la variabilità dei parametri farmacocinetici 
dell’irinotecano, in combinazione con cetuximab, in pazienti con genotipo UGT1A1*1/*1 e 
UGT1A1*1/*28 e analizzare il possibile effetto del profilo farmacocinetico sulla tossicità e 
risposta; 3) stabilire se il cetuximab ha un effetto sulla farmacocinetica dell’irinotecano. 
 Sunitinib: lo scopo di questo progetto è lo sviluppo e la validazione, in base alle linee guida 
rilasciate dalla Food and Drug Administration (FDA), di un metodo bioanalitico per 
quantificare sia il sunitinib sia il suo metabolita attivo, N-desetil sunitinib. 
 
Materiali e metodi  
In base agli scopi e alle peculiarità dei singoli progetti di questa tesi sono state applicate specifiche  
metodiche. 
I metodi messi a punto ed utilizzati per le analisi farmacogenetiche  sono i seguenti: 
pyrosequencing, saggio Taqman per la discriminazione allelica e sequenziamento diretto 
automatizzato. 
Per quanto riguarda invece le analisi di farmacocinetica sono stati utilizzati due metodi in HPLC-
MS/MS, uno dei quali, il metodo del sunitinib, è stato messo a punto e validato secondo le linee 
guida FDA. 
 
 
 
Risultati  
 Fluoropirimidine: i dati ottenuti da questo studio hanno dimostrato la validità clinica e la 
specificità del test farmaco genetico pre-trattamento basato sulla DPYD per prevenire 
l’insorgenza di tossicità gravi di grado ≥3. Tali risultati incoraggiano l’introduzione di questo 
test nella pratica clinica. 
 Irinotecano: al momento una sola paziente è stata ritenuta eleggibile secondo i criteri dello 
studio. La farmacocinetica di CPT-11 e dei suoi principali metaboliti è stata descritta grazie 
a prelievi ripetuti durante la prima (giorni 1-3) e la seconda (giorni 15-17) 
somministrazione. Sono stati inoltre calcolati i principali parametri farmacocinetici di CPT-
11 e dei suoi metaboliti tramite l’applicazione di un’analisi non compartimentale. 
 Sunitinib: il metodo per la quantificazione del sunitinib e del suo metabolita attivo è stato 
messo a punto e validato. Considerata la facilità e la rapidità di tale analisi , si può 
auspicare che tale metodo possa essere facilmente applicabile nella pratica clinica. 
 
Conclusioni 
Gli approcci descritti in questa tesi condividono lo stesso scopo finale: traslare, cioè, i risultati della 
ricerca nella pratica clinica e, di conseguenza, migliorare la vita dei pazienti oncologici. In questa 
ottica, i risultati di questo lavoro incoraggiano fortemente l’introduzione di una terapia 
personalizzata nel campo oncologico, dove urge la necessità di nuovi approcci per ottimizzare il 
dosaggio dei farmaci. 
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1. INTRODUCTION 
 
1.1. CHEMOTHERAPY: FROM CYTOTOXIC AGENTS TO TARGET THERAPY 
 
Oncology has become one of the major focus area also for pharmaceutical and biotechnology 
companies. In 2009, about 16000 of the 40000 Phase I, II, III trials listed on ClinicalTrials.gov were 
related to cancer treatment (www.clinicaltrials.gov). Such large interest stems from the need to 
improve treatments for multiple types of cancer. Although giant steps have been made from the 
first attempts with mustard compound of Alfred Gilman and Louis Goodman 1, the scientific 
community has a long way to go in finding the right drugs to overwhelm this disease.  
The early history of oncology was characterized by the development of cytotoxic drugs. Because of 
their promising results, drugs such as methotrexate and 5-fluorouracil (5-FU) triggered enthusiasm 
among clinicians in the post-war period and, up to these days, they still remain a pillar in the 
therapy of malignant diseases 2,3. Even if more selective therapies have been developed (e.g. 
antibodies or molecular targeting agents), treatment schemes with some of these new drugs 
continue to be associated with classical cytotoxic agents 4. Moreover, cytotoxic agents are also 
used as a support to either surgery or radiotherapy. 
Even if nowadays the molecular targets of most of the drugs in clinical use have been clarified 5, 
cytotoxic chemotherapy drugs damage proliferating cells and therefore the non-specificity of 
cytotoxic agents is their major drawback. Potential damage of normal tissues means that a cure 
with these chemotherapeutic agents is not often achieved 6.  
Over the last 10–30 years, new molecularly targeted agents have been discovered and showed 
great promise in the treatment of some diseases, such as gastrointestinal stromal tumors and 
chronic myeloid leukemia 7. This new era of cancer therapy has emerged leading to treatment in 
association with cytotoxic agents for an improved effect and, for several cancers, even moving 
away from nonspecific chemotherapy to chronic oral treatment with targeted molecular therapies 
7.These treatments are characterized by unique mechanisms of action and are highly specific for 
single or multiple key cellular biological pathways implicated in the cancer process. 
These therapeutic agents are now revolutionizing cancer treatment by transforming a few 
previously deadly malignancies into chronically manageable conditions. 
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However, these new molecules present new dares represented, for example, by their oral 
administration 8. In fact, whilst on the one hand the oral administration is certainly associated with 
a better patient’s quality of life and compliance, on the other hand it generates a complex step in 
their pharmacokinetics (PK), especially in the phase of drug absorption 8. In addition, poor 
tolerability and therapeutic failure are unfortunately common, and relapse is a nearly inevitable 
consequence of treatment interruption 9,10. Moreover, this shift to targeted agents is creating new 
paradigms in cancer care, with drug adherence becoming a more critical issue with increased 
numbers of oral chemotherapeutics 11. 
Briefly analyzing the history of anticancer drugs discovery, many efforts have been made in order 
to obtain more efficient, compelling, and competitive molecules. However, both traditional 
cytotoxic drugs and new target therapy show, as aforementioned a complex PK profile, associated 
with an intrinsic difficulty in optimizing their dosage also due to the huge inter-patient variability. 
As cancer treatment has become increasingly complex, the challenge for clinicians and scientists 
now is to manipulate treatments to maximize benefit and minimize harm for the individual 
patient. For this reason, huge efforts have to be done in order to refine the treatments and to 
personalize the therapy. 
 
1.2. CHEMOTHERAPY DOSING: THE CURRENT PRACTICE 
 
Most of the chemotherapeutic agents are characterized by a low therapeutic index and significant 
variability in therapeutic and toxic effects. 
For this reason, many efforts have been made to optimize the dosage and the administration of 
antiblastic drugs in order to obtain a maximal anti-tumor effect with acceptable levels of toxicity. 
In order to develop robust dose strategies, it is necessary to know tools able to predict clinical 
effects of a drug by direct or indirect measurements.  
In the last 50 years, optimal chemotherapy dosing, established through clinical trials, has been 
generally calculated using a patient's body surface area (BSA), which takes into account body 
weight and height. The first scientific findings that validated this kind of practice was obtained in 
1883 when it was discovered that small animals utilized relatively more oxygen and produced 
relatively more heat than larger animals. These findings could be explained because smaller 
animals have relatively larger surface areas per unit mass, when compared with larger animals 12. 
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These observations were confirmed and applied to humans, giving rise to the practice of 
expressing human basal metabolism in terms of BSA rather than body weight (BW).  
Prompted by publications by Pinkel 13 and Freireich and colleagues 14, the scientific community 
allowed the incorporation of the BSA formula into allometric studies with animals. In the 1950s, 
BSA-based dosing was introduced to extrapolate human chemotherapy doses from animals 
studies in order to conduct phase I studies and to determine patients’ dosing. After that, many 
pediatricians started using BSA for anti-cancer drug dosing, and medical oncologists followed them 
13. 
By correcting for BSA, it was generally assumed that cancer patients would receive a dose of a 
particular cytotoxic drug associated with an acceptable degree of toxicities without reducing the 
agent’s therapeutic effect. 
The customary approach in clinical practice is to calculate BSA using Du Bois and Du Bois’15 height-
weight formula: Area (cm2) = BW (kg) 0.425 x height (cm) 0.725 x 71.84. 
More recently, doubts have arisen to the real effects of BSA on the pharmacokinetics of antitumor 
agents. 
In fact, except for the inherent inaccuracies inherent in methods for BSA calculation (Du Bois 
estimated the maximal error as 5%), there is a substantial risk of arithmetical errors: errors in the 
use of dosage equations have been found indeed to account for more than 15% of medication 
prescribing errors. Moreover, it is to be noticed that in BSA dosing there are two calculation steps 
that may introduce errors. First, the patient’s BSA has to be calculated, that is dependent on the 
accuracy of weight and height measurements, and then the dose for the obtained BSA is to be 
determined. The first calculation is often avoided, as it is common to use nomograms to estimate 
the BSA. This kind of models, usually contain three parallel scales graduated for different variables 
(in this case height, weight, and BSA) so that when a straight line connects values of any two, the 
related value may be read directly from the third at the point intersected by the line. However, the 
reliability of these nomograms also tends to differ 16.  
Moreover, in clinical practice, the calculated anticancer drug doses are also frequently 
manipulated by rounding to the nearest convenient dose 17. Finally, for many cancer patients, 
body size will probably vary during the course of the disease, due to conditions such as cachexia 
and anorexia. Despite this, BSA is not always re-calculated between treatment cycles, although 
there are recommendations that BSA should be re-calculated when BW has changed by more than 
5-10% 18. 
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Furthermore, given the complexity of drug clearance, drug-related toxicity and anti-tumor activity, 
it is unlikely that only one factor such as BSA can be used to adjust the dosage. A lot of other 
factors can indeed influence the PK and PD of anti-tumor drug such as the organ functions, the 
presence of SNPs that can affect the enzymatic activity, the gender, the age, and the co-
morbidities (Figure 1).The resulting marked interpatient variability caused by all this factors is not 
considered by the BSA-dosing approach (Gurney 2001). 
In particular, the inaccuracy of this system is clear if we bearing in mind the cancer drug 
elimination. Typically, there is a 4-10 fold inter-patient variation in cytotoxic drug clearance, due to 
different activity of drug elimination processes related to genetic and environmental factors 
(Gurney, 1996). 
BSA-dosing does not account for these variation so, one possible consequence, is unexpected 
underdosing which leads to reduce effectiveness of chemotherapy 19. 
In conclusion, in order to overcome the BSA approach, the recent progresses in the cancer field 
introduced the concept of personalized therapy with the aim of tailoring medical treatment to the 
individual characteristics and needs of the single patient.  
 
 
Figure 1 Schematic summary of the main factors that can influence the systemic exposure to a drug. 
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1.3. CHEMOTHERAPY DOSING: THE INNOVATION OF THE PERSONALIZED 
THERAPY 
It is far more important to know what person the 
disease has than what disease the person has. – 
Hippocrates  
 
The clinical practice typical of the 20th century, based on the model “one dose fits all”, have 
shown, over the years, huge limitations that strongly compromised drug’s efficacy and 
dramatically underestimated the potentiality of several treatments. 
In fact, every day millions of people take drugs that will not help them: numerous studies 
demonstrate that the obtained response rates can deeply vary among different therapeutic 
classes. For instance, the 75% of patients treated with anticancer drugs seems to have no benefits 
from the treatment and unfortunately for most of them it is caused by an unsuitable drug dosage 
(Figure 2). In addition, 2.2 millions adverse drug reactions occur each year in the US, including 
more than 100000 deaths. 
 
 
Figure 2 Average percentage of the patient population for which a particular drug in a class is ineffective. From Spear 
et al., 2001 Clinical application of pharmacogenetics Trends in Molecular Medicine.  
 
These data fuelled the discussion in the scientific community and dramatically changed the 
approach for the drug administration, moving from “one dose fits all” model and fostering the 
introduction of the “personalized medicine” model (Figure 3).  
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Figure 3 Representation of the one-dose-fits-all approach versus personalized medicine. The left panel shows a 
situation in which everyone gets the same dose of a drug. The right panel shows a personalized medicine approach in 
which the dose of the drug is selected based upon the specific characteristics of the patients. (Paving the Way for 
Personalized Medicine, 2013). 
 
In general, the term “personalized medicine” is often described as providing “the right patient 
with the right drug at the right dose at the right time.” More broadly, “personalized medicine” 
may be thought of as the tailoring of medical treatment to the individual characteristics, needs 
and preferences of a patient during all stages of care, including prevention, diagnosis, treatment 
and follow-up.  
One of the earliest example of personalized therapy in the clinical practice could be found at the 
beginning of the 1900, when Reuben Ottenberg, for the first time, reported a blood compatibility 
test for transfusion using blood typing techniques and cross-matching between donors and 
patients to prevent hemolytic transfusion reactions. 
Another famous example is the discovery, in 1956, of the genetic bases for the selective toxicity of 
fava beans (“favism”) and the antimalarial drug primaquine that could be led back to a deficiency 
in the metabolic enzyme, glucose-6-phosphate dehydrogenase (G6PD).  
A more recent example is the finding that cytochrome P450 2D6, a polymorphic metabolizing 
enzyme, is identified as the culprit for causing some patients to experience an “overdose” or 
exaggeration of the duration and intensity of the effects of debrisoquine, a drug used for treating 
hypertension 20. 
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From here, major advancements in science and technology have allowed healthcare decisions to 
move on the “trial-and-error” approach and to set in motion the transformation of personalized 
medicine from an idea to a practice. 
Midway through the century, observations of individual differences in response to drugs gave rise 
to a body of research focused on identifying key enzymes that play a role in variation in drug 
handling and response and that served as the foundation for pharmacogenetics (PGx). More 
recently, rapid developments in genomics, together with advances in a number of other areas, 
such as computational biology, medical imaging, and regenerative medicine, are creating the 
possibility for scientists to develop tools to personalize diagnosis and treatment. 
 
Several definitions of personalized therapy have been written with the purpose of describing such 
a complex and multidisciplinary field. The National Cancer Institute (NCI) has defined personalized 
medicine “[…] as a form of medicine that uses information about a person’s genes, proteins and 
environment to prevent, diagnose and treat disease” 21. Another definition of personalized 
medicine has been described by the US President's Council of Advisors on Science and Technology 
as referring to "[…] the tailoring of medical treatment to the individual characteristics of each 
patient; to classify individuals into subpopulations that differ in their susceptibility to a particular 
disease or their response to a specific treatment so that preventive or therapeutic interventions can 
then be concentrated on those who will benefit, sparing expense and side effects for those who will 
not.” 22. 
As these definitions suggested, this issue is extremely wide and different points of view can 
highlight several facets of the same phenomenon. 
In fact, several terms, including “precision medicine,” “stratified medicine,” “targeted medicine,” 
and “pharmacogenomics,” are used interchangeably and each of them better describe one 
particular aspect of the personalized medicine. The National Academy of Sciences (NAS) has 
defined “Precision medicine” as “the use of genomic, epigenomic, exposure and other data to 
define individual patterns of disease, potentially leading to better individual treatment.” 
“Stratification” refers to the division of patients with a particular disease into subgroups, based on 
a characteristic of some sort, who respond more frequently to a particular drug or, alternatively, 
are at decreased risk of side effects in response to a certain treatment. Stratification can be 
thought of as a core element of personalized medicine. PGx – the study of variations of DNA and 
8 
 
RNA characteristics as related to drug response – is a critically important area of personalized 
medicine where significant progresses have recently been made.  
 
Oncology is one of the branches of medicine that strongly need the adoption of the personalized 
medicine due to the complexity of the disease and to its lethality. In 2016 about 1,685,210 new 
cancer cases are expected to be diagnosed in US and about 595,690 Americans are expected to die 
of cancer 23. In January 2015, the American President Barack Obama launched a national Precision 
Medicine Initiative, founding it with 215 million dollars, aiming at promoting the introduction of 
personalized medicine concepts into the clinical practice, with a special focus on oncology and 
genetics.  
In fact, cancer has been tackled for decades with cocktails of chemotherapeutic drugs that 
indiscriminately hit populations of rapidly growing cells. However, this strategy is effective only up 
to a point. A large part of patients’ treatment is indeed not only toxic but also ineffective: it is 
estimated that in only 25% of patients a response is achieved 24. 
The new hurdle, in this century, is to find the key genetic mutations that drive specifically cancer 
growth in order to optimize the use of the therapies already used in the clinical practice and to 
develop new personalized drugs (Figure 4). 
 
 
Figure 4 Using the genetic changes in a patient’s tumor to determine their treatment is known as precision medicine. 
(www.cancergov.com) 
 
Genomic and proteomic technologies have made possible to subclassify different kinds of solid 
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tumors according to differences in gene sequence and/or expression patterns.   
The development of imatinib against chronic myelocytic leukemia (CML) is the greatest success in 
the personalized cancer field so far 25. In CML, a single molecular event, the 9:22 translocation, 
leads to expression of the Abelson proto-oncogene kinase ABL fused to BCR (breakpoint cluster 
region), yielding a constitutively activated protein kinase, BCR-ABL, and then the malignant 
phenotype. Imatinib attacks the unique and specific protein obtained with the BCR-ABL 
translocation, inducing clinical and molecular remissions in >90% of CML patients in the chronic 
phase of disease 26. 
Razelle Kurzrock, (the director of the Center for Personalized Cancer Therapy at the University of 
California, San Diego) has said about this discovery: “In the 1980s, unless you got a bone-marrow 
transplant, the disease was an absolute death sentence in four to six years. Today, average survival 
is more than 20 years. And because the average age at diagnosis is 60, it’s almost a normal life 
expectancy.” 
However, imatinib success has not been easy to duplicate and, despite the extraordinary advances 
that have been made till now, we have a long way to go in understanding why different individuals 
respond differently to treatment.  
In fact, every tumor has a unique set of genetic mutations and this heterogeneity, which is found 
even among cells in a single tumor, means that matching a patient with the appropriate therapy 
can be a complex proposition. 
 
1.4. INNOVATIVE APPROACHES FOR THE PERSONALIZATION OF THE 
CHEMOTHERAPY DOSING 
 
In this thesis, different innovative approaches were studied in order to obtain a personalized 
cancer therapy.  
1. The first strategy concerns a PGx approach with the purpose to validate a personalized 
drug dosing based on specific patient genetic polymorphisms (SNPs) for two drugs. 
i. The SNPs in DPYD will be validated in a retrospective large group of patients 
as predictive markers of severe fluoropyrimidines (FLs) related toxicity, to 
support current guidelines suggesting a dose reduction in variant alleles carriers. 
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ii. The analysis of UGT1A1*28 will be adopted to stratify patients in a genotype-
driven phase Ib study to define, according to patient’ genotype, the correct 
irinotecan (CPT11) dose to minimize the risk of treatment related toxicity. 
The study described in this thesis is a genotype-driven phase Ib study: 
metastatic colorectal cancer (mCRC) patients treated with FOLFIRI regimen (5-
FU in association with CPT-11) plus cetuximab will be stratified in subgroups 
associated with a personalized dosage according to UGT1A1*28 genotype. 
 
2. The second strategy concerns the therapeutic drug monitoring (TDM) approach.  
i. The TDM of sunitinib will be used for dose optimization in solid tumor patients. 
Specifically, drug plasmatic concentration will be supervised during the treatment in 
order to optimize the clinical outcome and minimize side effects . 
 
1.4.1. PHARMACOGENETICS STRATEGY 
 
PGx, the study of variations of DNA and RNA characteristics as related to drug response, is one of 
the most interesting areas of personalized medicine today. The field arises from the convergence 
of advances in pharmacology (the science of drugs) and genomics (the study of genes and their 
functions) and seeks to understand how differences in genes and their expression affect the 
body’s response to medications. More specifically, PGx uses genetic information (such as DNA 
sequence, gene expression, and copy number variations) to explain interindividual differences in 
pharmacokinetics (PK)- and pharmacodynamics (PD) parameters, identifying responders and non-
responders, and predicting the efficacy and/or toxicity of a drug.  
Physiological variations within the human genome have a frequency of about 1 every 500±1000 
bases. These affect the interindividual variability that is observed also in drug response and are the 
object of PGx. Although there are a number of different types of polymorphic markers, over the 
last years, the scientific community has focused on SNPs, and on the potentiality they offer in 
determining the individual drug response profile. Conventionally, a SNP is defined as a nucleotide 
variation having an allele frequency greater than 1%, whereas, when the frequency is lower, the 
genetic variation is indicated as mutation or as rare variant. 
The 1.42 million known SNPs are found at a density of one SNP per 1.91 kilobases. This means that 
more than 90% of any stretches of 20 kilobases long sequence will contain one or more SNPs. The 
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density is even higher in gene containing regions 27. In 2001, the International SNP Map Working 
Group estimated that they have identified 60,000 SNPs within genes (‘coding’ SNPs), or one coding 
SNP per 1.08 kilobases of gene sequence. Moreover, they have evaluated that 93% of genes 
contain SNPs, and 98% are located within 5 kilobases of a SNP. For the first time, nearly every 
human gene and genomic region was marked by a sequence variation 27. After that, the National 
Center for Biotechnology Information (NCBI) established in 1998 the Single Nucleotide 
Polymorphism Database (dbSNP) (http://www.ncbi.nlm.nih.gov/SNP) in collaboration with the 
National Human Genome Research Institute (NHGRI). Since its inception in September 1998, 
dbSNP has served as a central, public repository for genetic variation. 
The last update of the dbSNP website was in November 2015 and referred to 316,710,573 
registered SNPs, 150,482,731 of them were found in Homo Sapiens 
(http://www.ncbi.nlm.nih.gov/SNP/snp_summary.cgi). These projects (beyond dbSNP we can 
enumerate also 1Kgenome project, UCSC, ensemble among the most important ones) could lead 
to an innovative way to conceive drug administration. Using SNPs as predictive and prognostic 
biomarkers, it may possible to tailor drug prescription and drug dosage, with a great potential 
clinical impact in case of drugs characterized by a low therapeutic index such as those 
administered in oncology 28–30. 
Furthermore, the introduction of predictive and prognostic biomarkers in the clinical practice, 
enables to enhance quality of life for patients and to decrease overall health care costs 31.  
On one hand, predictive PGx biomarkers are usually SNPs located in genes that are direct targets 
of drugs, molecules involved in DNA repair, or in drug metabolism, and are specifically associated 
with the response to a therapy, that can be defined as the probability to have a response or as the 
risk to develop toxicities. Prognostic PGx biomarkers, on the other hand, predict the natural course 
of a specific disease and patients’ outcome 32. Examples of prognostic oncology markers are SNPs 
located in proteins involved in tumor cell proliferation, dedifferentiation, angiogenesis, invasion or 
metastasis. 
Genetic testing represents one method to define these biomarkers. Typically, genetic testing will 
fall into one of three categories: 
 
1. diagnostics: the evaluation of genetic sequences to confirm the presence of disease (often 
used for oncology monitoring); 
2. prognostics: the evaluation of genetic mutations to determine susceptibility to a future 
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condition (for example, cystic fibrosis genotype testing); 
3. pharmacogenomics: the evaluation of genetic variations to identify patients likely to 
respond to a particular therapy (for example the mutations within RAS gene in colorectal 
cancer patients).  
Although there has been substantial hype over the potential of genetic testing to improve 
medication use, the American Food and Drug Administration (FDA) has recommend only few of 
them for therapeutic optimization and this provides valuable lessons as to the barriers to 
implementing “individualized” medicine. Several important PGx tests have been available from 
“Clinical Laboratory Improvement Amendments-approved laboratories” for many years, and yet 
their adoption in the clinic remains uncommon. Although there is a scarcity of evidence of clinical 
utility and cost-effectiveness with respect to many of the PGx tests, the evidence for a few of them 
is quite strong. 
Surely, one barrier to clinical implementation of PGx is the lack of freely available, peer-reviewed, 
updatable, and detailed information about PGx biomarkers to be introduced into drug guidelines.  
For this reason, several international and national consortiums dedicated to PGx has risen and 
published drug dosing guidelines with indications and recommendations about drug-related 
genetic tests and their integration in the clinical routine. 
Regarding the oncologic field, the main international consortiums that participated to the 
implementation of the dosing guidelines with PGx information are the Clinical Pharmacogenetics 
Implementation Consortium (CPIC) and the Dutch Pharmacogenetics Working Group of the Royal 
Dutch Association for the Advancement of Pharmacy (DPWG) that have published drug-speciﬁc 
guidelines based on patient genotype. 
CPIC was formed in 2011 as a shared project between PharmGKB and the Pharmacogenomics 
Research Network, while The Royal Dutch Pharmacist’s Association (KNMP) established the DPWG 
in 2005. The DPWG is formed by a multidisciplinary team that includes clinical pharmacists, 
physicians, clinical pharmacologists, clinical chemists, epidemiologists, and toxicologists. 
These consortiums provide guidelines that enable the translation of genetic laboratory test results 
into actionable prescribing decisions for specific drugs. These guidelines, indeed, were designed to 
help clinicians in understanding how available genetic test results should be used to optimize drug 
therapy. In the future, it is plausible that clinical high-throughput and pre-emptive genotyping 
could become more widespread.  
Each guideline adheres to a standard format. Genes, drugs, and dosing recommendations are 
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categorized in each document. Specifically, each guideline contains an introduction summarizing 
the drug dosing that is addressed as a result of specific genotyping tests, a focused literature 
review, gene based information, and drug-based information. Table 1 provides an example of key 
data needed by clinicians: the assignment of likely phenotypes based on genotypes. Each guideline 
also includes dosing recommendations for drugs based on genotype/phenotype, along with a 
strength for each dosing recommendation, based on detailed levels of evidence graded as to its 
quality. 
 
 
Likely phenotype Genotipe Examples of diplotypes 
Homozygous wild type or normal, 
high activity (~ % of patients) 
An individual carrying two or 
more functional (*1) alleles 
*1/*1 
Heterozygous or intermediate 
activity (~ % of patients) 
An individual carrying one 
functional allele (*1) plus one 
non-functional allele (*2, *_, *_) 
*1/*2, *1/*2A, *1/*28 
Homozygous variant or deficient 
activity (~ % of patients) 
An individual carrying two non-
functional alleles (*2, *_, *_) 
*2/*2, *2A/*2A, *28/*28 
Table 1 Example of assignment of likely phenotype based on genotype. 
 
The PGx guidelines available nowadays in the oncologic field regard 5-FU and its oral prodrug 
capecitabine (CAPE), CPT-11, mercaptopurine, tegafur, thioguanine, and tamoxifen  (Table 2). The 
most updated information related to PGx dosing guidelines can be found on PharmGKB- The 
Pharmacogenomics Knowledgebase (www.pharmgkb.org) 
 
 
14 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
1.4.1.1. PGx STRATEGY: THE CASE OF FLUOROPYRIMIDINE 
 
FLs are antimetabolite drugs able both to inhibit biosynthetic processes and to be incorporated 
into macromolecules, such as DNA and RNA, hindering their normal function. 
In particular, FLs are analogues of the uracil base and they cause the inhibition of the nucleotide 
synthetic enzyme thymidylate synthase (TS), responsible of the de novo syntesis of thymidylate, 
which is necessary for DNA replication and repair 33. 
FLs include 5-FU, CAPE, and tegafur. CAPE is an oral FL that is absorbed unchanged through the 
gastrointestinal wall and is converted to 5'-deoxy-5-fluorouridine (5’-dFUR) in the liver by the 
sequential action of carboxylesterase and cytidine deaminase. Tegafur is another prodrug 
administered per os that is enzymatically activated in the liver to 5‘-hydroxytegafur and 
subsequently to 5-FU (Figure 5). 
 
Drug Consortium Gene Last update 
capecitabine CPIC DPYD 18/09/2015 
 DPWG DPYD 10/08/2011 
5-fluorouracil CPIC DPYD 18/09/2015 
 DPWG DPYD 10/08/2011 
irinotecan PRO UGT 03/06/2015 
 DPWG UGT 10/08/2011 
mercaptopurine CPIC TPMT 18/09/2015 
 DPWG TPMT 10/08/2011 
tamoxifen DPWG CYP2D6 10/08/2011 
tegafur CPIC DPYD 18/09/2015 
 DPWG DPYD 10/08/2011 
thioguanine CPIC TPMT 18/09/2015 
 DPWG TPMT 10/08/2011 
Table 2 List of the main anticancer drugs with PGx dosing guidelines (PharmGKB).  
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        A                 B            C            D  
Figure 5 Chemical structures of uracil (A), 5-fluorouracil (B), capecitabine (C), and tegafur (D). 
 
Regarding the mechanism of action of 5-FU, it is an analogue of uracil with a fluorine atom at the 
C-5 position in place of hydrogen. For this reason, it can rapidly enter the cells using the same 
facilitated transport mechanism of uracil 34. 5-FU is converted intracellularly into several active 
metabolites such as fluorodeoxyuridine monophosphate (FdUMP), fluorodeoxyuridine 
triphosphate (FdUTP), and fluorouridine triphosphate (FUTP), which lead to RNA synthesis 
disruption and the inhibition of the TS (Figure 6). 
In fact, the 5-FU metabolite FdUMP binds to the nucleotide-binding site of TS, forming a stable 
ternary complex with the enzyme and CH2THF, thereby blocking binding of the normal substrate 
dUMP and inhibiting dTMP synthesis 35. 
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Figure 6 Metabolic pathway of FLs. Modified from Wilson, et al., 2014 Standing the test of time: targeting thymidylate 
biosynthesis in cancer therapy Nat. Rev. Clin. Oncol. 
 
Nowadays, these drugs are widely used in the treatment of a range of cancers, including 
colorectal-, breast-, head and neck-, and stomach cancer. 
However, despite the acknowledged efficacy of these drugs in the treatment of different solid 
tumors, FL treatment remains challenging as a result of a considerable inter-patient variability in 
terms of efﬁcacy and toxicity. 
The PGx research, aimed at deﬁning predictive markers of FL response, mainly focused on the 
dihydropyrimidine dehydrogenase (DPD), encoded by the gene DPYD, which is the ﬁrst and rate-
limiting enzyme of FL catabolic pathway 36. 
DPD deficiency occurs in 4–5% of the population and results in decreased inactivation of 5-FU. This 
can lead to an increase in active metabolites of 5-FU, which is associated with a higher risk of 
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severe and even fatal toxicity 37. Toxicity could be limited by exposing DPD-deficient patients to a 
decreased dose of FL, and by keeping plasma levels of 5-FU and its metabolites at therapeutic 
levels. 
Up to date, 167 SNPs altering the DPD aminoacidic sequence have been identified and many 
clinical studies have investigated their association with FL-related severe toxicities. 
SNPs can appear in heterozygous form (one SNP on one allele), homozygous form (two identical 
SNPs on two alleles) or double heterozygous form (two different SNPs on either one or two alleles, 
the latter is also called compound heterozygous). Two SNPs on two alleles lead to a larger 
decrease in DPD enzyme activity, compared with the heterozygous form. 
 
Among the most studied DPYD SNPs, DPYD-rs3918290 (DPYD*2A, DPYD IVS1411G>A or 
c.190511G>A) is surely one of the most well-known. 
It was first described by Vreken in a case report of two unrelated patients 38 and McLeod named it 
DPYD*2A in an article in which the nomenclature for a series of DPYD SNPs was defined 39. Variant 
allele frequencies have been reported to vary between ~0.1 and 1.0% in African-American and 
Caucasian populations, respectively 40. DPYD-rs3918290 is located at the intron boundary of exon 
14 that results in a splicing defect, leading to the skipping of the entire exon. The mature mRNA 
lacks a 165bp segment and the DPD mutant protein shows a very little residual activity. This was 
recently confirmed in a study by Offer et al. that analyzed in mammalian cells in the expression of 
several DPYD homozygous variants. The enzymatic activity of the protein codified by the gene with 
DPYD-rs3918290 was completely absent 41. This indicates that in heterozygous carriers, who have 
one dysfunctional - and one functional allele, ~50% of the normal DPD enzyme activity is 
mantained. 
Several papers 42–46 have confirmed the importance of this SNP both for its clinical impact and for 
its deleterious effect on the mature protein.  
Another well studied SNP is DPYD-rs67376798 (DPYD 2846 A>T), that has also been reported as a 
plausible candidate for predictive pharmacogenetic test.  
The variant allele of this SNP was first described by van Kuilenburg in 2000 47. DPYD-rs67376798 
results in a Asp949Val amino acid change localized near an iron-sulfur motif and leads to a 
structural change in the DPD that interferes with cofactor binding or electron transport 48. 
Reported variant allele frequencies vary from 0.1 to 1.1% in African-Americans and Caucasians, 
respectively 40. In vitro data show that homozygous expression of the DPYD-rs67376798 variant 
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allele results in an activity of 59% compared with wild-type (p = 0.0031) 41. Although the enzyme 
activity of DPYD-rs67376798 is significantly impaired, it is not comparable to the extent observed 
for DPYD-rs3918290, where homozygous expression resulted in a completely nonfunctional 
enzyme 49. This finding suggests that a heterozygous carrier would have around 25% reduction in 
DPD activity. 
The group of Morel 50 has found strong associations with both DPYD-rs3918290 and DPYD-
rs67376798 and severe 5-FU toxicity in a cohort of 487 patients receiving FL-based therapy. The 
same SNPs reported in the study of Morel were also associated with toxicity due to CAPE 
treatment at high significance levels 42. 
Terrazzino and his colleagues 51 in their meta-analysis further strengthened these associations. 
They presented pooled data from PGx studies and investigated the association between both 
DPYD-rs3918290 and DPYD-rs67376798 and the risk of grade more or equal than 3 toxicity 
following FL treatment. Their results are consistent with the evidence of an increased risk of 
overall severe toxicity. 
Moreover, in the largest study published to date (2886 stage III colon cancer patients), statistically 
significant associations were found between DPYD-rs3918290, DPYD-rs67376798 and increased 
incidence of grade 3 or greater 5FU-adverse reaction in patients treated with adjuvant 5-FU-based 
combination chemotherapy 45. 
 
Recent studies analyzed also DPYD-rs55886062 (DPYD*13 or DPYD 1679 T>G) as a candidate for 
predicting FL-toxicites. 
DPYD-rs55886062 was first described by Collie-Duguid et al. as ‘T1679G’ 52. This SNP causes 
Ile560Ser amino acid change in a flavine mononucleotide binding domain and the allele frequency 
was found to vary from 0.07 to 0.1% in Caucasians 40. 
The precise functional consequences of the DPYD-rs55886062 variant have not yet been 
unraveled, but are thought to be related to destabilization of a sensitive region of the protein 48. 
This hypothesis is reinforced by the observation that the heterozygous form of this SNP has been 
found only in patients with decreased enzyme activity 53. From the aforementioned study of Offer, 
it was demonstrated that the homozygous expression of the variant allele of this SNP resulted in a 
75% reduction of DPD enzyme activity compared with the wild-type 49, suggesting that this variant 
inactivates almost completely the protein. 
Patients with allele variants of DPYD-rs55886062 showed severe toxic side effects in several 
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studies 43,46,52. Moreover, Morel et al. described a heterozygous patient that experienced severe 
grade 4 toxicity. After a 6-week treatment interruption, 5-FU was safely reintroduced with 
individual PK adjustment, based on 5-FU plasma levels 50. 
 
This huge amount of information about the clinical impact of these SNPs fueled the discussion in 
the scientiﬁc community and gave rise to the publication of PGx FL dosing guidelines. In particular, 
the Clinical Pharmacogenetics Implementation Consortium (CPIC) and the Dutch 
Pharmacogenetics Working Group of the Royal Dutch Association for the Advancement of 
Pharmacy (DPWG) have published FL-speciﬁc guidelines with indications and recommendations 
about drug-related genetic tests and their integration in the clinical routine 54,55. Nowadays, 
personalization of the FL treatment can be performed with the pre-therapeutic test of three 
aforementioned genetic variants: DPYD-rs3918290, DPYD-rs55886062, and DPYD-rs67376798.  
In the CPIC guidelines patients heterozygous for at least one of these three SNPs are considered to 
have intermediate or partial DPD enzyme activity and a reduction of at least 50% of the initial dose 
for these patients is recommended. 
In addition, also the DPWG provides evidence-based guidelines and recommendations about dose 
adjustments to apply in DPYD variant allele carriers. Regarding this, the Dutch group recently 
updated 40 their online guidelines for FLs dose adjustments accordingly with the “gene activity 
score”. This method is based on the principle that variant alleles can differ in the extent to which 
they influence enzyme activity. Consequently, following the calculated gene activity scores for 
DPYD, an individualized dose recommendation for FLs can be given, as is shown in Table 3. 
 
 
 
Gene activity score % of standard dose 
0 Alternative drug 
0.5 25 
1 50 
1.5 75 
2 100 
Table 3 Initial dose recommendation for DPYD gene activity score. 
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After initial reduction, dosages can be further titrated based on clinical tolerance. Dose reductions 
are 75, 50 or 25% for gene activity scores of 0.5, 1, and 1.5, respectively. The gene activity score 
varies from 0 (no DPD activity) to 2 (normal DPD activity). 
Clues that other DPYD SNPs (e.g. DPYD-rs2297595, DPYD-rs1801160, DPYD-rs1801158, DPYD-
rs1801159, and DPYD-rs17376848) could have a role in the development of FL-related toxicities 
came from international guidelines 55 and looking at the most recent literature 43,46,56. These SNPs 
have been previously observed in patients with low DPD enzymatic activity 41, however there is no 
final proofs that promote them as possible predictive biomarker of FL-related toxicity.  
 
1.4.1.2. PGx STRATEGY: THE CASE OF IRINOTECAN 
 
CPT-11 (7-ethyl-10-[4(-1-piperidino)-1-piperidino] carbonyloxy camptothecin) is a semisynthetic 
derivative of the natural alkaloid camptothecin, an extract from the Chinese tree Camptotheca 
acuminate 5.  
It was introduced into the clinics in the late 1980s and it received accelerated approval by FDA in 
1996 and the full approval in 1998 
(http://www.accessdata.fda.gov/drugsatfda_docs/appletter/1998/20571s8ltr.pdf). Nowadays it is 
one of the most active drugs in the ﬁrst- and second-line treatment of this malignancy 57,58.  
Regarding the mechanism of action, in the liver CPT-11 is enzymatically converted by 
carboxylesterase to its most active cytotoxic metabolite, 7-ethyl-10hydroxy-camptothecin (SN-38) 
(Figure 7), which establishes an equilibrium between the pharmacologically active closed lactone 
ring and the inactive open ring hydroxy acid form by reversible pH-dependent hydrolysis. SN-38 is 
responsible for CPT-11 biologic effects, including efficacy and toxicity since compared with the 
parent drug, SN-38 is 100- to 1000-times more cytotoxic 59. 
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A           B      
Figure 7 Chemical structures of CPT-11 (A) and its main metabolite SN-38 (B) 
 
SN-38 is then glucoronized to SN-38 glucoronic acid and detoxified in the liver via conjugation by 
the UGT1A1 family, which releases SN-38G into the intestines for elimination. Approximately 70% 
of SN-38 becomes SN-38G, which has 1/100 of the antitumor activity and is virtually inactive. 
Simultaneously, and competing with the activation and detoxification pathways of irinotecan, the 
SN-38 oxidation pathway is mediated by the P450 CYP3A genes. Oxidation of CPT11 results in the 
inactive metabolites APC (7-ethyl-10-[4-N-(5-aminopentanoic acid)-1-piperidino] 
carbonyloxycamptothecin) and NPC (7-ethyl-10-[4-(1-piperidino)-1-amino] 
carbonyloxycamptothecin) (Figure 8). 
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Figure 8 Mechanism of action of CPT-11. Modified from Scripture et al., 2006 Drug interaction in cancer therapy 
Nature Reviews Cancer  
 
CPT-11 is one of the chemotherapeutic drug, together with FLs, that is listed among the drug with 
PGx warning. 
In particular, the PGx research mainly focused on the UGT1A family, responsible for conjugation of 
the active SN-38 to inactive SN-38G. 
Among the most studied SNPs within these genes, UGT1A1*28 (rs81753479) SNP is surely one of 
the most well-known. 
The UGT1A1*28 allele is characterized by seven thymine-adenine (TA) repeats within the 
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promoter region, as opposed to six that characterizes the wild-type allele (UGT1A1*1). These extra 
repeats impair proper gene transcription, resulting in decreased gene expression by approximately 
70% 60,61. Moreover, the increased number of repeats results in decreased rates of transcription, 
initiation, expression, and enzyme activity, that result in a reduced SN-38 detoxification and a 
prolonged exposure time of active SN-38 in the intestines. Thus, patients homozygous or 
heterozygous for the UGT1A1*28 commonly develop dose limiting severe neutropenia and late 
diarrhea and the current US package insert includes homozygosity of UGT1A1*28 as a risk factor 
for severe neutropenia 
(http://www.fda.gov/Safety/MedWatch/SafetyInformation/ucm215480.htm). 
UGT1A1*28 is prevalent within the Caucasian and African-American populations with frequencies 
of 0.26-0.31 and 0.42-0.56 respectively 62. 
Since 2011 the DPWG has evaluated therapeutic dose recommendations for CPT-11 based on 
UGT1A1 genotype: a reduction of the 30% of the standard dose was suggested for patients 
homozygous for the UGT1A1*28 allele and treated with doses higher than 250 mg/m2 55. 
More recently, a French joint working group comprising the National Pharmacogenetics Network 
(RNPGx) and the Group of Clinical Onco-pharmacology (GPCO-Unicancer) have published more 
complex guidelines for the use of UGT1A1*28 genotype when prescribing CPT-11 63. In summary, 
for initially scheduled doses between 180 and 230 mg/m2 every 2-3 weeks, UGT1A1*28/*28 
patients are at increased risk of developing hematological and/or digestive toxicity as compared to 
other genotypes and a 25-30% dose reduction at the first cycle is recommended, particularly in 
cases of associated risk factors (performance status >3). For initially scheduled doses ≥240 mg/m2 
every 2-3 weeks, UGT1A1*28/*28 patients are at a much higher risk of hematological toxicity 
(neutropenia) as compared to other genotypes. The guidelines thus recommend the 
administration of an intensified dose (240 mg/m2) only in UGT1A1*1/*1 patients, as well as in 
UGT1A1*1/*28 patients. The administration of an intensified dose (240 mg/m2) is only possible in 
UGT1A1*1/*1 patients, as well as in UGT1A1*1/*28 patients, in the absence of additional risk 
factors and under strict medical surveillance (Figure 9). 
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Figure 9 Scheme of the guidelines for the use of UGT1A1*28 genotype when prescribing CPT-11. 
 
On the background of the CPT-11 PGx dosing guidelines described above, this drug is a perfect 
candidate for genotype-driven phase Ib studies (Box 1). 
In particular, the group of Toffoli performed a dose-finding study in mCRC patients treated with 
FOLFIRI regimen and with the UGT1A1*1/*1 and UGT1A1*1/*28 genotypes. By dose escalating 
CPT-11 only in patients without the high-risk UGT1A1*28/*28 genotype (10% on average in 
patients of European descent), they demonstrated that the recommended dose of 180 mg/m2 for 
CPT-11 in FOLFIRI is considerably lower than the dose that can be tolerated by the non–
UGT1A1*28/*28 patients. In particular, patients with UGT1A1*1/*1 genotype can safely be 
treated with dose of 370 mg/m2, while the maximum tolerated dose for UGT1A1*1/*28 is 
assessed at 310 mg/m2  64.  
The same group, to better deepen the issue for the correct CPT-11 dosage, began another phase 
1b study, “A genotype-guided phase I study of CPT-11 administered in combination with 5-
fluorouracil/leucoverin (FOLFIRI) and bevacizumab as first-line therapy in metastatic colorectal 
cancer patients”. Patients enrolment began in 2009. The study was conducted in three centers 
(University of Chicago, Chicago, IL, USA; Centro di Riferimento Oncologico, Aviano, Italy; San 
Filippo Neri, Rome, Italy), and the protocol was approved by the Institutional Review Board of 
each participating site. All patients signed a written informed consent before entering the study 
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(Eudract 2009-012227-28; Protocol code CRO-2009-25, NCT01183494). 
The primary objective of this study was to determine the MTD of CPT-11 in FOLFIRI plus 
bevacizumab regimen during cycle 1 in UGT1A1*1/*1 and UGT1A1*1/*28 genotype patients. 
Secondary objectives included: 1) the evaluation of PK of CPT-11 and SN-38 with and without 
bevacizumab during cycle 1; and 2) the effect of higher doses of CPT-11 and genotype on the 
efficacy of FOLFIRI plus bevacizumab as determined by objective response rate (ORR) and 
progression-free survival (PFS). 
The MTD of genotype-directed CPT-11 was assessed at 260 mg/m2 for UGT1A1*1/*28 patients, 
and 310 mg/m2 for UGT1A1*1/*1 patients. Although these doses were still higher than the 
standard ones, they did not reach the level of the previous phase Ib study with FOLFIRI alone. 
Furthermore, in a preliminary analysis of 22 patients, bevacizumab decreased the area under 
curve  (AUC) of SN-38 (p = 0.026 by Wilcoxon matched pairs signed rank test), suggesting a role of 
this monoclonal antibody in the pharmacokinetic of CPT-11 65. 
 
 
 
 
 
 
BOX 1: Genotype-driven Phase Ib studies 
According to the Italian legislation (DPR n°439/2001,art.3), it is necessary to design a 
Phase 1 study with: 
 
 New pharmaceutical products never tested in human subjects 
 Pharmaceutical products resulted from a new association of already registered 
agents 
 Pharmaceutical products already registered in other countries but declared 
new by the Italian Ministry of Health 
 Pharmaceutical agents already registered but for which new pharmaceutical 
forms, excipients, recommendations, dosages, administration routes are 
proposed. 
The genotype-drive phase IB studies fall into the last category.  
Patients are indeed treated with drugs already used in the clinical practice but,  
according to PGx determinants, they are stratified and treated with specific drug 
dosages. 
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1.4.2. THERAPEUTIC DRUG MONITORING STRATEGY 
 
The interpatient variability in PK leads to plasma concentration fluctuation that may vary over 10-
fold range when fixed doses of chemotherapeutic agents are administered (Bardin 2014). For 
example, patients with a low clearance receive a relative overdose and will be at increased risk of 
toxicity. These patients may benefit from a lower dose than the standard one.  
TDM has been introduced in the clinical care from the early 1960s. It involves the measurement 
and interpretation of drug concentrations in biological fluids and the individualization of drug 
dosages or schedules to maximize therapeutic outcomes or to minimize toxicities, or both 66.  
In order to apply TDM in the clinical practice, the drug under investigation has to fulfil the 
following criteria: presence of considerable inter- or intra-individual PK variability, existence of a 
defined and ascertainable relationship between concentration and pharmacological effects, 
narrow therapeutic window, absence of a simple accessible parameter to evaluate clinical efficacy, 
and the availability of a defined and accurate method for drug quantification in biological fluids 67. 
This method is broadly applied to drugs from different therapeutic classes, such as cardiovascular 
agents, antiepileptics, antibiotics, respiratory smooth muscle relaxants, anti-inflammatory agents, 
some cancer agents, immunosuppressants, and antidepressants 68. 
Anticancer drugs fit many of the criteria commonly defined as prerequisites for utilizing TDM 
approaches. Firstly, the extent of inter-individual PK variability exhibited is large in the majority of 
cases, with coefficients of clearance variation of more than 50%. This large inter-individual PK 
variability is likely to be related to genetic differences as well as variations in the functional status 
of cancer patients 66. 
Secondly, relationships have been described between drug plasma concentrations and PD end-
points such as percentage decrease in neutrophil counts between pretreatment and nadir values 
69.  
In addition, when treating cancer patients, the determination of the highest efficacy from 
chemotherapy is an important principle because of the magnitude of the possible side effects, like 
myelosuppression, the can be even life-threatening and may be related to higher than optimal 
therapy. Nevertheless, sub-optimal therapy can greatly reduce the probability to defeat curable 
cancers. Consequently, a therapeutic range that defines efficacy concentrations as well as toxicity 
concentrations would have enormous clinical utility 70. 
Many clinical cancer trials 71,72 showed the benefits of maximum chemotherapy intensity 
underscoring the need to treat patients with doses that will produce concentrations in the upper 
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end of the nontoxic range to increase likelihood of response or cure. If toxic plasma 
concentrations can be defined for each agent, then TDM could be useful in identifying which 
agents are being overdosed or underdosed in any given regimen. TDM in cancer chemotherapy 
has additional advantages like enhancement of compliance, minimization of PK variability among 
patients, dose adjustment in patients with hepatic and renal dysfunction, and detection of drug 
interactions 73.  
Given the great potentialities associated to TDM, a sensitive, precise and reproducible assay 
available for the clinical use is required in order to implement its use in daily practice. The gold 
standard assay for determining the drug plasma concentration in human samples is represented 
by high-performance liquid chromatography coupled with mass spectrometry (HPLC-MS/MS). 
To apply these methods to patients’ samples, they need not only to be setup to detect the drug of 
interest but also to be validated according to international guidelines such as those of FDA, 
“Guidance for Industry Bioanalytical Method Validation”, and the European equivalent ones 
published by EMA (European Medicines Agency), “Guideline on bioanalytical method validation” 
74,75. 
 
1.4.2.1. TDM STRATEGY: THE CASE OF SUNITINIB 
 
Sunitinib malate is an oral multi-targeted tyrosine kinase inhibitor that selectively inhibits class III, 
V, and XII split-kinase domain of receptor tyrosine kinases (RTKs) 76. Most of the small number of 
kinase inhibitors that have been approved so far were developed with the aim of selectively 
inhibiting a particular kinase involved in cancer, like the BCR–ABL kinase that is recognized by 
imatinib. In part, this was due to concern that less-selective kinase inhibition would cause 
problems with toxicity. However, evidence shows that drugs that inhibit multiple kinases can have 
acceptable toxicity profiles and potentially enhance antitumor activity relative to more selective 
kinase inhibitors 77. 
In particular, data from preclinical studies and animal models suggested that simultaneous 
inhibition of the vascular endothelial growth factor receptor (VEGFR2) and the platelet-derived 
growth factor receptor (PDGFRβ) might produce greater antitumor effects than inhibition of either 
RTK alone 78,79. 
From these efforts, a rational design identified sunitinib as a potent inhibitor of VEGFR2 and 
PDGFRβ that had good solubility, bioavailability and protein-binding characteristics 80. In addition, 
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it inhibits also other proteins like PDGFRα, VEGFR1, fetal liver tyrosine kinase receptor 3 (FLT3), 
colony-stimulating factor receptor type 1 (CSF1R), neutrophic factor receptor (RET), and stem-cell 
factor receptor (KIT) 81. 
Sunitinib inhibits the phosphorylation of these receptors and consequently block the RTKs initiate 
downstream signaling affecting many of the processes involved in tumor growth, progression, and 
metastases. 82,83 (Figure 10).  
 
Figure 10 Mechanism of action of sunitinib. Modified from Sebolt-Leopold et al.,2006 Mechanisms of drug inhibition 
of signaling molecules Nature.  
 
Sunitinib is primarily metabolized by CYP3A4 to an equipotent N-desethyl metabolite, that also 
contributes to the inhibition of these receptors (Figure 11). 
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A B  
Figure 11 Chemical structure of sunitinib (A) and N-desethyl sunitinib (B) 
 
The antitumor activity of sunitinib has been shown in a number of preclinical tumor models, and 
its clinical efficacy has been demonstrated in patients with metastatic renal cell carcinoma (mRCC) 
(with FDA approval in 2006), gastrointestinal stromal tumor (GIST), metastatic breast cancer, and a 
variety of other solid tumors (e.g. neuroendocrine tumors). Moreover, sunitinib was approved by 
FDA also for the treatment of GIST in patients who have failed to respond to imatinib or were 
unable to tolerate it 84,85. 
Small molecules like sunitinib are mainly used at a fixed dose ignoring the possible need for dose 
individualization. Fixed dosing may indeed result in suboptimal treatment or excessive toxicity 
considering the high inter-individual variability in the PK of these therapies 8.  
The appropriate management of cancer patients thus requires careful monitoring of newer 
targeted therapies and the development of innovative approaches to treatment individualization. 
TDM may thus provide additional information on efficacy, adherence, and safety compared to 
clinical evaluation alone. This would contribute to increase the probability of efficient, long-lasting, 
therapeutic responses in patients and minimizing the risk of major adverse reactions 86. Finally, as 
these new treatments are expensive, a precise piloting of the most appropriate approach to dose 
them might represent a benefit for public health systems. 
However, only for imatinib the concentration thresholds have currently been suggested to guide 
treatment. To date, the European Society for Medical Oncology suggests indeed that “measuring 
imatinib blood concentrations may be important in all patients and is recommended in case of sub-
optimal response, failure, dose-limiting toxicity or adverse events”87.  
However, recent studies suggested sunitinib as another candidate for a TDM program. In fact, 
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increased exposure to sunitinib in patients with advanced solid tumors is associated with 
improved clinical outcomes (longer time to tumor progression, longer overall survival, a higher 
probability of a response and greater tumor-size decreases), as well as some increased risks of 
adverse effects (incidence of fatigue, increase of diastolic blood pressure, decrease of absolute 
neutrophil count) 88. Additionally, a recent retrospective analysis of 521 patients with mRCC has 
shown that plasma concentration might be better correlated to PFS than to the administered dose 
of drug 89. Thus, based on preclinical data 90 and on a phase I study 77, a target plasma 
concentration of sunitinib and active metabolite (N-desethyl-sunitinib) in the range of 50–100 
ng/mL has been suggested.  
Despite this information, in order to introduce the TDM of the sunitinib in the clinical practice it is 
necessary also to have a rapid, specific, sensitive and reproducible method. 
One of the most challenging peculiarity of sunitinib for the setup of an analytical method is 
represent by its isomerization in presence of light. More in detail, it has an exocyclic alkenyl group 
and is capable of showing Z-E isomerism. In the solid state sunitinib exists as the Z-isomer, which is 
the stable form of this isomer. Preliminary studies indicated that in solution sunitinib shows the 
presence of an unstable E-isomer when exposed to light. Similar photo-induced isomerism of 
molecules with double bonds has already been reported in literature 91,92 and has shown to result 
in the formation of the less stable isomer 92. 
When the light-exposed solutions of sunitinib are placed in the dark, the E-isomer reverts back to 
the Z-isomer, which is consistent with other molecules containing C=C or N=N bonds 93. In solution 
sunitinib converts to the E-isomer following light exposure and reverts to the Z-isomer in the dark.  
The group of Sistla demonstrated that while light protection minimizes the photoinduced 
formation of the E-isomer, storage in the dark can result in a decrease in the already formed E-
isomer. To determine the reversion kinetics, the analytical solution of sunitinib was first exposed 
to light for 23 hours to attain equilibrium. This solution was then protected from light at different 
temperatures to study the E- to Z-isomer conversion. The E-isomer was observed to revert to the 
Z-isomer following storage in the dark with an increase in the reconversion rate at higher 
temperatures. This observation indicates that the reversion of E- to Z- isomer is a thermal 
reversion 93 (Figure 12). 
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Figure 12 Interconversion of Z-E isomers of sunitinib 
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2. RATIONALE 
 
The great inter-variability in the PK and PD of the anticancer drugs and their low therapeutic index 
dramatically complicate the dosing of these drugs. Moreover, the traditional methods based on 
the measurement of the BSA do not account for the complex processes of anticancer drug 
metabolism and elimination and, over the years, the need for a new dosing approach has become 
increasingly evident. The giant steps made in the PGx field paved the way for a tailoring therapy 
leading to the publications of international, peer-reviewed guidelines that recommend a 
personalized dose based on the patient genotype. These PGx dosing guidelines referred, in 
particular, to cytotoxic drugs: over 40 years of experience in the clinical practice, indeed, has 
defined the right background to identify clearly the molecular and genetic bases of their pathway. 
For these drugs, several published data underlined a sharp PGx profile that led to the 
determination of genetic biomarker useful for optimize their dosage. 
Unfortunately, only for few anticancer drugs there is a clear defined biomarker, an available and 
feasible PGx test, and, consequently, peer-reviewed guidelines that help the clinicians in the 
definition of the right dosage for each patient. FLs and CPT-11 are among them and represent the 
most explicative examples of PGx implementation in the daily clinical practice. 
 
Regarding FLs, different international working groups, as described in section 1.4.1.1., strongly 
recommended the introduction of a pre-emptive PGx test for three DPYD SNPs. Despite the 
published guidelines and the vast amount of literature assessing the associations between DPYD 
variant alleles and the occurrence of severe toxicity related to FLs, the genotyping test is still 
scarcely widespread among clinicians. Moreover, the low frequencies of these variant alleles 
(around 1%) do not permit the design of prospective phase Ib dose escalation trials to define the 
MTD for each DPYD genotype. In order to overtake this hurdle, the real clinical validity of the pre-
treatment PGx test needs to be assessed in large sets of cancer patients and, consequently, the 
DPYD pre-emptive genotyping test should be implemented in the clinical practice with health 
technology assessment and cost-effectiveness monitoring. 
 
Regarding CPT-11, although the scientific community focused the attention on several UGT1A1 
SNPs 94,95, only UGT1A1*28 became part of the international PGx dosing guidelines, whereas, for 
the other SNPs, the evidences are still considered too weak. Due to the relatively high frequency 
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(about 10%) of UGT1A1*28 variant alleles in Caucasians, CPT-11 is a perfect candidate for 
genotype-driven phase 1b studies, in order to optimize its dosage in both mono- and association-
therapy. This represents a compelling need, considering that this drug was introduced into the 
clinics in the late 1980s and dose-finding analyses were conducted before the genetic basis of 
severe toxicity was established. Previous studies of our group, as described in section 1.4.1.2., 
have already demonstrated that the stratification of patients in FOLFIRI or FOLFIRI plus 
bevacizumab regimens according to UGT1A1*28 genotype led to a higher MTD both in 
UGT1A1*1/*28 and UGT1A1*1/*1 patients. These interesting results gave a strong rational to 
further examine the issue and, based on the genotype profile of the patients, determined the CPT-
11 MTD in other administration settings. 
 
For drugs such as targeted anti-cancer agents, which are only recently introduced in the clinical 
practice, no PGx biomarkers are known up–to-date for dosage optimization.  
In these cases there is the necessity to apply other methods to personalize the therapy. One of the 
most important drug in this class is sunitinib, an oral multi-targeted tyrosine kinase inhibitor, 
approved only in 2006. 
Evidences in literature defined the TDM as the best approach to monitor the sunitinib plasma 
concentration and, consequently, to obtain the best therapeutic effect with low adverse reactions. 
The limits of this approach regard, in a large part, the use of HPLC-MS/MS for the quantification of 
this drug. Although this instrument is the gold-standard for TDM, the methods are often laborious, 
time-consuming and not feasible for the application in the clinical routine. Moreover, as described 
in detail in section 1.4.2.1, one of the most challenging peculiarity of sunitinib for the set-up of an 
analytical method is represented by its isomerization in presence of light. The major part of the 
methods already published in literature takes into account this phenomenon and the design of all 
sample handling procedures under strict light protection strongly complicate the process. For this 
reason, it is necessary to develop and validate a specific, sensitive and reproducible method that 
overcomes the complex step due to the isomerization of the analyte and can be introduced in the 
clinical routine of a hospital. 
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3. AIMS 
The principal aim of this PhD thesis was to apply different approaches to optimize the dosing of 
anticancer drugs. This project has taken advantage of the molecular and bioanalytical background 
of each analyzed drug, with the common purpose of translating the best approach in the clinical 
practice. Thus, the ultimate aim is to have a real impact on the cancer patients and ameliorate 
their quality of life. 
The study design and the analytical approaches used to reach these goals are listed below: 
 Fluoropyrimidine project:  
Regarding the FLs, a retrospective study was designed with the aim of validating the 
speciﬁcity of three DPYD SNPs recommended by international guidelines (i.e. DPYD-
rs3918290, DPYD-rs55886062, and DPYD-rs67376798) in predicting the occurrence of 
severe toxicity events in a large set of cancer patients. This study included a broad range of 
FL-based regimens and cancer types representative of common clinical practice, assessing 
the clinical relevance of DPYD variants in a “real world” clinical setting. The secondary aim 
of this study was to evaluate whether the additional testing of other investigational DPYD 
variants (DPYD-rs2297595, DPYD-rs1801160, DPYD-rs1801158, DPYD-rs1801159, and 
DPYD-rs17376848) could increase the pharmacogenetic test sensitivity and it is worthy to 
be integrated in the FL dosing guidelines. 
 Irinotecan project:  
A phase 1b study called “A genotype-guided phase I study of irinotecan administered in 
combination with 5-fluorouracil/leucoverin (FOLFIRI) and cetuximab as first-line therapy in 
metastatic colorectal cancer patients”, was approved by the competent authorities in 
December 2014 (EudraCT 2013-005618-37 Protocol code CRO-2014-01). The aims of this 
study were: 1) to define the MTD, the Dose limiting toxicity (DLT), and the phase II 
recommended dosage of CPT-11 administered in the FOLFIRI regimen plus cetuximab in 
mCRC patients treated as first-line chemotherapy according to UGT1A1*28 genotype; 2) to 
evaluate the variability of CPT-11 PK, in combination with cetuximab, in patients with 
UGT1A *1/*1 and UGT1A *1/*28 genotype and the effect of the PK profile on toxicity and 
response rate; 3) to evaluate the PK profile of CPT-11 and its major metabolites in absence 
and in presence of cetuximab administration, in order to define the effect of the chimeric 
monoclonal antibody on CPT-11 PK properties. 
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 Sunitinib project: 
This project aimed at developing and validating, according to the FDA and EMA guidelines, 
an analytical method for the quantification of sunitinib and its main metabolite (N-desethyl 
sunitinib) without any limitations in terms of light protection in order to strongly facilitate 
sample handling. 
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4. MATERIAL AND METHODS 
 
4.1. FLUOROPYRIMIDINE PROJECT 
 
4.1.1.  PATIENTS ENROLMENT AND TREATMENT 
This retrospective study, sponsored by the CRO-National Cancer Institute of Aviano, Italy, included 
patients with different solid tumors and treated with FL-based chemotherapeutic regimen. 
The inclusion criteria for this study were: 
 histologically confirmed diagnosis of solid cancer; 
 available peripheral blood biological sample; 
 signed written informed consent approved by the local Ethical Committee; 
 assumption of a FL-based treatment for at least three cycles unless interrupted due to a 
severe treatment-related toxicity occurrence; 
 Caucasian origins. 
 
Based on the these criteria, a set of 603 patients treated with a FL-based chemotherapeutic 
regimen was selected from a prospective patients’ collection of 5,126 clinical cases of the 
Experimental and Clinical Pharmacology Unit of Centro di Riferimento Oncologico (CRO)-National 
Cancer Institute, Aviano. 
Patients’ medical records were examined to collect the following clinical information: 
 baseline patient assessment; 
 chemotherapy information 
 toxicity data related to the first three therapy cycles (classified according to NCI—Common 
Toxicity Criteria version 3). 
Dosage, schedule, and duration of treatment were based on FL current clinical setting. 
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4.1.2. MOLECULAR ANALYSES  
Sample collection and storage 
For PGx analyses, a 3mL whole blood sample was collected from each patient, and stored in 
freezer at -80° C. Blood specimens were collected in sterile tubes with any anticoagulant agent but 
heparin was not admitted. 
 
Genomic DNA extraction  
The extraction of genomic DNA from whole blood was performed with the automated extractor 
BioRobot EZ1 (Qiagen SPA, Milano, Italy). The Card “EZ1 DNA Blood”, in association with the Kit 
“EZ1 DNA Blood Kit 350 μL”, was used for the extraction of genomic DNA from 350 μl of whole 
blood obtaining 200 μL as final volume. Once introduced the appropriate card and start the 
program, the BioRobot allows to process 6 samples simultaneously, without any intervention by 
the operator.  
This technology is based on the use of silica-coated magnetic particles. DNA is isolated from 
lysates in one step through its binding to the silica surface of the particles in the presence of a 
chaotropic salt. The particles then are separated from the lysates using a magnet and the DNA is 
efficiently washed and eluted in a buffer. DNA yields depend on the sample type, number of 
nucleated cells in the sample, and the protocol used for purification of DNA. For the protocol 
applied in this thesis, the yield should be approximately of 5-12 μg of DNA in 200 μL. 
The extracted DNA is stored at 2-8° C and its purity is determined by calculating the ratio of 
corrected absorbance at 260 nm to corrected absorbance at 280 nm, i.e., (A260 – A320)/(A280 – 
A320). Pure DNA has an A260/A280 ratio of 1.7–1.9. 
 
Polymerase chain reaction  
The technique of DNA polymerase chain reaction (PCR) was invented in 1983 by K. Mullis and 
allows the production of a large number of copies of a specific DNA sequence in vitro. It also 
permits to isolate and amplify any gene from any organism and then analyze the sequence, to 
perform cloning or mutagenesis procedures, or even to establish diagnostic tests that detect the 
presence of mutated forms of the gene. In the in vitro process, DNA is initially heated to 
temperatures close to boiling, in order to denature it and thus obtain single-stranded mold, then 
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Taq polymerase is used to catalyze the duplication of the parental strand. To start the synthesis 
reaction, this enzyme requires a primer represented by a small sequence of single-stranded DNA.  
In the reaction tube two primers are added, one to allow the synthesis of the sense strand (sense 
or forward primer) and one for the synthesis of the antisense (antisense or reverse primer). The 
two primers define the target region to be amplified. 
PCR requires several reagents and reaction conditions that vary with the time. In particular, the 
samples are subjected to a series of thermal cycles that are summarized below:  
 An initial period at elevated temperature (94-95°C) that allows the DNA denaturation, in 
order to separate the template strands that act as a mold.  
 A variable number of consecutive cycles of amplification, each of which consists of three 
phases corresponding to three different temperatures:  
1. complete DNA denaturation, carried out by heating at elevated temperature (94-95° C);  
2. pairing (annealing) of sense and antisense primers with complementary sequences on the 
DNA template. In this phase the temperature is lowered to values which may vary from 50° C 
to 65° C according to the specific characteristics of the primers used;  
3. extension (elongation) of the primers and synthesis of new strands by the Taq 
polymerase, at a temperature of 72°C optimum for the enzyme activity.  
To obtain the amplification of the desired DNA sequence, this cycle of three steps must be 
repeated several times, typically from 25 to 40 times. A final period at 72°C to complete the 
elongation.  
This series of thermal cycles is carried out thanks to a programmable instrument, the thermal 
cycler, capable of changing the temperature very quickly and keep it constant for a given period. 
The result of a PCR is that, at the end of n cycles of amplification, the reaction mixture contains a 
theoretical maximum number of double-stranded DNA equal to 2n (where "n" represents the 
number of amplification cycles). In the first cycle of PCR, the two primers anneal with the two 
strands of the denatured template, thus providing the trigger for the polymerase that synthesizes 
complementary strands. As result of this cycle, two new strands, longer than the region to be 
amplified, whose end parts correspond to the sequence of the primers used to identify the target 
sequence, are created. In the second cycle, the primers anneal to the original template again and 
so it produces other new strands of undefined length. In subsequent cycles only fragments of the 
desired length are formed and they contain the specific region you want to amplify (Figure 13).  
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Figure 13 Polymerase Chain Reaction (PCR). 
 
 
The reagents used in a PCR are listed above: 
 
1) Reaction Buffer 
 It is a Tris-HCl and KCl based buffer necessary to reproduce the optimal conditions for the activity 
of the polymerase thus increasing the throughput or the number of nucleotides that the enzyme 
can insert in succession before separating from the template strand.  
2) Mg2+ 
 It is essential for the activity of Taq polymerase as its bond with the enzyme stabilizes it in a three-
dimensional conformation that facilitates its activities. The Taq polymerase shows its highest 
activity around a concentration of free Mg2+ equal to 1.2-1.3 mM. However, this value is 
influenced also by the concentration of nucleotides, as there is a link between equimolar Mg2+ and 
dNTPs. For this reason, some methods consider Mg2+ concentrations higher than those indicated 
above, although this could led to an incorrect incorporation of the nucleotides.  
3) dNTPs 
The solutions of dNTPs contain the four nitrogenous bases of DNA: dATP, dGTP, dTTP and dCTP. 
For a good efficiency of the PCR the four nucleotides must be present in equimolar around 50-200 
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μM. A too high concentration may increase the incorrect rate of incorporation, while a too low 
concentration may reduce the efficiency of the reaction.  
4) Primers 
Primers design can be performed manually, or more frequently with software that facilitate the 
choice such as "Primer3Plus" (http://www.bioinformatics.nl/cgi-
bin/primer3plus/primer3plus.cgi/). The aim of primer design is to obtain a balance between two 
goals: efficiency and specificity of amplification. Given a target DNA sequence, primer design 
software attempts to strike a balance between these two goals by using pre-selected default 
values for each of the primer design available. In particular, optimal primer pairs should be closely 
matched in Melting Temperature (Tm) and must not be able to form loops and primer dimers. 
Primer length (about 20-base pairs), sequence and GC contents are taken into account to select 
proper primers sequences.  
5) DNA polymerase 
The Taq polimerase is derived from the Thermophilus acquaticus bacterium, it is stable at high 
temperatures and works with maximum efficiency between 72°-75°C. The thermal stability is a 
critical feature of this enzyme. Taq polymerase at 72°C has an enzymatic activity that allows the 
incorporation of 50-60 nucleotides per second, which corresponds, approximately, to 3 Kb per 
minute. The optimal concentration of Taq DNA polymerase ranges from 0.5 to 2.5 U. A too high 
concentration may decrease the specificity of the reaction, while a too low concentration may not 
enable the conclusion of all cycles.  
 
4.1.3.  METHODOLOGIES FOR POLYMORPHISMS ANALYSIS  
 
NCBI (National Center for Biotechnology Information) databases and tools were used to select the 
analyzed SNPs. The NCBI presents a web site showing links to databases containing information 
about genes (Gene), polymorphisms (dbSNP), scientific literature (PubMed), besides search and 
analysis tools. These and other additional databases (SNP500, PharmGKB, and 1000 Genomes 
Browser) were consulted for assay design (genetic sequences, SNPs description, primer design), 
during this work of thesis. Subsequently, according to the type of the selected SNP and to the 
specific characteristics of the surrounding nucleotide sequence, the most suitable method of 
genotyping has been chosen.  
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In particular, in this PhD thesis, semi-automated, recently developed genotyping methods have 
been used. They are based on PCR reactions and allow the identification of genetic SNPs in a very 
simple and easy way: pyrosequencing (PSQ), allelic discrimination based on TaqMan chemistry, 
and direct sequencing.  
 
Pyrosequencing  
Pyrosequencing is an analytical technology for SNP identification consisting of a real-time 
pyrophosphate detection method (Fakhrai-Rad et al., 2002; Ronaghi et al., 2001).  
This technique is based on indirect bioluminometric assay of the pyrophosphate (PPi) that is 
released from each dNTP upon DNA chain elongation. Klenow polymerase mediated the base 
incorporation, PPi is released and used as substrate, together with adenosine 5’-phosphosulfate, 
for the ATP sulfurylase, which results in the formation of ATP. Subsequently, the ATP accomplishes 
the conversion of luciferin to its oxi-derivative by luciferase. The ensuing light output is 
proportional to the number of added bases, up to about four bases. To allow processivity of the 
method, dNTPs in excess are degraded by apyrase, which is also present in the starting reaction 
mixture and continuously degrades ATP and unincorporated dNTPs. This switches off the light and 
regenerates the reaction solution. The dNTPs are added one by one to the template during 
sequencing procedure. It should be noted that deoxyadenosine alfa-thio triphosphate is used as a 
substitute for the natural dATP since it is used efficiently by the DNA polymerase, but not 
recognized by the luciferase (Figure 14). The process is fully automated and adapted to a 96-well 
format, which allows rapid screening of large panel of samples.  
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Figure 14 Pyrosequencing chemistry: biochemical reactions and enzymes involved in the generation of light signals by 
DNA pyrosequencing.  
 
Following a first phase of sample preparation, the plate is loaded on an instrument, the PSQ 96MA 
Pyrosequencing, which determines and provides directly the genotype at the level of the analyzed 
SNP.  
Pyrosequencing analysis is performed on PCR-amplified DNA. One of the PCR primers must be 
biotin-labeled for immobilization to streptavidin coated sepharose beads. This allows the 
separation of the two DNA strands produced by PCR, since the assay must be carried out on single 
stranded DNA. If reverse primer is biotynilated the assay is called forward, otherwise, if the 
forward primer is biotin-labeled, the assay is called reverse.  
PCR reaction product is mixed with streptavidin coated High Performance Sepharose beads 
(Amersham Biosciences, Uppsala, Sweden) in the presence of a binding buffer (Tris 10 mM, 
Sodium Chloride 2 M, EDTA 1 mM and Tween 20 0.1%, pH 7.6). The mixture is allowed to shake for 
10 min at room temperature. The samples are subsequently transferred to a 96-well filter plate 
and vacuum (vacuum manifold for 96 well filter plate, Millipore) is applied to remove all liquid. 
Denaturating solution (Sodium Hydroxide 0.2 M) is added to denature double stranded PCR 
product DNA. After 1 minute incubation, vacuum is applied to remove the solution and the non 
immobilized DNA. The beads are washed twice with a washing buffer (Tris 10 mM, pH 7.6) in the 
presence of the vacuum. The beads with the immobilized template are resuspended by adding 45 
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μl annealing buffer (Tris 20 mM, Magnesium Acetate Tetra-Hydrate 2 mM, pH 7.6) and sequencing 
primer (2 μM) is added to each sample. Design of sequencing primers for pyrosequencing follows 
the same criteria as for the PCR primers, except that the Tm of these primers may, if necessary, be 
lowered. The sequencing primer could thus be shorter than the PCR primers, typically 15 bp. The 
position of the primer is flexible within 5 bases from the SNP and can be designed on both the 
positive (reverse assay) or on the negative (forward assay) strand. Thirty-five μl of this mixture is 
transferred to a Pyrosequencing 96 wells plate (PSQ 96 Plate Low).  
The plate is incubated for 5 min at 60° C to allow the complete sequencing primer annealing on 
the template DNA. After samples cooling, the plate is transferred on the pyrosequencing 
instrument. The biotin labeled DNA template, annealed to the sequencing primer, is incubated 
with enzymes (DNA polymerase, ATP sulfurylase, luciferase, and apyrase) and the substrates 
(adenosine 5’phosphosulfate and luciferin). The first of the four dNTPs is added to the reaction. 
DNA polymerase catalyzes the incorporation of the dNTP into the DNA strand, complementary to 
the base in the template strand. Each incorporation event is followed by the previously described 
reaction cascade, leading to the generation of visible light in amount that is proportional to the 
number of nucleotide added. The light produced in the luciferase-catalyzed reaction is detected by 
a charge coupled device (CCD) camera and seen as peak in a pyrogram. The height of each peak 
(light signal) is proportional to the number of incorporated nucleotides.  
As the process continues, the complementary DNA strand is built up and the nucleotide sequence 
is determined from the signal peaks in the pyrogram.  
"PSQ Assay Design" software was used for the planning of the described assays: it allows to easily 
choose the set of primers (sense and antisense primers for PCR and sequencing primer for 
subsequent analysis at PSQ) most suitable for the study of each SNP. The analysis of the results is 
accomplished with the "PSQTM 96 MA software".  
In this thesis DPYD-rs3918290 was genotyped using a pyrosequencing analysis. The region of 
interest was amplified using primers forward 5’- CGGCTGCATATTGGTGTCAA-3’ and reverse 5’-
[Btn]CACCAACTTATGCCAATTCTCTTGT-3’. The PCR products were amplified using AmpliTaq Gold® 
DNA Polymerase. 
PCR conditions were: 5 min denaturation at 95°C then 35 cycles of 30 s denaturation at 95°C, 30 s 
annealing 60°C and 1 min extension at 72°C and a last cycle consisting of 5 min extension at 72°C. 
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Taqman® Assay  
The allelic discrimination consists in the determination of the two variants of a single nucleic acid 
sequence by means of the "5' fluorogenic nuclease assay". In particular, this technique exploits the 
exonuclease property in the direction 5’→3' of the Taq polymerase when it encounters, during its 
activity of DNA fragment elongation, an oligonucleotide perfectly matched with the DNA template 
used for the elongation. Through this method, it is possible to investigate SNPs.  
TaqMan® allelic discrimination is based on a Real Time PCR (RT PCR) that involves the sense and 
antisense primers needed for the amplification of the SNP containing fragment but also an 
oligonucleotide (probe) able to pairing with the template. The probe pairs in an intermediate 
position between the sense and the antisense primer and it is functionalized at the two ends. At 
one part there is a "quencher" fluorophore (TAMRA) which acts as a silencer of fluorescence, 
while, at the other one there is a "reporter" constituted by a fluorescent fluorophore (FAM or VIC). 
The action of silencing by the quencher occurs by transfer of energy from one fluorochrome to the 
other one when they are near to each other. In the reaction two different allele-specific probes, 
labeled with different fluorophores (fluorochrome FAM or VIC), are placed: one contains a perfect 
match to the wild type (allele 1) and the other one presents a perfect match to the mutation 
(allele 2). The allelic discrimination assay classifies unknown samples as homozygous for the wild-
type, heterozygous, or homozygous for the variant allele.  
TaqMan probe-based chemistry uses a fluorogenic probe to detect specific PCR product as it 
accumulates during PCR cycles. During the denaturation step, the reporter (R) and the quencher 
(Q) are attached to the 5' and 3' ends of a TaqMan probe. When both dyes are attached to the 
probe, reporter dye emission is quenched. During each extension cycle, the hot-start DNA 
polymerase system cleaves the reporter dye from the probe. After being separated from the 
quencher, the reporter dye emits its characteristic fluorescence which is recorded by a detector 
(Figure 15). 
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Figure 15 Schematic representation of TaqMan® technology. 
  
 
The probes are chosen according to certain characteristics:  
 the Tm must be at least 5°C higher than the Tm of the two PCR primers because they must 
bind to the nucleotide sequence when executing the synthesis of the complementary strand;  
 the oligonucleotide must have a length of about 20-30 bp and 50% of G and C;  
 the extension phase must be performed at a temperature lower than the 72°C used in the 
PCR, in order not to cause the detachment of the probe from the template (for this reason we use 
high concentrations of MgCl2);  
 the probe must not form dimers or even pair with itself.  
 
Samples are analyzed using the Applied Biosystems 7500 Real-Time PCR System instrument. The 
allelic discrimination was performed with the SDS software 2.3 (Applied Biosystems).  
For SNP assay a preformed “TaqMan® SNP Genotyping Assay” is employed: it is available on-line in 
the catalogue of Applied Biosystems (http://www3.appliedbiosystems.com/AB_Home/index.htm). 
As an alternative, you can use the service offered by the same company that, on sending the gene 
sequence containing the nucleotide variation, develops and tests specifically an assay called 
"Custom SNP Genotyping assay TaqMan®".  
The practical procedure of the TaqMan® technology is very simple and allows to analyze quickly 
the genotype using a universal mix (master mix) and a solution containing PCR primers and the 
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two allele-specific probes. The step of sample preparation involves the use of 96-well plates with 
specific optical properties. The reaction mixture is prepared by combining the specific mix for the 
SNP under investigation (SNP Assay 20X or 40X), containing primers (sense and antisense) and the 
two probes labeled with FAM or VIC, to the Master Mix (TaqMan Genotyping Master Mix 2X). The 
latter one is universal for all genotyping analyses and contains dNTPs, Taq Polymerase, MgCl2 and 
salts in a suitable concentration creating an adequately buffered environment. The solution is 
dispensed into wells and, finally, genomic DNA is added (approximately 20 ng of DNA for each 
sample).  
Once set up, the plate is covered with an adhesive film and centrifuged for a few minutes to 
eliminate the presence of any air bubbles at the bottom of the wells. Then the plate is loaded into 
the ABI PRISM 7900HT machine, where the RT-PCR conditions (temperature, duration and cycles) 
and the test volumes (20 μl) are determined, and the markers (FAM and VIC) are assigned to 
polymorphism’s alleles. The amplification is carried out with a thermal cycler integrated into the 
instrument using the following thermal profile:  
50° C for 2 min;  
95° C for 10 min;  
40 cycles for (92° C for 15 seconds; 60° C for 1 minute)  
 
At the end of the PCR reaction an end point scanning of the 96-well plate containing the samples is 
carried out, in order to detect the fluorescence signal produced in each well by the two 
fluorophores (FAM and VIC) associated to the allele-specific probes. Finally, thanks to the 
processing of obtained data by software SDS 2.3, the assignment of the genotype corresponding 
to each sample occurs.  
 
In this thesis, DPYD-rs67376798, DPYD-rs17376848, and DPYD-rs1801160 were analyzed by pre-
designed TaqMan SNP genotyping assays with the Applera TaqMan Universal Master Mix used on 
ABI 7900HT (AB Applied Biosystems, Foster City, CA) according to the manufacturer’s instructions. 
 
Direct Sequencing 
In 1974, an American team and an English team independently developed two methods to 
sequence DNA. The Americans, led by Maxam and Gilbert, used a “chemical cleavage protocol”, 
while the English group, led by Sanger, designed a procedure similar to the natural process of DNA 
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replication (Sanger 1977). Even though both teams shared the 1980 Nobel Prize, Sanger’s method 
became the standard because of its practicality.  
Actually, it takes advantage of the peculiar characteristics of the DNA polymerases. These enymes 
copy single-stranded DNA templates adding nucleotides to a growing chain. Chain elongation 
occurs at the 3´ end of a primer, an oligonucleotide that anneals to the template. The extension 
product grows by the formation of a phosphodiester bridge between the 3´-hydroxyl group at the 
growing end of the primer and the 5´-phosphate group of the incoming deoxynucleotide (Watson 
et al., 1987).  
DNA polymerases can also incorporate analogues of nucleotide bases. The “dideoxy method of 
DNA sequencing” developed by Sanger takes advantage of this by using 2´,3´-dideoxynucleotides 
(ddNTPs) as substrates. When one of this unnatural ddNTP terminators is incorporated at the 3´ 
end of the growing chain, chain elongation is terminated selectively at A, C, G, or T because the 
chain lacks a 3´-hydroxyl group (Speed, 1992). 
The DNA polymerase used for this method is called AmpliTaq® DNA Polymerase, and it is a mutant 
form of Taq DNA polymerase containing a point mutation in the active site, replacing 
phenylalanine with tyrosine at residue 667 (F667Y). This mutation results in less discrimination 
against dideoxynucleotides, and leads even to a much more peak intensity pattern (Tabor and 
Richardson, 1995). Moreover, this enzyme contains a point mutation in the amino terminal 
domain, replacing glycine with aspartate at residue 46 (G46D), which removes almost all of the 5´-
3´ nuclease activity. This eliminates artifacts that arise from the exonuclease activity. 
Furthermore, the enzyme has been formulated with a thermally stable inorganic pyrophosphatase 
that cleaves the inorganic pyrophosphate (PPi) byproduct of the extension reaction and prevents 
its accumulation in the sequencing reaction. In the presence of high concentrations of PPi the 
polymerization reaction can be reversed (Kornberg and Baker, 1992), a reaction called 
pyrophosphorolysis: in this reaction, a nucleoside monophosphate is removed from the extension 
product with the addition of PPi to form the nucleoside triphosphate. 
In a sequencing reaction, if a dideoxynucleotide is frequently removed at a particular position and 
replaced by a deoxynucleotide, eventually there is little or no chain termination at that location. 
This results in a weak or missing peak in the sequence data (Tabor and Richardson, 1990). 
 
 The dideoxynucleotides are labeled at 3’ with different dyes that are used to identify the A, C, G, 
and T extension reactions. Each dye emits light at different wavelengths when excited by an argon 
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ion laser. All four colors and therefore all four bases can be detected and distinguished in a single 
gel lane or capillary injection (Figure 16).  
 
Figure 16 Schematic representation of automated Sanger sequencing technology. 
 
 
After PCR amplification, the resulting product is in solution along with PCR primers, dNTPs, 
enzyme, and buffer components, that could affect the performance of the sequencing reaction 
and lead to generation of noisy and non-specific data. For this reason, it is necessary to remove 
them. 
There are several methods for purifying PCR products: 
 Column purification 
 Enzyme purification (e.g. EXOsap) 
 Tips purification 
In this thesis, we used the Rapid Diffinity Tip2® marketed by Sigma. Diffinity RapidTip2 effectively 
removes dNTPs, primers, primer dimers and DNA polymerase while providing greater than 90% 
recovery of pure DNA fragments from 100 bp to 10 kb. The tip is filled with a proprietary 
adsorption technology that has a differential affinity for PCR components. The impurities are 
removed from the solution as it enters the pipette tip and, after mixing for just one minute, 
dispensing the solution yields purified, high quality DNA ready to use for downstream applications 
is obtained. 
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 After the purification, the amplification step requires the use of a proper mix containing dNTPs 
and labeled ddNTPs. 
For each sample, a 10 μL mix was set-up as listed above: 
- 1.2 μL buffer 
- 1 μL BigDye (dNTPS, ddNTPs, DNA polymerase) 
- 1 μL sequence primer (0.33 μM) 
- 4.8 μL milliQ water 
- 2 μL purified amplicon 
 
The amplification of the samples takes place following this thermal cycler program: 
-96°C 1 min 
-50°C 30 seconds 30 cycles 
-60°C 2 min 
 
All the reactions start from the same nucleotide and end with a specific base, when the 
dideoxynucleotides are added. Thus, in solution DNA chains with different lenghts covering all the 
nucleotides’ positions are obtained 96. After the amplification, unincorporated dye terminators 
have to be removed. Excess dye terminators in sequencing reactions indeed can interfere with 
basecalling. Several protocols are currently used to purify these products. In this thesis, a simple 
and cheap precipitation method was applied based on the use of a resin-based protocol in 96-well 
plate format. This resin – generally hydrated superfine Sephadex-G50– retains salts, reactants, 
primers and unincorporated dyes while allowing the purified DNA to pass through this matrix 
during centrifugation. The purified samples are collected in a clean plate. 
 Once these reactions are completed, the DNA is chemically denaturated with formammide and 
also thermally denatured with a rapid cycle of heating and freezing. 
The samples, then, are ready to be loaded in the Genetic Analyzer ABI Prism 3130 (Applied 
Biosystems, Foster City,CA), where a capillary electrophoresis associated with fluorescence 
detection happens. 
Since the four dyes emit fluorescence signals at different wavelengths, a laser reads the gel to 
determine the identity of each band. The results are then depicted in the form of a chromatogram, 
which is a diagram of colored peaks that correspond to the nucleotide in that location in the 
sequence. 
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The obtained data are then analyzed using the free download software Chromas lite 
(www.technelysium.com.au/chromas.html). 
 
In this thesis, four SNPs (DPYD-rs55886062, DPYD-rs1801158, DPYD-rs1801159, DPYD-rs2297595) 
were genotyped by Sanger sequencing. Three of them (DPYD-rs55886062, DPYD-rs1801158, DPYD-
rs1801159) were genotyped simultaneously.   
The region of interest was amplified using primers forward 5’- CGGATGCTGTGTTGAAGTGATTT-3’ 
and reverse 5’- GTGTAATGATAGGTCTTGTCAAATAGT-3’, designed using the web-based tool 
primer3plus (http://www.bioinformatics.nl/cgi-bin/primer3plus/primer3plus.cgi/). PCR products 
were amplified using AmpliTaq Gold® DNA Polymerase.  
The PCR thermal profile is the following: 10 min denaturation at 95°C then 37 cycles of 30 s 
denaturation at 95°C, 30 s annealing 63°C and 30 s extension at 72°C and a last cycle consisting of 
7 min extension at 72°C. 
The region containing the other SNP analyzed with Sanger sequencing (DPYD rs2297595) was 
amplified using these primers: forward 5’-TGTTTGAGGATGTAAGCTAGTTTCA-3’ and reverse 5’- 
AAACTTGAACATTTGGAAAAAGAACA-3’. PCR products were amplified using AmpliTaq Gold® DNA 
Polymerase . 
PCR conditions were: 10 min denaturation at 95°C then 37 cycles of 30 s denaturation at 95°C, 30 s 
annealing 61°C and 30 s extension at 72°C and a last cycle consisting of 7 min extension at 72°C. 
 
4.1.4. CLINICAL DATA COLLECTION AND ELABORATION  
 
Patients’ clinical data have been collected by oncologists using the suitable created Case Report 
Form (CRF) (see results).  
All personal and clinical data were catalogued in appropriate databases, prepared in accordance 
with the Privacy Policy, in order to be associated with genetic data. 
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4.1.5. STATISTICAL ANALYSIS 
 
Clinical data are presented as means and standard deviation or as absolute frequencies and 
percentages as appropriate. 
Differences in mean were analyzed with Mann–Whitney test, whereas differences in absolute 
frequencies were analyzed with Fisher exact test. The frequency of each variant was compared 
with the published frequencies in dbSNP and tested for deviation from Hardy–Weinberg 
equilibrium. 
Multivariate logistic regression analysis was used to access variables independently associated 
with toxicity, and the following variables were considered for inclusion: sex, age, association 
therapy, FL administration, administration setting and DPYD polymorphisms. In case of complete 
or quasicomplete separation (as in the case of rare allelic variants) a penalized model was used 
(Firth model). Model evaluation was performed using a bootstrap approach. The bootstrap 
resampling technique was used to confirm the reliability of the final parameter estimates and their 
95% confidence intervals (CI). The median and bootstrapped 95% CI of the ORs were obtained 
from 2000 bootstrap replicates. 
An explorative analysis was carried out for DPYD-rs2297595, DPYD-rs1801160, DPYD-rs1801158, 
DPYD-rs1801159, and DPYD-rs17376848 to investigate a possible clinical effect of these SNPs. We 
performed this exploratory analysis in a selected subgroup of cases. Specifically, we compared the 
group of all the patients with at least one event Grade 3 or more during the first three cycles of FL-
therapy (95 cases) with a control group randomly extracted from the set of patients without 
severe toxicity (Grade 0–2 only) and homogeneous for the most relevant clinical demographic 
characteristics (i.e., age, association therapy, FL administration, and setting). In order to have at 
least three controls for each toxicity case, 315 subjects were selected. The frequencies DPYD 
variants in this subgroup population should reflect the incidences in the overall population of 
controls used for comparison with the cases. 
 
In order to define the clinical validity of a pre-treatment DPYD test, the diagnostic power of the 
were calculated. 
The following terms are fundamental to understanding the validity of clinical tests:  
1. True positive: the patient has the disease and the test is positive.  
2. False positive: the patient does not have the disease but the test is positive. 
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3. True negative: the patient does not have the disease and the test is negative  
4. False negative: the patient has the disease but the test is negative (Figure 17).  
 
Figure 17 Schematic representation of the fundamental parameters to define the validity of a clinical test. The 
condition representsthe insurgence (+) or not (-) of severe toxicity, while the test represents the presence (+) or not (-) 
of the variant allele. 
 
When evaluating a clinical test, the terms sensitivity and specificity are used. They are 
independent of the population of interest subjected to the test.  
The sensitivity of a clinical test refers to the ability of the test to correctly identify those patients 
with the disease.  
             
              
                             
 
 
The specificity of a clinical test refers to the ability of the test to correctly identify those patients 
without the disease.  
 
             
              
                              
 
 
The terms positive predictive value (PPV) and negative predictive value (NPV) are used when 
considering the value of a test to a clinician and are dependent on the prevalence of the disease in 
the population of interest. 
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The PPV of a test is a proportion that is useful to clinicians since it answers the question: ‘How 
likely is it that this patient has the disease given that the test result is positive?’  
 
                           
              
                               
 
 
The NPV of a test answers the question: ‘How likely is it that this patient does not have the disease 
given that the test result is negative?’  
 
                           
              
                              
 
 
P Values less than 0.05 were considered as statistically significant. A Bonferroni correction for 
multiple testing of three SNPs (DPYD-rs3918290, DPYD-rs55886062, and DPYD-rs67376798) was 
applied for p obtained from bootstrap approach. 
All the analyses were carried out with Stata 11.2 (Stata-Corp, TX). 
 
4.2. SUNITINIB PROJECT 
 
4.2.1. HIGH PERFORMANCE LIQUID CHROMATOGRAPHY COUPLED WITH 
MASS SPECTROMETRY METHOD  
 
Mass spectrometry is a powerful analytical tool for both drug quantitative and qualitative analysis. 
In particular, Accurate and sensible quantification is obtained by operating in tandem mass 
(MS/MS) mode. MS/MS is necessary because many compounds have the same intact mass, while 
the fragmentation pattern is compound specific. The combination of parent mass and its fragment 
ions is used to monitor selectively the compound that has to be quantified. MS/MS fragmentation 
is also fundamental for qualitative information, because the mass spectrum of every compound is 
unique and it can be used like a chemical fingerprint to characterize the sample, even in case 
where only picogram amounts of analyte are available. 
Moreover, coupling the mass spectrometer with LC provided significant improvements in assay 
sensitivity, specificity and capability to analyze samples with very different concentration ranges. 
Indeed, LC-MS has become the method of choice for quantitative drug analysis to support PK and 
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drug metabolism studies 97. The increase in sensitivity and specificity caused three important 
effects: 
 the possibility to detect drugs and metabolites at very low concentration; 
 the possibility to use very small amount of sample (that is particularly important in 
preclinical studies conducted in small animals or in pediatric studies); 
 a selective analytes detection in presence of complex matrices such as tissues or whole 
blood. 
In LC-MS experiment the sample is introduced into the mass spectrometer after its separation in a 
LC column. Charged ions of the analytes are then produced into the ion source of the mass 
spectrometer. These ions are separated by the MS analyzer on the basis of their mass to charge 
(m/z) ratio. There are different types of MS ion sources, but the most commonly used in 
pharmacokinetic studies is Electrospray Ionization (ESI), an atmospheric pressure ionization.  
ESI is a soft ionization technique and does not cause decomposition of labile compounds. It is 
characterized by an efficient ion production, mainly by protonation or cationization reactions, and 
it can operate in either positive or negative ion mode. 
Electrospray spectra are produced by passing a liquid stream through a metal capillary maintained 
at high voltage (2000-5000 V). This forces the spraying of charged droplets from the needle with a 
surface charge of the same polarity of the charge on the needle. 
In a typical ESI source (Figure 18), the solution is injected in a stainless steel capillary. Between this 
capillary and their counter electrode, a voltage in the order of 3–5 kV is applied. Under these 
conditions, the formation of a solution cone just outside the capillary occurs. The cone formation 
is due to the presence of charged species inside the solution, which experiment the electrostatic 
field existing between the capillary and the counter electrode 98. After the cone production, the 
droplets formation from the cone apex is observed, charged droplets further migrate through the 
atmosphere to the counter electrode 98. Droplets formation is strongly influenced by solvent 
chemical–physical characteristics, ionic analytes concentration, inorganic salts concentration, and 
the applied voltage. The so generated charged droplets decrease their radius after solvent 
evaporation still conserving their total charge amount. The energy required for the solvent 
evaporation is due to the environment thermal energy, further enhanced through by the use of a 
heated capillary or by collisions with heated gas flow. As the droplet radius decreases, the surface 
charge density increases; when the radius reaches the Rayleigh stability limit, the electrostatic 
repulsion equals the surface tension. For lower radii, the charged droplets are unstable and 
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decompose through a process defined “Columbic Fission” 99. This produces smaller droplets that 
ultimately liberate unsolvated charged analyte molecules.  
 
 
Figure 18 Schematic representation of the ions formation process in positive ESI source. Under these conditions the 
capillary is placed at a positive voltage, while the counter electrode is placed to a negative voltage. 
 
From the ion source, ions are transferred to the mass spectrometer, where they are analyzed. 
A triple quadrupole mass spectrometer is characterized by three consecutive quadrupole 
analyzers: the first and the third ones work as mass filters, while the second as a collision cell. A 
quadrupole consists of four parallel rods arranged symmetrically around a central axis.  
Opposite rod pairs are connected electrically and a voltage, consisting of both radiofrequency (RF) 
and direct-current (DC) components, is applied with the RF components on the different pairs 
being 180° out of phase. The RF value is a constant of a specific quadrupole type, while the DC 
voltage is varied in order to allow only ions of a particular m/z to follow a stable trajectory through 
the rods and reach the detector, while all other ions hit the quadrupoles because of their unstable 
path. 
According to the aims of the analysis, the first and the third quadrupole can be used in different 
scan modes to acquire and visualize data. Each quadrupole can be set to filter only one m/z ratio 
or to scan over a wide m/z range. The most common scan mode for a quantitative analysis is 
defined as Selected Reaction Monitoring (SRM), characterized by the use of two quadrupoles as 
mass filters: the first quadrupole selects the precursor ion of the analyte and the second, after 
fragmentation in the collision cell, selects the specific product ion.  
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Several steps are needed to optimize every phase of a bioanalytical method. In particular, the set-
up considered: 
 the definition of the processing method for the analytical samples, 
 the optimization of the chromatographic conditions,  
 the optimization of the MS/MS conditions. 
 
4.2.2.  DEVELOPMENT OF A BIOANALYTICAL METHOD 
 
Standards and chemicals 
Analytical reference standard of sunitinib was purchased from Sigma-Aldrich Co. (Milan, Italy) 
while N-desethyl sunitinib and the deuterated internal standard sunitinib D10 were purchased 
from Toronto Research Chemicals, Inc. (North York, Ontario, Canada). LC-MS grade methanol and 
formic acid were supplied by Sigma-Aldrich Co. (Milan, Italy) and Baker (JT Baker, Deventer, NL), 
respectively. Filtered, deionized water was obtained from a Milli-Q Plus system (Millipore, 
Billerica, MA, USA). The transfusion unit of the National Cancer Institute (Aviano, Italy) provided 
control human plasma/K2EDTA, used to prepare daily standard calibration curves and quality 
control (QC) samples from healthy volunteers. 
 
Standards and quality control solutions 
Stock solutions for sunitinib, N-desethyl and IS were prepared in dimethyl sulfoxide (DMSO) at a 
concentration of 1.00 mg/mL. Dilution in acetonitrile from the solutions of sunitinib and N-
desethyl sunitinib (for standards and QC) were prepared at concentration of 100 μg/mL, 10 μg/mL 
and 1 μg/mL. A series of working solutions (G to A) to prepare the plasma standard points of the 
calibration curve and the plasma QC samples (L, M and H) were obtained by mixing and diluting 
the stock. The IS working solution was prepared at 0.1 μg/mL by diluting the stock solution with 
acetonitrile. All the solutions were kept in polypropylene tubes and stored at -80°C. 
 
Preparation of standards and quality control samples 
A seven-point plasma calibration curve was prepared freshly every day during the validation study. 
Each calibration sample was prepared by adding 1.5 μL of the respective standard solution from G 
to A (ULOQ) to 28.5 μL of pooled blank human plasma to obtain the final concentrations reported 
in Table 4. Each calibration curve included a blank sample and a zero blank sample (plasma 
57 
 
processed with the IS). At least three concentrations of quality control (QC) need to be prepared: 
one within three times the LLOQ (low QC), one in the midrange (middle QC), and one approaching 
the high end (high QC) of the range of the expected study concentrations. 
To prepare QC samples, 1.14 mL aliquots of control human plasma were mixed with 60 μL of each 
working QC solutions (L, M and H) obtaining the QC plasma concentration reported in Table 4. 
Several 30 μL-aliquots of the three QCs were stored at −80°C to check the analytes stabilities and 
as controls for future assays.  
 
 SUNITINIB 
(ng/mL) 
N-DESETHYL SUNITINIB 
(ng/mL) 
G 0.1 0.1 
F 0.5 0.5 
E 10 2.5 
D 50 10 
C 100 50 
B 250 100 
A 500 250 
QC L 0.25 0.1 
QC M 25 25 
QC H 400 250 
Table 4 Final concentrations of calibration curve points and QC. 
 
Processing samples  
After have thawed plasma samples, they were vortexed for 10 s and centrifuged at 3000 g for 10 
min. Then 30 μL of the actual sample, standard or QC sample were transferred to a 1.5 mL 
Eppendorf polypropylene tube, and 1.5 μL of the IS working solution (0.1 μg/mL) were added and 
the mixture was vortexed.  
Plasma is rich in proteins, lipids and other contents that may interfere with the investigational 
drug. The complexity of the biological matrix presents challenges for efficient sample preparation 
and adequate sensitivity for mass spectrometry analysis of drugs. For this reason, a protein 
precipitation is made adding 150 μL of CH3OH. Each tube was thoroughly vortexed for 10 s and 
centrifuged at 13000 g for 10 min. Then 100 μL of the obtained supernatant were transferred to 
an autosampler glass vial pending analysis. 
Since all the sample handling steps described above occur without any light-protection, we have 
introduced an additional step in order to revert the isomerization and thus to obtain only the 
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active Z-isomer that we want to measure. For this reason, the samples were heated at 90°C for 5 
min in a thermostatic bath and, then, transferred into the autosampler. This last step is the only 
one in the entire processing procedure that needs to be done in the dark (Figure 19). 
Different amounts (2–5 μL), inversely related to the concentrations, were injected into the HPLC 
system to minimize the carry-over effect. Moreover, after the injection of the ULOQ, three 
samples of mobile phase and one blank sample were injected to demonstrate the absence of 
carry-over effect. This procedure guaranteed that no peak higher than 10% of LLOQ was detected.  
 
 
Figure 19 Schematic representation of the processing sample procedure. 
 
Chromatographic conditions  
The HPLC system consisted of a SIL-20AC XR auto-sampler and LC-20AD UFLC XR pumps 
(Shimadzu, Tokyo, Japan). Samples were separated on a Synergy Fusion RP C18, 4 μM, 80 Å, 2 x 50 
mm (pre-column: Gemini-NX C18 4.0 x 2.0 mm) and thermostatically controlled at 50°C. The 
mobile phases were 0.1% CHOOH/bidistilled water (MP A) and 0.1% CHOOH/acetonitrile (MP B). 
The HPLC system was set up with a flow rate of 0.3 mL/min and the following linear gradient:  
step 1: the initial condition of 90% MP A held for 0.5 min; 
step 2: from 90% MP A to 30% over 1 min; 
step 3: constant for 1.2 min; 
step 4: from 30% MP A to 60% over 0.3 min; 
step 5: : from 60% MP A to the initial condition over 0.5 min and reconditioning for 4 min. 
The total run time was 7.5 min. 
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Mass spectrometry conditions  
The HPLC system was coupled with an API 4000 triple quadrupole mass spectrometer AB SCIEX 
(Massachusetts, USA). Standard solutions prepared in 0.1% CH3COOH acetonitrile/ water 1:1 (50 
ng/mL) of sunitinib, n-desethyl sunitinib, and IS were infused at a flow rate of 10 μL/min in order 
to optimize all the MS parameters. Positive ion mode was used to obtain the mass spectra (MS1) 
and the product ion spectra (MS2). The instrument was equipped with a Turbo Ion Spray source 
operated at 625°C and with ion spray voltage of 5000 V. The biological samples were analyzed 
with electrospray ionization (ESI), using zero air as nebulizer gas (30 psi) and as heater gas (70 psi). 
Nitrogen was employed as curtain gas (20 psi) and as collision gas at medium intensity (CAD). After 
fragmentation, the characteristic product ions of the compounds were monitored in the third 
quadrupole at m/z 326, m/z 283 and m/z 238.  
Quantification was done in SRM mode using the following transitions: m/z 399 > 326 for sunitinib, 
m/z 371 > 283 for N-desethyl sunitinib, and m/z 409 > 328 for IS. To quantify the chromatographic 
peaks, data were processed with Analyst 1.5.2 (quantification with MultiQuant 2.1) software 
package (AB SCIEX). 
 
4.2.3.  VALIDATION OF A BIOANALYTICAL METHOD 
 
Selective, sensitive, and validated analytical methods for the quantitative evaluation of drugs and 
their metabolites are critical for the successful conduct of nonclinical and clinical pharmacology 
studies. Indeed, the quantitative measurements of drugs, metabolites, and biomarkers in 
nonclinical and clinical studies provide essential information in the assessment of safety and 
efficacy of drugs. Drug or biomarker concentrations frequently serve as the primary or secondary 
endpoints of many clinical studies in drug development. Consequently, the reliability or quality of 
that data underpins the study outcome 74,100. For this reason, validating bioanalytical methods 
includes performing all of the procedures that demonstrate that a particular method used for 
quantitative measurement of analytes in a given biological matrix (e.g. blood, plasma, serum, or 
urine) is reliable and reproducible for the intended use 74. 
The measurements should be based on established principles and scientists should utilize a 
common, vetted paradigm of practices, independent of the analytical platform to demonstrate 
that the assays provide reliable data. The necessity to establish the main guiding principles for the 
validation of the analytical method and to disseminate them to the pharmaceutical community 
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was received, in 1990, by the first American Association of Pharmaceutical Scientist (AAPS)/ FDA 
Bioanalytical Workshop 101. Scientists in the bioanalytical field worked with the regulatory 
community to establish a common language and expectations in generating pharmacokinetic data 
for drugs and metabolites. These validation principals were introduced into regulations by Health 
Canada in 1992 102 and then by the FDA which published the first edition of its Guidance on 
Bioanalytical Method Validation in 2001 103. 
This guidance explains the course of action for the validation of analytical procedures such as gas 
chromatography; high-pressure liquid chromatography; GC-MS; LC-MS; ligand binding assays, 
immunological assays and microbiological procedures. In doing so the specific features of these 
methods in the quantitative determination of drugs and metabolites in biological matrices, such as 
blood, serum, plasma, urine and different tissues are taken into account. Validation involves 
documenting, through the use of specific laboratory investigations, that the performance 
characteristics of the method are suitable and reliable for the intended analytical applications. The 
acceptability of analytical data corresponds directly to the criteria used to validate the method. 
Fundamental parameters for this validation include the following: accuracy, precision, selectivity, 
sensitivity, reproducibility, stability. The FDA guidance described in detail all this parameters and 
the correct way to validate them. 
Since the publishing of this guidance in 2001, the dialogue has broadened significantly through 
scientific conferences not only within the USA, but globally. In 2011 the Guidance on Bioanalytical 
Method validation was introduced in EU 75. Successively, in September 2013 the FDA released a 
draft revision of the Guidance for Industry Bioanalytical Method Validation that included a number 
of changes to the expectations for bioanalysis74. 
In particular, taking into account the AAPS/FDA Workshop on Incurred Sample Reanalysis 104, this 
revised version has introduced an additional measure of assay reproducibility: the Incurred Sample 
Reanalysis (ISR). This analysis is now well established as an important element of bioanalysis and is 
intended to verify the reliability of the reported subject sample analyte concentrations. ISR is 
conducted by repeating the analysis of a subset of subjects’ samples from a given study in a 
separate run to critically support the performance of assays. 
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Recovery 
The percentage extraction recovery was determined for each analyte (sunitinib, N-desethly 
sunitinib, IS) at three plasma concentrations (QCL, QCM and QCH) prepared in quintuplicate. The 
peak area of each analyte extracted from plasma QC samples were compared to those from 
standards prepared in methanol. 
The recovery of IS is evaluated in the same way at a plasma concentration of 0.1 µg/mL. The 
recovery experiments were performed at three different concentrations (QCL, QCM and QCH).  
Moreover, for every analyte and IS, the percentage recovery was even determined by comparing 
the peak area of the analyte extracted from plasma QC samples, prepared at the three 
concentrations, with the peak area of the extracted matrix prepared in five replicates and added 
with the same amount of the analytes. 
Recovery of the analyte and the IS need not to be 100%, but it is important that the extent of 
recovery is consistent, precise and reproducible. 
 
Linearity 
The linearity of the calibration curves was validated over five different working days. Each day, a 
calibration curve was prepared by spiking the biological matrix with known concentrations of the 
analyte (as reported in Preparation of Standard and Quality Control samples section) to define the 
relationship between concentration and instrument response. It consisted of seven standard 
points in a range chosen on the base of expected concentrations in the samples and was obtained 
using the same biological matrix of samples to measure. For each standard point, the ratio of the 
HPLC–MS/MS peak area for sunitinib and N-desethyl sunitinib to the IS was calculated and plotted 
against the nominal concentration of each analyte in the sample. 
The linearity for each calibration curve was assessed by weighted least squares method, using 1/x2 
as weighting factor. 
The y axis intercept (q) and the slope (m) of the equation y = mx + q were calculated elaborating 
the yj and xi values obtained from the calibration points, where: 
 
yj  
Aj
Ais
         Aj = peak area of the j-eme analyte 
Ais = peak are of the Internal Standard 
xi = actual concentration of the analyte in the curve point sample. 
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The goodness of the fitting was evaluated by the Pearson’s determination coefficient R2. 
The reproducibility of each calibration curve was assessed by the mean, standard deviation (SD) 
and coefficient of variation (CV%) of the estimated m and R2. The back-calculated values of 
individual calibrants had to be within ≤ 15% of their theoretical concentration (≤ 20% at the limit 
of quantitation). 
 
Intra-day and inter-day precision and accuracy and reproducibility 
Precision and accuracy of the method were evaluated on five different days by determining the 
analyte in three replicates at different nominal concentrations corresponding to the three quality 
control (QC) samples. Five different standard calibration curves were prepared and processed 
each day to analyze the QCs. 
The precision of an analytical method describes the closeness of individual measures of an analyte 
when the procedure is applied repeatedly to multiple aliquots of a single homogeneous volume of 
biological matrix. This parameter, at each QC concentration, was reported as the CV%, expressing 
the standard deviation as a percentage of the mean calculated concentration and it must not 
exceed 15% of CV. 
The accuracy of an analytical method describes the closeness of mean test results obtained by the 
method to the actual value (concentration) of the analyte. This parameter was determined by 
expressing the mean calculated QC concentration as percentage of the nominal concentration. In 
each run, the measured concentration for at least six out of nine QC samples had to be within 15% 
of the nominal value. Only one QC sample could be excluded at each concentration level.  
ISR is intended to verify the reliability of the reported subject sample analyte concentrations. ISR is 
conducted by repeating the analysis, with the same bioanalytical method procedures, of a subset 
of subject samples from a given study in separate runs on different days to critically support the 
precision and accuracy measurements established with spiked QCs. The selection of samples for 
reanalysis should be done guaranteeing adequate coverage of the PK profile in its entirety 
including a sample around the maximum concentration (Cmax) and in the elimination phase. The 
analyses can be considered equivalent if two-thirds (67%) of the percentage difference [(repeat-
original)*100/mean] of the results is within 20%.  
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Limit of detection, limit of quantification and selectivity  
The limit of detection (LOD) was defined as the concentration at which the signal-to noise ratio 
was 3. The limit of quantitation (LOQ) was defined as the smallest amount of the analyte that 
could be measured in a sample with sufficient precision and accuracy (within 20% for both 
parameters) and as the concentration at which the signal-to-noise (S/N) ratio was at least 5. The 
LOQ was chosen as the lowest concentration on the calibration curve (LLOQ). 
The LLOQ of the present method was assessed by adding G working solution to six samples of 
blank human plasma. Selectivity was proved using six independent sources of blank human 
plasma, which were individually analyzed and evaluated for interference: a single 28.5 μL-aliquot 
from each of the six matrices was spiked with the analytes at the LLOQ concentration. Both LLOQ 
and selectivity had to have acceptable accuracy (20%) and precision (between 80% and 120%).  
 
Matrix effect 
Matrix effects arise due to effects of endogenous components of the plasma matrix on the 
ionization of the analytes of interest and IS. In the ESI source a process of charging and desolvation 
transforms the analytes in the liquid phase into gas ions that are introduced in MS analyzer. It 
seems clear that the coeluting compounds interfering with either the desolvation or the charging 
step alter the ionization of the analyte105. Although they are generally the principal cause, not only 
endogenous components in the biological matrix (e.g. salts, amines, triglycerides) cause matrix 
effect, also some exogenous compounds (plasticizers from sample containers or anticoagulants in 
case of plasma) are susceptible to alter the ionization process 106. Furthermore, other substances 
can be present in the mobile phase and can alter the signal of the analyte by causing ion 
suppression or enhancement. Nevertheless this is not considered a ME source since it is not 
sample specific 105.  
Current FDA requirements underline the importance to assess this phenomenon in mass 
spectrometry, because it may compromise the precision, the accuracy, the sensitivity and the 
selectivity of the developed method and, consequently, the reliability of analytical data produced. 
The same definition reported in the FDA guidance for matrix effect is given by EMA in the 
Guideline on bioanalytical method validation of 2011 75. Both guides agree that the variability in 
the matrix effect, which would cause lack of reproducibility in the method, should be studied using 
six lots of blank matrix from individual donors. Indeed, a quantitative evaluation of matrix effect 
should be achieved by comparing the response of the analyte in solvent to the response obtained 
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by spiking the analyte into six extracted independent sources of black human plasma. The matrix 
effect is calculated as the ratio of the peak area in the presence of matrix to the peak area in 
absence of matrix at the three different QC concentrations (L, M and H) of each analyte. The CV 
should be within 15%. 
In addition, a common method to evaluate qualitatively the matrix effect is the post-column 
infusion, described by Bonfiglio and colleagues 107, which permits to identify the chromatographic 
region where the matrix effect manifests itself 105. A constant concentration of the analyte is 
introduced in the ion source of the mass spectrometer by using an infusion pump connected with 
a zero-dead-volume “T” junction after the HPLC column, while a blank extracted sample is injected 
onto the chromatographic system. The signal of the infused drug, followed in a SRM scan mode, is 
steady, unless endogenous components eluting from the column cause a reduction or a gain of the 
response. To assure the reliability of the results, it is important that these ion suppression or 
enhancement effects do not happen near the analyte’s retention time. To perform the post-
column infusion experiments standard solutions, prepared in 0.1% CH3COOH acetonitrile/water 
1:1 (50 ng/mL) for each analyte and IS, were infused by a syringe pump. 
 
Stability 
Studying the stability of the analyte in stock solutions and matrix is vital to ensure the reliability of 
the results provided by the analytical method. These include assesses that cover all the situations 
that can be encountered during the whole analytical procedure such as freeze-thaw stability, short 
and long term stability, stock stability and post preparative stability. 
The stability of the analyte of interest was evaluated by analyzing the QC matrix samples in 
triplicate at each QC concentration level. Bench-top stability was determined after 4 h at room 
temperature and the stability of the processed samples in the autosampler was assessed by 
repeatedly analyzing the processed QC samples 24, 48 and 72 h after the first injection. To check 
freeze/thaw stability, a freshly prepared aliquot of each QC sample concentration was processed 
and analyzed, and then again after one and two freeze/thaw cycles. Long-term stability need to be 
assessed in plasma and in working solutions stored at approximately −80°C. Each analyte was 
considered stable at each concentration when the differences between the freshly prepared 
samples and the stability of testing samples did not deviate more than 15% from the nominal 
concentrations. 
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4.3. IRINOTECAN PROJECT 
 
The title of the genotype-guided phase 1b study in which I am involved is “A genotype-guided 
phase I study of irinotecan administered in combination with 5-fluorouracil/leucovorin (FOLFIRI) 
and cetuximab as first-line therapy in metastatic colorectal cancer patients”. The protocol of this 
trial has been revised and approved by the CRO ethical committee, the AIFA (Agenzia Italiana del 
Farmaco) and the ISS (Istituto Superiore di Sanità) and the main characteristics of this study are 
briefly described above. 
 
4.3.1. PATIENTS CHARACTERISTICS 
 
The eligibility criteria for this study are:  
 histologically or cytologically confirmed diagnosis of mCRC expressing EGFR;  
 RAS wild-type status;  
 no prior chemotherapy for metastatic disease;  
 age ≥18; 
 Eastern Cooperative Oncology Group (ECOG) performance status (PS) of 0 or 1;  
 life expectancy > 3 months;  
 measurable or evaluable disease (defined as > 1 cm on spiral computed tomography scan);  
 adequate organ function, including bone marrow (absolute neutrophil count (ANC) 
≥l500/µL, haemoglobin ≥9g/dL, platelets ≥100000/µL); hepatic (total bilirubin <1.6 mg/dL, 
international normalized ratio or ≤2x for Gilbert’s Syndrome, aspartate 
aminotransferase/alanine aminotransferase <2.5 x upper limit of normal for patients 
without liver metastases, <5 x upper limit of normal for patients with liver metastases); and 
kidneys (serum creatinine ≤1.5 x upper limit of normal) function; 
 patients who are eligible to be registered in the study, based upon the above criteria, will 
be genotyped for UGT1A1*28 polymorphism and stratified into two groups based on the 
presence of *1/*1 or *1/*28 genotype. Patients with both variant alleles *28/*28 will be 
excluded; 
 for patients valuable for response (secondary end point), at least one measurable cancer 
lesion as defined by RECIST, i.e. lesions that can be accurately measured in at least one 
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dimension with the longest diameter ≥20 mm using conventional techniques or ≥10 mm 
using spiral computerized tomography scan;  
 signed informed consent and local ethical committee approval are requested.  
 
The exclusion criteria are:  
 cardiac pathology (cardiac decompensation, infarction during the period of 6 months 
preceding the study, atrioventricular block, serious arrhythmia); 
 patients with specific contraindications for the use of EGFR inhibitors (pulmonar fibrosis, 
interstitial pneumonia history); 
 unresolved diarrhea and bowel obstruction;  
 hemorrhagic syndrome; 
 documented cerebral metastasis;  
 serious active infectious disease;  
 serious functional alteration of visceral and metabolic disease;  
 pregnancy status;  
 radiotherapy or major surgery within 4 weeks; 
 all patients in fertile age must have been under contraceptive treatment;  
 presence of previous or concomitant neoplasm with exclusion of in situ cervical cancer;  
 non collaborative and/or unreliable patients;  
 patients with a chronic toxicity ≥grade 2; 
 refusal of informed consent; 
 patients who could not attend periodic clinical check-ups. 
 
4.3.2.  DRUG ADMINISTRATION, DOSE ESCALATION AND DLT/MTD 
DEFINITIONS 
 
Patients will be treated with FOLFIRI regimen plus cetuximab, where CPT-11 will be administered 
at doses higher than the standard dose in patients with UGT1A1 *1/*1 and *1/*28 genotypes. 
The starting dose of CPT-11 for the two groups of patients (UGT1A1 *1/*1 and *1/*28  groups) will 
be 260 mg/m2 administered as a 120 min intravenous infusion every 2 weeks.  
The dosage of CPT-11 was escalated applying a “3 + 3” cohort expansion design to reach the 
maximally tolerated dose (MTD) 108.  
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The rationale for the 3 + 3 cohort expansion design is pragmatic with regard to determining 
toxicity-based dose escalation. Three patients are required for the initial cohort size in order to 
determine whether a 33% toxicity rate has been reached and, in this case, dose-escalation has to 
be stop. Treatment may be escalated to the next higher dose level if no DLT occurs; however, if 
one drug-related DLT occurs in these three patients, the cohort is expanded to six patients to 
verify that the toxicity rate has reached 33% (i.e., two of six or fewer patients). When the toxicity 
rate reaches 33% in a cohort, the next lower dose level will be called the MTD and the cohort will 
be expanded typically to 10 patients total to establish the preliminary safety profile of the study 
agent 109 (Figure 20) 
. 
 
Figure 20 Schematic description of the 3+3 cohort expansion design. 
 
Applying this design, the dosage of CPT-11 will be increased to 310, 370, and 420 mg/m2, and 
further CPT-11 doses will be increased of 14%; 5-FU will be administered as 400 mg/m2 bolus right 
after the end of the CPT-11 infusion, followed by 2400 mg/m2 over a 46-h continuous infusion plus 
LV 200 mg/m2 every two weeks. Cetuximab will be administered every two weeks as an 
intravenous infusion at a dose of 500 mg/m2 with prophylactic intravenous steroids and anti-
histaminic agents. No dose modification will be performed for 5-FU, LV and cetuximab. One cycle 
is 28 days (two CPT-11 administrations). Before starting CPT-11, patients will be pre-treated with 
atropine 0.5 mg, dexamethasone 8 mg, granisetron 3 mg or ondansetron 8 mg. Diarrhoea will be 
promptly treated with loperamide 4 mg at the onset, and then with 2 mg every 2 h, until the 
patient will be diarrhoea-free for at least a minimum of 12 h. Growth factors (i.e., G-CSF) will be 
allowed only in patients who will have Grade ≥ 3 neutropenia at previous cycles. 
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DLT is defined as haematological Grade 4 toxicity or non-haematological grade 3-4 toxicity and 
developed or persisted despite supportive measures (i.e. anti-diarrhoeas or anti-emetics). DLT will 
be evaluated during the first cycle of chemotherapy. Toxicity is classified and graded according to 
the United States NCI’s common toxicity criteria (version 4.03).  
The cumulative haematological and non-hematological toxicities as well as the number of dose 
reductions and a delay in starting the next cycle of treatment will be used as secondary indicators 
to differentiate the two genotype cohorts of patients. 
Patients can continue receiving the same dose of CPT-11 in absence of major toxicity according to 
the following criteria: before re-treatment, full recovery from any non-hematological toxicity, 
absolute neutrophil count 1500/µL and platelet count 100000/µL, are required. Chemotherapy 
is discontinued on evidence of disease progression, or the appearance of new lesions on serial 
magnetic resonance or CT scans. 
 
4.3.3. PHARMACOKINETICS STUDIES 
To improve the current knowledge about the potential pharmacokinetic and pharmacodynamic 
interactions between cetuximab and CPT-11, this open label drug-drug interaction study evaluates 
the pharmacokinetic profile of CPT-11 in absence and presence of cetuximab in the same patient 
within the first chemotherapy cycle. 
In all patients enrolled in the study and at each dose level, the pharmacokinetic profile of CPT-11 
alone will be evaluated at the first chemotherapy treatment (on days 1-3) during which cetuximab 
will be administered on day 3 (48 h from the end of CPT-11 administration). Instead, the 
pharmacokinetics of CPT-11 in combination with cetuximab will be performed on days 15-17 of 
the second treatment of the first cycle of therapy where a second dose of cetuximab will be 
administered concomitantly to CPT-11.  
 
Serial blood samples are collected into tubes containing K-EDTA (4.9 mL). The sampling times is: 
before drug administration and at 1.0, 2.0, 2.25, 2.50, 3.0, 4.0, 6.0, 8.0, 10.0, 26.0 and 50.0 h 
following the start of the CPT-11 infusion during both the treatments of the first cycle of therapy, 
as schematized in Figure 21. 
Plasma is obtained immediately by centrifugation of blood samples (3000 g for 10 min at 4°C), 
then splitted into 2 aliquotes and stored at -80°C in 2 different freezers.  
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Figure 21 Schematic representation of the sampling times scheduled for the pharmacokinetic study during the first 
and second administration of the first chemotherapy cycle.  
 
The quantification of the total plasma concentration of CPT-11 (lactone plus carboxylate) and its 
main metabolites (SN-38, SN-38G and APC) in plasma samples is performed by using a new LC-
MS/MS method previously developed and validated according to FDA guidelines by Experimental 
and Clinical Pharmacology Unit of CRO-Aviano. As regard this analytical method, which I have 
applied for the analysis of patient’s plasma samples enrolled in the phase Ib clinical trial reported 
above, all the development and validation parameters can be found in the already published 
paper 110. 
 
4.3.4. PHARMACOKINETICS PARAMETERS 
Pharmacokinetics (PK) describes the temporal patterns of response to drug administration 
following acute or chronic dosing. In order to understand and control the therapeutic action of 
drugs in the human body, it is necessary to know how much drug will reach the site(s) of drug 
action and when this will occur. In fact, understanding and employing pharmacokinetic principles 
can increase the probability of therapeutic success and reduce the occurrence of adverse drug 
effects in the body 5. 
PK studies are essential to determine how the body handles drug, that is, how drug is absorbed, 
distributed, metabolized and eliminated. All these processes are influenced by patient’s 
characteristics (i.e., genetics, body size, age, and co-morbidity) and by dosage, drug formulation, 
route of administration and by the possible co-administration of other drugs. Bioavailability is a 
term used to indicate the fractional extent to which a dose of drug reaches its site of action or a 
biological fluid from which the drug has access to its site of action. By definition, when a drug is 
administered intravenously, its bioavailability is 100% and, on the contrary, when a drug is 
administered via other routes, its bioavailability decreases because of several losses during the 
absorption phase.  
T0 1h 2h 2.25h 2.50h 3h 6h 26h 50h
T0 1h 26h 50h
4h
2h 2.25h 2.50h 3h 4h 6h
Day 1-3
Day 15-17
8h
8h
10h
10h
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Drug circulating in the bloodstream is responsible of pharmacological activity and its level is 
regulated by several processes: the organs uptake; the drug binding with plasma proteins (albumin 
is a major carrier for acidic drugs; α1-acid glycoprotein binds basic drugs. The binding is usually 
reversible), red cells or platelets; the permeability of tissue membranes and the drug metabolism 
and elimination. 
Drugs are eliminated from the body either unchanged by the process of excretion or converted to 
metabolites. In fact, drug elimination occurs by two processes, excretion and metabolism; 
excretion is the irreversible loss of chemically unchanged drug in urine and in faeces (renal 
excretion of unchanged drug is a major route of elimination for 25–30% of drugs), and metabolism 
is the conversion of one chemical species to another. Excretory organs, the lung excluded, 
eliminate polar compounds more efficiently than substances with high lipid solubility. Lipid-soluble 
drugs thus are not readily eliminated until they are metabolized to more polar compounds. Drug 
metabolism is obtained by two types of enzymatic reactions: phase I (biotransformation) 
characterized by reactions of oxidation, hydroxylation, reduction and hydrolysis and phase II 
(conjugation) characterized by reactions of addition of a new functional group such as 
glucuronide, sulphate, methyl and acetyl groups, glutathione and amino acids. Even if drug 
metabolism is the physiological way to detoxification, some metabolites can retain (or increase) 
the pharmacological activity.  
Measuring drug plasma concentration in samples collected at specific time points, it is possible to 
obtain the plasma concentration-time profile and the shape and the mathematical elaboration of 
this profile provide the main pharmacokinetic parameters reported in Table 5. 
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Parameter Name Significance Key features 
Cmax 
Maximum plasma 
concentration 
The highest drug concentration 
observed in plasma following 
administration 
Cmax and Tmax are correlated and 
both depend on how quickly the 
drug enters into and is eliminated 
from the body Tmax 
Time until Cmax is 
reached 
The time at which the highest 
drug concentration occurs 
AUC 
Area under the 
concentration-time 
curve 
The measure of the total 
systemic exposure to the drug 
It represents the amount of 
unchanged drug that has reached 
the general circulation and it is 
useful to define the bioavailability of 
a drug 
Vd 
Volume of 
distribution 
The apparent volume into 
which the drug is dissolved 
It depends on binding to plasma 
proteins and tissues and it is useful 
to correlate the drug concentration 
in plasma with its amount in the 
body 
t1/2 
Half-life in the 
terminal phase 
The time taken for the plasma 
concentration to fall by one half 
once distribution equilibrium 
has been achieved 
It is independent of the amount of 
drug in the body and it is useful for 
the determination of the frequency 
of drug administration 
Cl Clearance 
The rate of drug elimination by 
all routes normalized to the 
concentration of the drug 
It is the sum of all organs clearance, 
especially hepatic and renal 
clearance 
Table 5 Main pharmacokinetic parameters and their clinical significance. 
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5. RESULTS 
 
5.1. FLUOROPYRIMIDINE PROJECT 
 
5.1.1. PATIENTS CHARACTERISTICS 
 
For this multicenter study, a set of 603 patients was retrospectively selected from a collection of 
5126 cases enrolled in a multi-institution biobank stored at the Experimental and Clinical 
Pharmacology Unit of CRO-Aviano. 
The aim of the study was to define the role of DPYD SNPs in a “real-world” group of patients 
therefore the subjects selected for this study suffered for different solid tumors and were treated 
with different FL-based treatments. 
More in detail, 432/603 (71.6%) patients had a diagnosis of CRC, 143/603 (23.7%) of breast cancer 
and 28/603 patients (4.7%) suffered for other solid tumors. Accordingly with the clinical use of FL, 
the major part of the patients (528/603, 87.6%) were treated with an association therapy (Table 6) 
and only 75/603 (12.4%) were treated with a monotherapy of 5-FU or CAPE. 
The complete baseline patients characteristics are listed in Table 6. 
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Characteristics N          % 
Sex 
Male 310 51.4 
Female 293 48.6 
Age, years 
Median (range) 62 (17-99)  
FL-based association therapy 
Yes 528 87.6 
1FOLFIRI 210 39.8 
CMF 143 27.1 
2FOLFOX 132 25.0 
CAPOX 29 5.5 
FOLFOXIRI 7 1.3 
TPF 5 0.9 
3Other 2 0.4 
No 75 12.4 
5-FU/FA 49 65.3 
CAPE 26 34.7 
Administration Setting 
Neo-adjuvant/Adjuvant 336 55.7 
First-line metastatic 236 39.2 
N.A. 31 5.1 
Any kind of toxicity4  
5G0 65 10.8 
5G1-G2 443 73.5 
5G3-G5 95 15.7 
Table 6 Baseline characteristics of the 603 enrolled patients  
1
2/210 were treated with FOLFIRI regimen associated with bevacizumab 
2
2/132 were treated with FOLFOX regimen associated with bevacizumab 
3
1 patient was treated with CAPOXIRI regimen and 1 patient was treated with DOC regimen  
4
Maximum grade of toxicity developed within the first 3 drug administrations. 
5
According to NCI-CTC version 3 
Abbreviations: G, grade; 5-FU, 5-flurouracil; CAPE, capecitabine ; FOLFIRI, 5-fluorouracil+leucovorin+irinotecan; 
CMF, cyclophosphamide+methotrexate+5-fluorouracil; FOLFOX, 5-fluorouracil+leucovorin+oxaliplatin; CAPOX, 
capecitabine+oxaliplatin+irinotecan; FOLFOXIRI, 5-fluorouracil+leucovorin+oxaliplatin+irinotecan; TPF, 
Docetaxel+cisplatin+5-fluorouracil; CAPOXIRI, capecitabine+oxaliplatin+irinotecan; DOC, 
docetaxel+oxaliplatin+capecitabine; 5-FU/FA, 5-fluorouracil+folinic acid. 
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Dosage, schedule, and duration of treatment were based on FL current clinical setting and the 
starting standard dose of FL for the principal regimens is reported in Table 7. 
 
According to our study criteria. 65 out of 603 patients (10.8%) did not develop any toxicity, 
443/603 patients (73.5%) developed Grade 1–2 toxicities, while 95/603 (15.7%) subjects 
developed severe toxicity (Grade ≥3), , during the first three treatment cycles. These data are 
consistent with previously published studies. In fact, the percentage reported in our study (15.7%) 
is comparable with the one reported by Froehlich et al. 43 (14%) who analyzed the toxicities with 
Grade 3 or higher developed after the first two cycles of treatment. Loganayagam et al. 46 
reported 24% of Grade 3 or higher toxicity rate in the first four cycles of treatment. 
 
Within the group of patients with Grade ≥3 toxicity, 44/95 (46.3%) developed non-hematological 
toxicities, 28/95 (29.5%) hematological toxicities and 23/95 (24.2%) both. 
Among the 95 patients with severe toxicities, the most common Grade ≥3 toxicities developed 
during the first three cycles were neutropenia and diarrhea, followed by leukopenia, stomatitis, 
REGIMEN FL ADMINISTRATION  DOSAGE DURATION 
FOLFIRI 5-FU Continuous 
infusion 
400 mg/m2 bolus  
+2400 mg/m2 
on day 1 every 2 weeks 
CMF 5-FU Continuous 
infusion 
600 mg/m2 on day 1 and day 8 
FOLFOX 5-FU Continuous 
infusion 
400 mg/m2 bolus 
+600 mg/m2 
on day 1 and day 2 
FOLFOXIRI 5-FU Continuous 
infusion 
3200 mg/m2   from day 1 to day 2 
TPF 5-FU Continuous 
infusion 
1000 mg/m2 from day 1 to day 4 
5-FU/FA 5-FU Continuous 
infusion 
370-400 mg/m2 daily from day 1 to day 14, 
treatment repeated every 28 days 
CAPE CAPE Oral 
administration 
1250 mg/m2 twice daily from day 1 to day 14, 
treatment repeated every 21 days 
CAPOX CAPE Oral 
administration 
1000-850 mg/m2 twice daily from day 1 to day 14 
Table 7 Dosage, administration mode and duration of FL in the principal regimens used in the clinical practice. 
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and nausea/vomiting. More details about the severe toxicities developed by the patients during 
the first three treatment cycles are reported in Table 8. 
 
  
 
 
 
 
 
 
 
 
 
5.1.2. CLINICAL DATA MANAGEMENT 
 
Clinical data collection was a key process in the management of the study due to its importance in 
ensuring high-quality and reliable results.  
The medical records of the enrolled patients were analyzed retrospectively and a specific case 
report form (CRF) was filled out in order to collect all the necessary information, according to the 
aims of the study. For the patients enrolled in other centers, the CRF formats were delivered to 
the responsible clinicians. 
The CRFs were composed by different forms (Appendix 1): 
 
1. Patient registration form (Form 1): used for the collection of patient personal data. 
2. Primitive tumor form (Form 2): used to delineate the tumor characteristics (diagnosed 
disease stage, primitive tumor surgery) and the therapeutic course that the patient underwent 
before FL treatment. 
                                                               Total of patients (n=603) 
Adverse event N % 
Hematologic toxic effects 
Neutropenia 44 33.1 
Leukopenia 9 6.8 
Other hematological toxicities1 6 4.5 
Non-hematologic toxic effects   
Diarrhea 4 30.0 
Nausea/vomiting 9 6.8 
Stomatitis 9 6.8 
Epatic toxicity 9 6.8 
Other non-hematological toxicities2 7 5.2 
Table 8 Most common adverse events (Grade ≥3) developed during the first 
three cycles of treatment. 
1
Piastrinopenia, trombocitopenia, non neutropenic infection. 
2
Enteritis, asthenia, alopecia, neurotoxicity. 
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3. Chemotherapy form (Form 3): used to describe clinical information (weight, height, BSA, 
PS) and the chemotherapy regimen (date of start, schedule and dose). 
4. Chemotherapy toxic event form (Form 4): used to collect the information of the cycle 
therapy in which a severe toxicity occurred. The reason for a possible interruption of the 
treatment, the consequence of the toxic event and the history of prior FL-based treatment were 
also requested. 
5. Toxic event form (Form 5): used to collect the toxicities developed during the cycle in which 
the severe toxic event occurred.  
 
5.1.3. GENOTYPING RESULTS 
 
All the enrolled 603 patients were genotyped for three DPYD variants (DPYD-rs3918290, DPYD-
rs67376798, and DPYD-rs55886062). The successful genotyping ranged from 97% (588 cases, 
DPYD-rs55886062) to 100% (603 cases, DPYD-rs3918290) due to the low quality of some DNA 
samples. All the DPYD variant alleles were detected only in heterozygosity and the genotypes 
distributions of these SNPs are consistent with data from NCBI (http://www.ncbi.nlm.nih.gov/SNP) 
(Table 9). 
 
Polymorphism  Total  N°  %  Observed allelic 
frequency  
NCBI allelic 
frequency  
DPYD-rs3918290 603     
GG  591 98.1 G=99.05 G=99.1 
AG  12 1.9 A=0.95 A=0.9 
DPYD-rs67376798 588     
AA  583 99.1 A=99.55 A=99.6 
AT  5 0.9 T=0.45 T=0.4 
DPYD-rs55886062 595     
TT  593 99.7 T=99.85 T=99.9 
AA  2 0.3 A=0.15 A=0.1 
Table 9 DPYD-rs3918290, DPYD-rs67376798, and DPYD-rs55886062 genotyping data and the comparison between 
the frequencies observed in the study population and the NCBI ones. 
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For the secondary aim of this study, additional five DPYD SNPs (DPYD-rs1801158, DPYD-rs1801159, 
DPYD-rs2297595, DPYD-s17376848, and DPYD-rs1801160) were investigated in a subgroup 
constituted by 95 cases, who were all the patients in our study with Grade 3–5 toxicities during the 
first three cycles of chemotherapy. Additionally, these analyses were conducted also in 315 
randomly selected control patients who experienced Grade 0–2 toxicity. No significant difference 
in terms of sex, age, association therapy, FL administration and setting was found between the 
315 patients’ subgroup and the overall population of controls. The minor allele frequencies (MAF) 
of DPYD-rs1801158, DPYD-rs1801159, DPYD-rs2297595, DPYD-rs17376848, and DPYD-rs1801160 
were 4.3%, 17.1%, 10.5%, 1.9% and 6.5%, respectively, consistently with previously reported data 
(http://www.ncbi.nlm.nih.gov/SNP). 
 
5.1.4. CLINICAL VALIDITY OF DPYD SNPs FOR THE PREDICTION OF SEVERE 
TOXICITY  
 
Eighteen patients (3.0%) carried at least one variant allele for any of the three SNPs that 
represented the first aim of our study.   
In particular, 11 for DPYD-rs3918290, 5 for DPYD-rs67376798, 1 for DPYD-rs55886062, 1 both for 
DPYD-rs3918290 and DPYD-rs55886062).Interestingly, 11 out of 18 patients (61.1%) developed 
Grade ≥3 toxicity.  
Among the 603 patients, the incidence of Grade ≥3 toxicity in DPYD-rs3918290, DPYD-rs67376798 
or DPYD-rs55886062 heterozygous genotype carriers were 8/12 (66.7%), 3/5 (60.0%) and 1/2 
(50.0%) respectively.  
To limit the possibility of false positive findings due to multiple testing and to provide an internal 
validation, we performed a bootstrap test on our results and applied the conservative Bonferroni 
correction. 
We found a significant association between the occurrence of Grade ≥3 toxicity after a FL-based 
treatment and the presence of the variant allele of DPYD-rs3918290 or DPYD-rs67376798.  
These results remain significant also after bootstrap analysis and after correction for multiple 
testing (Table 10). 
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 DPYD-rs3918290 
 DPYD-rs3918290 was significantly associated with Grade ≥3 toxicity of any type (Bonferroni 
adjusted p=0.003, OR: 12.6, 95% CI from 2.9 to 51.0). The association remained significant also 
when considering hematological or non-hematological severe toxicity separately (Bonferroni 
adjusted p=0.003, OR: 12.2, 95% CI from 2.8 to 53.3; and p=0.003, OR: 10.8, 95% CI from 2.7 to 
42.9, respectively). 
One DPYD-rs3918290 variant allele was carried by 12 patients, and eight of them (66.7%) 
developed severe toxicity according to the study criteria. All of them experienced Grade 4 toxicity; 
in particular four patients experienced hematological toxicity, three non-hematological toxicity, 
and one both.  
Six of these 12 patients (50.0%) interrupted the treatment due to toxicity and the other four 
(33.3%) required a therapy delay, or a FL dosage reduction, according to the normal clinical 
practice. Only one patient was heterozygous for both DPYD-rs3918290 and DPYD-rs55886062, and 
this subject died for toxicity (Grade 4 diarrhea and stomatitis) after the first cycle of adjuvant 
treatment with 5-FU mono-therapy in combination with leucovorin (LV) for stomach cancer. Four 
subjects (33.3%) carried the DPYD-rs3918290 SNP in heterozygosity without Grade ≥3 toxicity. 
Nevertheless, one of those patients experienced Grade 2 diarrhea and Grade 2 anemia during the 
first three cycles and another one suffered Grade 2 rectal hemorrhage. In these two patients, the 
treatment needed to be delayed of 10 and 28 days, respectively (Table 11). 
 Total 4Toxicity G≥3 
Genotype n n (%) OR 295%CI  3p 
DPYD-rs3918290             
GG 591 87 (14.7) 11     
AG 12 8 (66.7) 12.6 2.9 - 51.0 0.003 
DPYD-rs67376798            
AA 583 92 (15.8) 11     
AT 5 3 (60.0) 7.8 1.5 - 41.8 0.048 
Table 10 Association of DPYD-rs3918290 and DPYD-rs67376798 with Grade 3-5 toxicity after bootstrap.  
1
Reference Category.  
2
Adjusted for sex, age, and association therapy. 
3
With Bonferroni correction. 
4
According to NCI-CTC version 3.  
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ID   
 
 
Primary 
tumor site 
 
Therapy 
 
Treatment 
 
Toxicity 
 
Toxicity 
Cycle 
 
Treatment Interruption 
(Cause) 
 
Treatment Delay        
(Cause) 
 
Dose Reduction 
(Cause) 
1 Rectum FOLFIRI Metastatic Diarrhea G2 
Anemia G2 
3 No Yes 
(Toxicity) 
No 
2 Colon FOLFIRI Metastatic Rectal hemorrhage G2 3 Yes 
(Toxicity) 
Yes 
(Toxicity) 
No 
3 Colon FOLFIRI Metastatic No / No No No 
4 Colon FOLFIRI Metastatic No / No No No 
5 Colon CAPE Adjuvant Leukopenia G4 
Neutropenia G4 
Diarrhea G4 
1 Yes 
(Toxicity) 
No No 
6 Nasopharynx TPF Neo-adjuvant Diarrhea G4 2 Yes 
(Toxicity) 
No No 
7 Stomach 5-FU/FA Adjuvant Stomatitis G4 
Diarrhea G5 
1 Yes 
(Toxic death) 
No No 
8 Colon CAPE Adjuvant Neutropenia G4 
Thrombocytopenia G4 
1 Yes 
(Toxicity) 
No No 
9 Stomach DOC Metastatic Neutropenia G4 1 Yes 
(Toxicity) 
No No 
10 Colon CAPOX Adjuvant Vomiting G4   
Diarrhea G4 
1 Yes 
(Toxicity) 
No No 
11 Rectum FOLFOX Adjuvant Neutropenia G4 3 No Yes 
(Toxicity) 
Yes 
(Toxicity) 
12 Colon FOLFOX Adjuvant Neutropenia G4 1 No Yes 
(Toxicity) 
No 
Table 11 Clinical information of heterozygous patients for DPYD-rs3918290. 
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 DPYD-rs67376798 
DPYD-rs67376798 was significantly associated with the occurrence of any kind of Grade ≥3 toxicity 
and this result was still significant after bootstrap analysis and Bonferroni correction (Bonferroni 
adjusted p=0.048, OR: 7.8, 95% CI from 1.5 to 41.8). The association with DPYD-rs67376798 was 
still significant when considering only non-hematological Grade≥3 toxicity (p=0.022, OR: 7.1, 95% 
CI from 1.3 to 37.8). However, this association was lost after the application of the Bonferroni 
correction (p=0.066). No association was found between DPYD-rs67376798 and severe 
hematological toxicity (Bonferroni adjusted p=0.366, OR: 2.6, 95% CI from 0.2 to 24.4). 
In total, five patients were heterozygous for DPYD-rs67376798 and three of them (60.0%) 
developed Grade ≥3 toxicities. These three patients suffered Grade 3 non-hematological toxicity 
(hepatic toxicity, asthenia, diarrhea, and alopecia), one of these experienced also concomitant 
Grade 3 neutropenia. Two of these subjects required treatment delay or a drug dosage reduction 
and one needed to interrupt the therapy. Two patients (40.0%) heterozygous for DPYD-
rs67376798 did not develop any severe toxicity according to the study criteria. One of them 
experienced Grade 2 diarrhea and Grade 2 stomatitis after the first cycle of therapy leading to a 
delay of 6 days in the second drug administration. The other one developed neutropenia Grade 1 
during the first cycle (Table 12). 
 
ID Primary 
site of 
tumor 
Therapy Treatment Toxicity Toxicity 
Cycle 
Treatment 
Interruption 
(Cause) 
Treatment  
Delay 
(Cause) 
Dose 
Reduction 
(Cause) 
1 Rectum 5-FU/FA Adjuvant Neutropenia G1 1 No No No 
2 Colon FOLFIRI Metastatic Diarrhea G2   
Stomatitis G2 
1 Yes  
(Disease 
progression) 
Yes 
(Toxicity) 
No 
3 Breast CMF Adjuvant Alopecia G3    
Hepatic Toxicity 
G3 
3 Yes 
(Toxicity) 
No No 
4 Colon FOLFOX Adjuvant Diarrhea G3 1 No Yes 
(Toxicity) 
No 
5 Rectum FOLFIRI Metastatic Neutropenia G3   
Asthenia G3  
Diarrhea G3 
1 No Yes 
(Toxicity) 
Yes 
(Toxicity) 
Table 12 Clinical information of heterozygous patients DPYD-rs67376798 
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 DPYD-rs55886062 
In our population sample, only two patients were heterozygous for DPYD-rs55886062. One patient 
(who carried in heterozygosity also DPYD-rs3918290 and was already mentioned above) died from 
toxicity and the other one suffered from G2 leukopenia, G1 stomatitis and G1 cystitis that led to a 
dose reduction (Table 13).  
Nevertheless, probably due to the low frequency of this SNP, no significant association with severe 
toxicity was observed (Bonferroni adjusted p=0.131, OR: 6.0, 95% CI from 0.6 to 61). 
 
 
Genotyping and statistical analyses were performed also on the five additional DPYD variants 
(DPYD-rs1801158, DPYD-rs1801159, DPYD-rs2297595, DPYD-s17376848, and DPYD-rs1801160) 
that are considered for the secondary aim of the study. No significant association between these 
SNPs and Grade ≥3 toxicity of any kind was found in this explorative analysis. 
 
5.1.5. PREDICTIVE POWER OF THE PHARMACOGENETIC TESTS 
 
To verify the real clinical impact of the SNPs cited by CPIC guidelines, the sensitivity, specificity, 
PPV and NPV for these DPYD variants have been computed in our group of patients (Table14). 
These values were calculated both for each individual SNP and for every possible combination of 
them. Both the single and the combination analyses showed a low sensitivity (between 1% and 
12%) and a high specificity (between 99% and 100%). The highest sensitivity was reached taking 
into account the simultaneous analysis of DPYD-rs3918290, DPYD-rs67376798, and DPYD-
ID Primary 
site of 
tumor 
Therapy Treatment Toxicity Toxicity 
Cycle 
Treatment 
Interruption 
(Cause) 
Treatment  
Delay 
(Cause) 
Dose 
Reduction 
(Cause) 
1 Stomach 5-FU/FA Adjuvant Stomatitis G4 
Diarrhea G5 
1 Yes 
(Toxic 
death) 
No No 
2 Breast CMF Adjuvant Leukopenia G2 
Cystitis G1 
Mucositis G1 
3 No Yes 
(Other) 
Yes 
(Toxicity) 
Table 13 Clinical information of heterozygous patients for DPYD-rs55886062. 
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rs55886062 (12%), the lowest one was obtained considering only DPYD-rs55886062 analysis (1%). 
The specificity reached 100% taking into consideration the single analysis of DPYD-rs67376798 and 
of DPYD-rs55886062, and was 99% for all the other possible SNPs combinations. 
The PPV spanned from 50% to 67% and the highest one was reached taking into account only 
DPYD-rs3918290 (Table14). 
The NPV presented small oscillation between 84% and 86% and the highest values were achieved 
evaluating either the combination of DPYD-rs3918290 and DPYD-rs67376798 or the combination 
of all the considered three SNPs (Table14). 
The PPV and the NPV for the three-markers test were 61% and 86%, respectively. 
 
 
The sensitivity of the pharmacogenetic test considering both DPYD-rs3918290, DPYD-rs67376798, 
DPYD-rs55886062, and the additional five DPYD SNPs was higher (64%) than the test combining 
only the three CPIC markers (12%). This most comprehensive test presented a fairly low specificity 
reaching a value of 63%. The PPV and the NPV for the eight-markers test were 26% and 91%, 
respectively. 
 
 
 
 
 
DPYD variant Sensitivity (%) Specificity 
(%) 
PPV  
(%) 
NPV  
(%) 
rs3918290 8 99 67 85 
rs67376798 3 100 60 85 
rs55886062 1 100 50 84 
rs3918290 + rs67376798 12 99 65 86 
rs3918290 + rs55886062 9 99 62 85 
rs3918290 + rs67376798 + rs55886062 12 99 61 86 
Table 14 Sensitivity, specificity, PPV, and NPV of the three DPYD variants in single analysis and in different 
variants combination. 
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5.2. SUNITINIB PROJECT 
 
5.2.1. STUDY ON THE E/Z ISOMERIZATION 
 
The major part of the published analytical methods developed for the quantification of sunitinib 
and its main metabolite described the sample handling under strict light protection. Sample 
preparation in light-protected conditions is time-consuming and requires a dark room.  
In order to obtain a fast, specific, and easy to use method, we setup a processing procedure able 
to avoid the light protection relying on the peculiar characteristics of sunitinib isomerization. 
Sistla et al.93, indeed, showed that the E isomer reverted to the Z isomer following storage in the 
dark with an increase in the reconversion rate at higher temperatures (lnK vs. 1/T: r 2=0.96). This 
observation indicates that the reversion of E to Z isomer is a thermal reversion. 
Based on these data we have studied the reversion kinetics of sunitinib in the dark at different 
temperatures. 
More in detail, at first, an extracted sample, after light exposure, (for the extraction method, see 
“material and methods”) was split in different glass vials and put in a heated bath, at 60°C for 5 
(T1), 10 (T2), 15 (T3) and 20 (T4) min. The peak area of the two isomers were compared to the one 
obtained from the same extracted light-exposed sample directly injected without heating process 
(T0). 
Figure 22 shows the differences in terms of peak area in the different conditions. Already after 5 
min at 60°C the peak area of E-isomer was more than 5-fold lower than T0 sample while the peak 
area of the Z-isomer resulted proportionally increased. Table 15 shows the area of E and Z isomers 
at different time-points and the sum of the two isomers areas. The reproducibility of the total area 
guaranteed that the decrease of the E-isomer area was due to its conversion in the active isomer 
and excluded the possibility of analyte degradation. 
After 10 min at 60°C, the equilibrium between E- and Z-isomers was reached and no variations in 
their areas were obtained prolonging the time of incubation. 
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Figure 22 Interconversion from E- to Z- isomer in different temperature conditions. The samples were analyzed at T0, 
without any heating process (blue line), and respectively after 5 (pink line), 10 (dark green line), 15 (red line), and 20 
min (light green line) at 60°C. 
 
Time E-isomer Area (%) Z-isomer Area (%) Total Area (%) 
T0 6.94 e+5 (44.12) 8.79 e+5 (55.87) 15.73 e+5 (100) 
T1 (5 min) 1.34 e+5 (8.69) 14.14 e+5 (91.30) 15.48 e+5 (100) 
T2 (10 min) 0.36 e+5 (2.27) 15.72 e+5 (97.72) 16.08 e+5 (100) 
T3 (15 min) 0.23 e+5 (1.44) 16.00 e+5 (98.55) 16.23 e+5 (100) 
T4 (20 min) 0.30 e+5 (1.95) 15.53 e+5 (98.04) 15.83 e+5 (100) 
Table 15 Areas of E-isomer, Z-isomer, and the sum of the two isomers areas measured at T0 (without any heating 
process), T1, T2, T3, and T4 at 60°C. 
 
In order to further decrease the E-isomer signal and to reduce the time required for the 
treatment, additional experiments have been made increasing the heat bath temperature up to 
90°C.  
Therefore, extracted samples were heated at 90°C for 5 min and then placed in the autosampler 
(heated at 40°C) to be analyzed by means of LC-MS/MS. Moreover, with the aim to determine the 
PK profile of the two analytes, the following experiments were performed at two different 
concentrations: 50 and 500 ng/mL). Finally, in order to understand if prolonging the time in the 
autosampler could further increase the Z- to E-isomers ratio, the same sample was re-analyzed 20 
times to investigate the kinetics of the isomer reconversion in dark conditions in the autosampler 
for about 3 hours. 
Z-isomer 
E-isomer 
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In the following Figure 23, the peaks of Z-and E-isomers of samples prepared at the concentration 
of 50 ng/mL are reported. 
 
Figure 23 Panel A: Z- and E-isomer peaks of the sample at a concentration of 50 ng/mL after different intervals in dark 
condition. The sample was analyzed at T0, immediately after the step at 90°C for 5 min (blue line), and then re-
analyzed after 10 (T1), 20 (T2), 30 (T3), 100 min (T10), and 200 (T20) min in the autosampler at 40°C. Panel B: 
Enlargement of the E isomer peaks. 
As clear by the previous Figure 23, at 50 ng/mL, the signal of the E-isomer was barely noticeable 
from the noise signal, anyway, an attempt of quantification was done and the results are reported 
in the following table (Table 16): 
Sunitinib 50 ng/mL 
Time E-isomer Area (%) Z-isomer Area (%) Total area (%) 
T0 0.004 e+5 (0,666) 0,582 e+5 (99,334) 0,586 e+5 (100) 
T1 (10 min) 0.003 e+5 (0,410) 0,681 e+5 (99,590) 0,684 e+5 (100) 
T2 (20 min) 0.003 e+5 (0,413) 0,697 e+5 (99,587) 0,700 e+5 (100) 
T3 (30 min) 0.003 e+5 (0,377) 0,692 e+5 (99,623) 0,695 e+5 (100) 
T10 (100 min) 0.002 e+5 (0,319) 0,706 e+5 (99,681) 0,708 e+5 (100) 
T20 (200 min) 0.003 e+5 (0,347) 0,766 e+5 (99,653) 0,769 e+5 (100) 
Table 16: Areas of E-isomer, Z-isomer, and the sum of the two isomers areas of samples prepared at a concentration 
of 50 ng/mL. The samples were measured at T0 (analyzed immediately after the step at 90°C for 5 min), and after 10 
(T1), 20 (T2), 30 (T3), 100 (T10), and 200 (T20) min in the autosampler at 40°C). 
The results obtained using the concentration of 500 ng/mL are reported in the following Figure 24 
and Table 17. 
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Figure 24 Panel A: Z- and E-isomer peaks of the sample at a concentration of 500 ng/mL after different intervals in 
dark condition. The sample was analyzed at T0, immediately after the step at 90°C for 5 min (blue line), and then re-
analyzed after 10 (T1), 20 (T2), 30 (T3), 100 (T10), and 200 (T20) min in the autosampler at 40°C. Panel B: Enlargement 
of the E isomer peaks. 
 
Suntinib 500 ng/mL 
Time E-isomer Area (%) Z-isomer Area (%) Total area (%) 
T0 0.049 e+5 (0.735) 6.669 e+5 (99.265) 6.718 e+5 (100) 
T1 (10 min) 0.048 e+5 (0.670) 7.084 e+5 (99.330) 7.132 e+5 (100) 
T2 (20 min) 0.046 e+5 (0.645) 7.106 e+5 (99.355) 7.152 e+5 (100) 
T3 (30 min) 0.042 e+5 (0.592) 7.083 e+5 (99.408) 7.125 e+5 (100) 
T10 (100 min) 0.027 e+5 (0.374) 7.240 e+5 (99.626) 7.267 e+5 (100) 
T20 (200 min) 0.023 e+5 (0.321) 7.247 e+5 (99.679) 7.270 e+5 (100) 
Table 17 Areas of E-isomer, Z-isomer, and the sum of the two isomers areas of the sample prepared at a 
concentration of 500 ng/mL. The sample was measured at T0 (analyzed immediately after the step at 90°C for 5 min), 
and after 10 (T1), 20 (T2), 30 (T3), 100 (T10), and 200 (T20) min in the autosampler at 40°C). 
 
The increasing of the temperature promoted the E- to Z-isomer conversion, thus increasing the Z-
isomer signal and decreasing the E-isomer signal at both the investigated concentrations (50 and 
500 ng/mL). In fact, the percentage of the E-isomer even after 20 min at 60°C was equal to 1.951% 
(T4, Figure 22), while after only 5 min at 90°C it resulted reduced to 0.666 and 0.735% at 50 (T0, 
Figure 23) and 500 ng/mL (T0, Figure 24), respectively. 
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The maintenance of the samples into the autosampler, thus in dark condition and at 40°C, resulted 
to be not worth of consideration for the set up of the method due to the very slightly difference 
between different re-injected samples. In fact, the E-isomer percentage decreased from 0.666% to 
0.347% and from 0.735 to 0.321% in about 3 hours at 50 and 500 ng/mL, respectively. Moreover, 
in each analytical run a series of samples, collectively called system suitability test, are requested 
to be analyzed before samples injection to verify instrument conditions. The system suitability test 
requires about 1 hour and, from these results, it is possible to assume that this period is enough 
for stabilize the Z- to E-isomer ratio. 
Since the N-desethyl sunitinib structure is similar to the sunitinib one, the isomerization process 
involved also this metabolite. 
For this reason, the same experiments were performed in sample at low and high concentration of 
N-desethyl sunitinib heated at 90°C for 5 min. 
The results obtained are comparable with the sunitinib ones, the E-isomer signal was barely 
observable from the noise signal, and it resulted even lower than the sunitinib one (Figure 25,26 
and Table 18,19). 
 
 
Figure 25 Panel A: Z- and E-isomer peaks of N-desethyl suntinib of the sample at a concentration of 50 ng/mL after 
different intervals in dark condition. The sample was analyzed at T0, immediately after the step at 90°C for 5 min (blue 
line), and then re-analyzed after 10 (T1), 20 (T2), 30 (T3), 100 min (T10), and 200 (T20) min in the autosampler at 40°C. 
Panel B: Enlargement of the E isomer peaks. 
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N-desethyl sunitinib 50 ng/mL 
Time E-isomer Area (%) Z-isomer Area (%) Total area (%) 
T0 
0.004 e+5 (0.893) 0.480 e+5 (98.615) 0.484 e+5 (100) 
T1 (10 min) 
0.004 e+5 (0.755) 0.478 e+5 (99.245) 0.482 e+5 (100) 
T2 (20 min) 
0.002 e+5 (0.533) 0.476 e+5 (99.467) 0.478 e+5 (100) 
T3 (30 min) 
0.002 e+5 (0.362) 0.481 e+5 (99.638) 0.483 e+5 (100) 
T10 (100 min) 
0.001 e+5 (0.298) 0.468 e+5 (99.702) 0.469 e+5 (100) 
T20 (200 min) 
0.001 e+5 (0.226) 0.472 e+5 (99.774) 0.473 e+5 (100) 
Table 18 Areas of N-desethyl sunitinib E-isomer, Z-isomer, and the sum of the two isomers areas of samples prepared 
at a concentration of 50 ng/mL. The samples were measured at T0 (analyzed immediately after the step at 90°C for 5 
min), and after 10 (T1), 20 (T2), 30 (T3), 100 (T10), and 200 (T20) min in the autosampler at 40°C). 
 
 
Figure 26 Panel A: Z- and E-isomer peaks of N-desethyl suntinib of the sample at a concentration of 500 ng/mL after 
different intervals in dark condition. The sample was analyzed at T0, immediately after the step at 90°C for 5 min (blue 
line), and then re-analyzed after 10 (T1), 20 (T2), 30 (T3), 100 min (T10), and 200 (T20) min in the autosampler at 40°C. 
Panel B: Enlargement of the E isomer peaks. 
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N-desethyl sunitinib 500 ng/mL 
Time E-isomer Area (%) Z-isomer Area (%) Total area (%) 
T0 
0.022 e+5 (0.404) 5.473 e+5 (99.596) 5.495 e+5 (100) 
T1 (10 min) 
0.019 e+5 (0.366) 5.257 e+5 (99.634) 5.276 e+5 (100) 
T2 (20 min) 
0.015 e+5 (0.290) 5.324 e+5 (99.710) 5.339 e+5 (100) 
T3 (30 min) 
0.014 e+5 (0.262) 5.398 e+5 (99.738) 5.412 e+5 (100) 
T10 (100 min) 
0.010 e+5 (0.190) 5.472 e+5 (99.810) 5.482 e+5 (100) 
T20 (200 min) 
0.010 e+5 (0.192) 5.456 e+5 (99.808) 5.466 e+5 (100) 
Table 19 Areas of N-desethyl sunitinib E-isomer, Z-isomer, and the sum of the two isomers areas of samples prepared 
at a concentration of 500 ng/mL. The samples were measured at T0 (analyzed immediately after the step at 90°C for 5 
min), and after 10 (T1), 20 (T2), 30 (T3), 100 (T10), and 200 (T20) min in the autosampler at 40°C). 
 
To conclude, the conditions chosen for E-isomer reconversion to Z-isomer consisted of a heating 
process at 90°C for 5 mi. 
 
5.2.2. HPLC-MS/MS CONDITIONS  
 
To optimize the mass spectrometer conditions, an infusion of each standard solution and IS at 50 
ng/mL in mobile phases (50:50) was used. The response of sunitinib and its main metabolite was 
assessed in positive and negative ion mode but the better one was obtained in positive mode. 
Using an ESI source in positive ion mode, sunitinib and its main metabolite formed mainly a 
protonated molecule [M+H]+ . 
The precursor ion of sunitinib, N-desethyl sunitinib, and sunitinib D-10 as IS (m/z 399.2, m/z 371.2, 
and m/z 409.3 respectively) passed through the first quadrupole into the collision cell and the 
collision energy (CE) and the Collision Cell Exit Potential (CXP) were optimized to obtain their 
product ions with a high signal. 
The fragmentation patterns are represented in Figure 27. 
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A           B  
Figure 27 Chemical structures of sunitinib (A) and N-desethyl sunitinib (B) and identification of the main fragment 
ions. 
For each compound, the daughter ion with the highest signal was used as quantifier, as follows: 
399.2>326.2 for sunitinib, 371.2>283.2 for N-desethyl sunitinib, 409.3>326.2 for IS, all expressed in 
m/z. Two additional daughter ions, for each analyte and IS, were chosen as qualifiers and the 
details of the transitions and the correspondent CE and CXP were reported in Table 20. 
Compound Q1 
(m/z) 
DP 
(V) 
EP (V) Q3 
(m/z) 
CE (V) CXP (V) 
sunitinib 399 72 11 326.2 28 21 
283.1 36 18 
238.1 60 14 
N-desethyl-
sunitinib 
371 57 10 283.2 27 14 
326.2 22 18 
238.2 54 21 
sunitinib-D10 (IS) 409 67 11 326.2 30 21 
283.2 39 18 
238.2 63 14 
Table 20 Source- and compound-dependent parameters and ion transitions of each analyte and IS 
used for the mass spectrometer method. 
 
Figure 28 presents typical SRM chromatograms, using the quantifier transitions noted above. 
Panel A shows an extracted blank plasma sample; Panel B displays an extracted blank plasma 
sample with IS added; Panel C shows an extracted plasma sample at the LLOQ with IS added, and 
Panel D displays a point of the calibration curve at a concentration equal to 250 ng/mL for 
sunitinib and 100 ng/mL for N-desethyl sunitinib.  
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Figure 28 Representative SRM chromatograms. Panel A: SRM chromatograms of a human blank plasma sample; Panel 
B: SRM chromatograms of a human blank plasma sample with IS added; Panel C: S/N of sunitinib and N-desethyl 
sunitinib at the LLOQ (0.1 ng/mL for both the analytes); Panel D: SRM chromatograms of an extracted plasma sample 
of a calibration curve point. The concentrations measured were 250 ng/mL for sunitinib and 100 ng/mL for N-desethyl 
sunitinib. 
 
The elution of the analytes was rapid and selective with adequate separation of all the peaks 
within 2.5 min: sunitinib, N-desethyl sunitinib and IS were eluted at approximately 2.61, 2.55, and 
2.61 min, respectively. No interfering peaks were observed at these retention times, and the peaks 
were completely resolved from plasma matrix, with a good shape. 
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5.2.3. METHOD VALIDATION  
The main parameters considered for the validation of the methods, accordingly with the FDA 
guidelines, were recovery, linearity of the calibration curve, precision and accuracy, limit of 
detection, limit of quantitation and stability. 
However, for a completely validation it is necessary to test our method in patients samples and to 
conduct the ISR to verify the reliability of the reported subject sample analyte concentrations. 
For this reason, we already prepared a request for the institutional review board (IRB) of the CRO 
institute in order to obtain plasma samples of patients and complete the validation process. 
Recovery 
The extraction method is based on simple deproteinization with five volumes of CH3OH relative to 
plasma sample. The recovery, evaluated in five replicates at three QC concentrations, was in the 
range 93.9-111.1% (CV ≤ 9.2%) for sunitinib and 95.7-108.1% (CV≤ 12.3%) for N-desethyl sunitinib, 
as shown in Table 21. The recovery of IS was evaluated in five replicates at a concentration of 100 
ng/ml and it was 104.9 % (CV 5.2 %).  
 
Analyte Nominal concentration 
(ng/mL) 
Recovery (%) ± SD CV % 
sunitinib 0.25 100.5±9.3 9.2 
25 93.9±5.4 5.8 
400 111.1±1.0 0.9 
N-desethyl 
sunitinib 
0.25 104.6±12.9 12.3 
25 95.7±5.9 6.1 
200 108.1±2.9 2.7 
sunitinib-D10 (IS) 100 104.9±5.4 5.2 
Table 21 Recovery of the analytes and the IS from human plasma. 
 
Calibration curves 
Table 22 reports the results for the calibration curves of sunitinib and its main metabolite freshly 
prepared every day during the validation study, and the accuracy and precision for each standard. 
The peak-area ratios of the analyte/IS compared to the nominal concentrations were plotted and a 
least-squares linear regression, weighted by the reciprocal of the concentrations, were plotted and 
a weighted quadratic regression function (1/x2) was applied to generate calibration curves (Figure 
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29). The calibration curves prepared on five different days showed good linearity and acceptable 
results of the back-calculated concentrations over the validated range of 0.1–500 ng/mL for 
sunitinib and 0.1-250 ng/mL for N-desethyl sunitinib.  
 
 
Figure 29 Calibration curves of sunitinib and N-desethyl sunitinib in human plasma 
 
Pearson’s coefficient of determination R2 was ≥99.3 for each run, the mean accuracy was always 
close to 100% (range from 95.8% to 102.9% for sunitinib and from 92.3 to 106.2% for N-desethyl 
sunitinib) and the precision, expressed as CV%, ranged from 1.6 to 7.7 % for sunitinib, from 0.8 to 
10.8% for N-desethyl sunitinib. The carry-over effect was minimized injecting three samples of 
mobile phase between successive test samples and after the injection of the ULOQ. This action 
guaranteed peak response no higher than 10% of LLOQ. 
 
Analytes Nominal conc. 
(ng/mL) 
Mean ± SD Precision % Accuracy % 
sunitinib 0.1 0.10±0.00 1.6 101.0 
0.5 0.48±0.04 7.7 95.8 
2.5 2.41±0.14 5.6 96.5 
10 10.25±0.47 4.6 102.5 
50 49.38±2.04 4.1 98.8 
250 256.67±12.29 4.8 102.7 
500 514.50±16.16 3.1 102.9 
N-desethyl 
sunitinib 
0.1 0.10±0.00 0.8 101.2 
0.5 0.47±0.02 3.9 94.2 
2.5 2.31±0.11 4.8 92.3 
10 9.72±1.05 10.8 97.2 
50 51.48±2.96 5.7 103.0 
100 104.93±9.07 8.6 104.9 
250 265.41±19.16 7.2 106.2 
Table 22 Linearity, accuracy, and precision data for calibration curves of sunitinib and N-desethyl sunitinib 
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Intra-day and inter-day precision and accuracy  
The precision and accuracy of the method were evaluated by analyzing three replicates of QC 
samples (QCL, QCM and QCH) within a single-run analysis for intra-day assessment and over five 
consecutive runs for inter-day assessment. The accuracy and precision (CV%) obtained are shown 
in Table 23. 
 Analytes Nominal 
concentration 
(ng/mL) 
Mean ± SD Precision % Accuracy % 
Intra-day 
(N=5) 
sunitinib 0.25 0.25±0.03 11.0 98.5 
25 25.93±0.69 2.7 103.7 
400 447.86±5.10 1.1 112.0 
N-desethyl 
sunitinib 
0.25 0.26±0.03 11.7 103.7 
25 26.71±2.57 9.6 106.9 
200 223.30±6.28 2.8 111.7 
Inter-day 
(N=15) 
sunitinib 0.25 0.26±0.02 6.1 102.5 
25 25.40±1.27 5.0 101.6 
400 423.48±29.23 6.9 105.9 
N-desethyl 
sunitinib 
0.25 0.25±0.02 9.1 99.1 
25 24.18±1.76 7.3 96.7 
200 214.45±14.17 6.6 107.2 
Table 23 Intra and inter-day precision and accuracy of the method for the analysis of sunitinib and its main metabolite 
in human plasma samples. 
 
The method was very precise, with intra- and inter-day CV ≤ 11.0 % and ≤ 6.9% for sunitinib, ≤ 
11.7% and ≤9.1% for N-desethyl sunitinib. Moreover, the method showed intra- and inter-day 
accuracy within the range from 98.5 ad 112.0% and from 101.6 and 105.9% for sunitinib, from 
103.7 to 111.7% and from 96.7 and 107.2% for N-desethyl sunitinib.  
 
Limit of detection, limit of quantification, selectivity and matrix effect 
The LOD was defined as the concentration at which the S/N was at least 3. The LOD was 32 pg/ml 
for sunitinib and 29 pg/ml for N-desethyl sunitinib. The LLOQ was defined as the lowest 
concentration that could be measured with a precision within 20% and accuracy between 80% and 
120%. Furthermore, the LLOQ values were chosen on the basis of the concentration range 
expected in plasma samples of patients.  
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Therefore, the LLOQ was fixed at 0.1 ng/mL for both sunitinib and N-desethyl sunitinib and was 
validated through analysis of six replicates. The accuracy and precision at the LLOQ were 
determined by analyzing six replicates of the sample at the LLOQ concentration. The accuracy and 
CV% were, respectively, 87.4% and 14.7% for sunitinib, 107.8% and 8% for N-desethyl sunitinib. 
The method was not affected by endogenous components in the matrix or other components in 
the sample. In fact, spiking six different sources of human plasma with sunitinib and its main 
metabolite at a concentration corresponding to the LLOQ, the precision was 8.4% for sunitinib and 
5.9% for N-desethyl sunitinib, respectively, and the accuracy was 89.5% for sunitinib and 114.9% 
for N-desethyl sunitinib, respectively. There were no significant variations (<15%) in the peak area 
of each analyte in the six lots of matrix, therefore it was possible to exclude the presence of any 
matrix effect of ion suppression or enhancement. 
 
Stability 
The stability of sunitinib and its main metabolite, under different conditions, was assessed by 
analyzing QC samples, prepared in triplicate. All these analytes in human plasma were stable for 4 
h at room temperature (Table 24).  
For the peculiarity of this method, it is particularly important to assess the stability in autosampler 
after the extraction. In fact, the temperature set for the autosampler in order to enhance and 
stabilize the conversion to the active Z-isomer is at 40°C, while standard methods usually consider 
an autosampler temperature of 4°C. 
Therefore, we demonstrated the stability of the extracted samples for 48 h in the autosampler at 
40°C. (Table 25). 
 T = 4h (RT) 
Analytes Nominal 
conc. 
(ng/mL) 
Mean ± SD Prec. % Acc. % 
sunitinib 0.25 0.23±0.01 5.9 90.6 
25 23.37±0.86 3.7 93.5 
400 440.84±22.23 5.0 110.2 
N-desethyl 
sunitinib 
0.25 0.25±0.03 12.6 101.0 
25 22.81±1.12 4.9 91.2 
200 227.44±4.10 1.8 113.7 
Table 24 Short term stability of sunitinib and its main metabolite in human 
plasma samples at room temperature (RT) 
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 T = 48h in autosampler (40°C) 
Analytes Nominal 
conc. 
(ng/mL) 
Mean ± SD Prec. % Acc. % 
sunitinib 0.25 0.23±0.02 8.4 90.6 
25 23.94±1.95 8.1 95.8 
400 418.56±24.90 5.9 104.6 
N-desethyl 
sunitinib 
0.25 0.25±0.02 7.2 101.3 
25 25.20±0.45 1.8 100.8 
200 209.57±7.56 3.6 104.8 
Table 25 Stability of sunitinib and its main metabolite in human plasma 
samples in autosampler for 48h  
 
Sunitinib and N-desethyl sunitinib were stable in human plasma over two freeze/thaw cycles: 
precision as CV% and accuracy for freeze/thaw samples were ≤8.6% and within 99.9–108.2% for 
sunitinib, ≤12.4% and within 101.9–106.1% for N-desethyl sunitinib, (Table 26).  
 
 After 2 freeze-thaw cycles 
Analytes Nominal 
conc. 
(ng/mL) 
Mean ± SD Prec. 
% 
Acc. 
% 
sunitinib 0.25 0.26±0.02 6.5 105.9 
25 24.97±0.74 3.0 99.9 
400 432.80±37.20 8.6 108.2 
N-desethyl 
sunitinib 
0.25 0.26±0.02 9.2 104.8 
25 26.52±0.26 1.0 106.1 
200 203.82±25.24 12.4 101.9 
Table 26 Stability of sunitinib and its main metabolite, in human plasma samples, after 2 freeze-thaw cycles and after 
4 months of storage at -80°C. 
 
Several aliquots of QC samples has been stored at -80°C in order to complete the assessment of 
the long-term stability. This part of the validation will be conducted in the next months in order to 
define the stability on the analytes in plasma at 1, 3 and 6 months. 
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5.3. IRINOTECAN PROJECT 
 
5.3.1. PATIENTS CHARACTERISTICS 
In the two centers involved in this ongoing study, four patients were screened for the UGT1A1*28 
SNP and for the panel of mutations within the RAS gene family necessary to be eligible for this 
study. More in detail, the mutational analysis for K-RAS/N-RAS/B-RAF is necessary to assess that 
the patient is wild-type for all the mutations present in the exons 2, 3 and 4 of K-RAS and N-RAS in 
correspondence of the amino acid residues 12, 13, 59, 61, 117, and 146 111. Moreover, the wild-
type status needs to be assessed for the B-RAF mutation within the exon 15 at the residue 600. 
Due to the relative high frequencies of these mutations in CRC patients and to the additional step 
of the UGT1A1*28 screening, the enrollment is quite low and, at the moment, only one patient 
resulted eligible for this study. 
The details of the enrollment status of this study are summarized in Table 27. 
 
  UGT1A1 EXON 2 EXON 3 EXON 4 EXON 15 
Patient Enrollment 
status 
UGT1A1*28 K-RAS N-RAS K-RAS N-RAS K-RAS N-RAS B-RAF 
1 Eligible *1/*1 wt wt wt wt wt wt wt 
2 Not eligible *28/*28 wt wt wt wt wt wt wt 
3 Not eligible *28/*28 wt wt wt wt wt wt wt 
4 Not eligible *1/*1 wt mut wt wt wt wt wt 
Table 27 Genotype information about the four screened patients. 
 
5.3.2. COLLECTION AND STORAGE OF THE SAMPLES 
 
The patient was hospitalized for 3 days during the two treatments of the first therapy cycle and 
the sampling was strictly monitored by the dedicated staff (MD clinical staff and research nurses 
dedicated to clinical studies). The blood samples were collected, immediately centrifuged and split 
into two plasma aliquots that were stored at -80°C. 
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The samplings were recorded, in details, in forms suitable to indicate the correct timing and any 
possible variation from it. Some basic information of the patient, such as the PS, the BSA, the 
scheduled treatment, the CPT-11 dose, and the date of start of the therapy were also reported 
(Appendix 2).  
5.3.3. PHARMACOKINETICS ANALYSIS 
The PK of the enrolled patient was followed during the days 1-3 and the days 15-17, accordingly to 
the protocol design. Even if, during the validation process, the stability of CPT-11 and its main 
metabolites was assessed at 4 months in plasma, patients’ samples are analyzed as soon as 
possible after the collection. For this reason, the data regarding the first patient enrolled in this 
study are already available. In Figure 30 the plasma concentration-versus-time curves of CPT-11, 
SN-38, SN-38G, and APC are shown. They were determined, during the first cycle of therapy, using 
the validated LC-MS/MS method 110, in the patient receiving 260 mg/m2 of CPT-11 as a 2-h 
continuous intravenous infusion. 
 
Figure 30 Plasma concentration-versus-time profiles of CPT-11 and its main metabolites (SN-38, SN-38G, 
and APC) in one patient receiving 260 mg/m2 of irinotecan during the I (C1D1) and the II (C1D15) 
administration of the first therapy cycle. 
 
CPT-11 plasma concentrations appeared to decline in a bi-exponential manner, with a rapid initial 
phase and an extended terminal phase. Looking at the PK profiles, it is possible to observe that 
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APC presents a curve very similar to CPT-11 while the two regarding SN-38 and SN-38G show the 
same multi-exponential manner to decline with a very prolonged terminal phase.  
In order to define the pharmacokinetic interactions between CPT-11 and cetuximab, the 
pharmacokinetic profile of CPT-11 was evaluated in absence and presence of the monoclonal 
antibody in the same patient. The pharmacokinetic profile of CPT-11 alone was assessed at the 
first chemotherapy treatment in which cetuximab was administered on day 3 (50 h after the start 
of CPT-11 infusion). Whereas, CPT-11 pharmacokinetics in combination with cetuximab was 
performed during the second treatment of the first cycle, when the antibody was administered 
before CPT-11 dosage. 
In order to calculate very accurately the PK parameters, the exact timing of the sampling is needed 
and in the left column of Table 28 and 29 is reported the actual sampling time used to define the 
PK profile obtained during the first and the second treatments of the patient so far enrolled. 
 
Days 1-3 
 Time Scheduled  
time 
Actual 
time 
1 0' 09.30 09.30 
2 1.0 h 11.35 11.40 
3 2.0 h 12.35 12.40 
4 2.25 h 12.45 12.47 
5 2.50 h 13.00 13.03 
6 3.0 h 13.30 13.30 
7 4.0 h 14.30 14.35 
8 6.0 h 16.30 16.33 
9 8.0 h 18.30 18.30 
10 10.0 h 20.30 20.30 
11 26.0 h 12.30 12.30 
12 50.0 h 12.30 12.30 
Table 28 Sampling at day 1-3 occurred at the following time-points: before drug administration, and at 1.0, 2.0, 2.25, 
2.50, 3.0, 4.0, 6.0, 8.0, 10.0, 26.0, 50.0 h following the start of irinotecan infusion. The scheduled time and the actual 
time for each sampling are also reported. 
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Days 15-17 
 Time Scheduled  
time 
Actual 
time 
1 0' 11.30 11.30 
2 1.0 h 15.00 14.58 
3 2.0 h 16.00 15.59 
4 2.25 h 16.15 16.15 
5 2.50 h 16.30 16.35 
6 3.0 h 17.00 17.00 
7 4.0 h 18.00 17.59 
8 6.0 h 20.00 20.15 
9 8.0 h 22.00 22.15 
10 10.0 h 24.00 24.00 
11 26.0 h 16.00 16.00 
12 50.0 h 16.00 16.00 
Table 29 Sampling at day 15-17 occurred at the following time-points: before drug administration, and at 
1.0, 2.0, 2.25, 2.50, 3.0, 4.0, 6.0, 8.0, 10.0, 26.0, 50.0 h following the start of irinotecan infusion. The 
scheduled time and the actual time for each sampling are also reported. 
 
In the following tables (Table 30 and 31) the main PK parameters of CPT-11 and its metabolites, 
obtained during the first and the second treatment respectively, are reported. They were 
determined applying a non-compartmental analysis. 
Days 1-3 
Compound 
Cmax  
(ng/mL) 
tmax 
(h) 
AUClast 
(hr*ng/mL) 
AUCinf 
(hr*ng/mL) 
t1/2 
(h) 
Vz 
(mL/m2) 
Cl 
(mL/hr/m2) 
CPT-11 2599.96 1.08 16968.01 17448.08 10.60 227849.34 14901.35 
SN-38 8.20 1.08 164.16 426.44 75.66 - - 
SN-38G 33.97 1.92 767.06 1652.60 58.24 - - 
APC 507.14 2.47 6576.38 6732.95 9.31 - - 
Table 30 PK parameters obtained in one patient receiving 260 mg/m2 of irinotecan as a 2-h continuous 
intravenous infusion during the first administration (Day 1-3) of the first chemotherapy cycle.  
 
 
 
 
 
 
 
101 
 
Days 15-17 
Compound 
Cmax  
(ng/mL) 
tmax 
(h) 
AUClast 
(hr*ng/mL) 
AUCinf 
(hr*ng/mL) 
t1/2 
(h) 
Vz 
(mL/m2) 
Cl 
(mL/hr/m2) 
CPT-11 1933.13 2.25 14420.32 14667.84 9.15 234100.75 17725.86 
SN-38 10.93 0.97 198.31 277.22 23.57 - - 
SN-38G 22.18 2.25 521.74 722.15 24.05 - - 
APC 304.92 2.58 3644.86 3700.01 8.07 - - 
Table 31 PK parameters obtained in one patient receiving 260 mg/m2 of irinotecan as a 2-h continuous 
intravenous infusion during the second administration (Day 15-17) of the first chemotherapy cycle.  
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6. DISCUSSION 
 
The different approaches described in this PhD thesis shared the same final aim: to translate the 
research results in the clinical practice and, consequently, to ameliorate the cancer patients’ life 
through the implementation of the clinical routine. 
In fact, after years of research in the field of the personalized therapy, the time is ripe to leave the 
traditional “one-dose-fit-all” method, and to apply a real tailored therapy for each patient. 
In order to reach this ambitious goal, in this PhD thesis, different innovative strategies were 
chosen and in one case, our results led to the introduction, in the hospital routine, of new tests 
that improves the chemotherapy dosing. 
More in detail, regarding the FLs, the retrospective study on a group of 603 cancer patients clearly 
assessed the clinical validity of three DPYD genotypes and, together with the international 
guidelines and the more recent literature, enhanced the set-up of a PGx diagnostic service at CRO 
institute.  
The search for the optimized CPT-11 dose in one of the most effective regimen such as FOLFIRI 
plus cetuximab is ongoing in the genotype-guided phase Ib study entitled: “A genotype-guided 
phase I study of irinotecan administered in combination with 5-fluorouracil/leucoverin (FOLFIRI) 
and cetuximab as first-line therapy in metastatic colorectal cancer patients”. 
Unfortunately, until now, only one patient turned out to be eligible for this protocol. However, 
previous studies on different CPT-11-based regimens assessed the importance of this kind of 
studies to personalize the therapy according to the UGT1A1*28 genotype 64,65.  
Regarding sunitinib, no significant PGx data were available, therefore the strategy adopted to 
ameliorate the drug dosage was the TDM. The greater effort in this case, regarded the set-up of a 
method that could really be used in the clinical routine. Since this method was developed in a 
diagnostic perspective, it has been already validated accordingly to the FDA and EMA guidelines 
and the request to the IRB in order to obtain patients’ samples was submitted to test the method 
robustness in quantifying real samples. 
The results of each strategy and their consequent possible implementation in the clinical practice, 
are discussed, in detail, below. 
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6.1.  FLUOROPYRIMIDINES PROJECT 
 
In recent years, a great emphasis has been given to the genetic basis of FL-related side effects, 
especially with regard to severe toxicity. A set of studies 47,112,113 highlighted the pivotal role of 
DPYD gene polymorphisms in the insurgence of severe toxicity and led to the definition of 
pharmacogenetic guidelines for the diagnostic use of some DPYD SNPs testing (i.e. DPYD-
rs3918290, DPYD-rs67376798, and DPYD-rs55886062) 54. 
These results were further validated in successive studies which assessed the role of these SNPs in 
three recent meta-analysis 36,51,114. 
Terrazzino et al. evaluated 4094 patients (15 studies) for DPYD-rs3918290 and 2308 patients for 
DPYD-rs67376798. They confirmed the clinical validity of these SNPs as risk factors for the 
development of FL-associated severe toxicities. The second meta-analysis, performed by 
Rosmarin et al., included data of 4855 patients (17 studies). They described eight DPYD variants, 
among which DPYD-rs3918290 and DPYD-rs67376798 also showed convincing evidence of an 
association with toxicity. The third meta-analysis of Meulendijks et al., included data of 7365 
patients (eight studies) and confirmed the association between severe toxicity and the variants 
DPYD-rs3918290 and DPYD-rs67376798, but also for DPYD-rs55886062 and another SNP not 
considered in our study, DPYD-rs56038477. 
Despite the efforts of the scientific community to thrust the introduction of the DPYD PGx tests in 
the everyday clinical practice for FL treatment personalization, clinicians only occasionally decide 
to rely on these clinical tools. A traditional non-genetic strategy (i.e. based on the body surface 
area, organ function, etc.) is currently adopted to prevent FL-related toxicity 115.  
One of the principal hurdle that potentially hampered the clinical implementation of prospective 
DPYD testing could be the perceived lack of scientific evidences. In fact, many clinicians strongly 
demanded a randomized clinical trial (RCT) to prove definitely the effectiveness of these tests. 
However, the only prospective RCT for upfront DPD deficiency screening was terminated 
prematurely for ethical reason. More in detail, one patient in the control arm B (patients 
retrospectively tested for a DPD deficiency) died due to a 5-FU early-onset toxicity and it was 
confirmed that this patient was DPD deficient 116. 
Therefore, this kind of trials have to be deemed unethical and unnecessary if we considered that 
some other predictive biomarkers, such as K-RAS 117, were previously implemented without 
evidence from an RCT. 
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Moreover, adequate evidences can also be provided by prospective clinical trials 36,42,45, and 
retrospective patients collections like ours. 
Therefore, in our study, we found a significant association between the occurrence of grade ≥3 
toxicity after a FL based treatment and DPYD-rs3918290 or DPYD-rs67376798, consistently with 
previously reported data 42,45,46,118. We internally validated these associations applying the 
bootstrap methodology, and the results were still significant after correction for multiple testing. 
This association is consistent with the reported phenotypic effect of DPYD-rs3918290 and DPYD-
rs67376798 variants, which have a deleterious impact on the mature protein leading to the 
occurrence of severe toxicity ascribable to an impaired FL detoxification process (conversion of 5-
FU to dihydrofluorouracil) 41. 
Quite notably, when considering only severe life-threatening toxicity, the DPYD-rs3918290 
polymorphism appeared particularly impacting on patients’ safety, since all the eight heterozygous 
subjects in the severe toxicity group developed grade ≥4 toxicity.  
DPYD-rs55886062 is also considered by the international pharmacogenetic guidelines as a 
predictive biomarker for toxicity 54. According to the extremely low minor allele frequency in our 
study population (0.3%), DPYD-rs55886062 heterozygosity was observed only in two patients. One 
of these exhibited a compound heterozygosity with DPYD-rs3918290 and died of toxicity. The 
other patient developed a grade 2 toxicity that required a delay in the treatment administration 
and a FL dosage reduction.  
Therefore, although in our study the association between the DPYD-rs55886062 variant allele and 
grade ≥3 toxicity was not statistically significant, probably because of the low prevalence of the 
polymorphism, we think that its involvement in FL related severe toxicity must be considered. 
Toxic death after FL administration is extremely uncommon (about 0.5%) 119. It has been 
hypothesized that the simultaneous presence of more than one defective DPYD variant could 
exacerbate the toxicity. We found that the only patient who carried two defective DPYD variants 
(DPYD-rs55886062 and DPYD-rs3918290) died from toxicity after the first cycle of adjuvant 
treatment with 5-fluorouracil/LV. This is consistent with the results of Lee and colleagues 45, 
reporting a toxic death after the treatment of a patient carrying two DPYD variants (DPYD-
rs67376798 and DPYD-rs3918290). It must be considered that both patients experiencing a toxic 
death (in our and Lee’s study) exhibited the DPYD-rs3918290, although the associated DPYD 
variant was different (either DPYD-rs55886062 or DPYD-rs67376798).  
 
105 
 
The assessment of the predictive power of the upfront pharmacogenetic genotyping for the DPYD 
polymorphisms requires definition of the test specificity, PPV, NPV, and sensitivity. Based on the 
PPV values, DPYD-rs3918290 appears the most informative SNP (67%) even if comparing the 
combined analysis including all the three SNPs (61%). However, the sensibility of the tests 
remained low with all the possible combination (at least 12%) while the specificity was assessed at 
values ≥ 99%. Finally, the NPV values were relatively high and ranger from 84% to 86%. 
Important to note is that values for diagnostic test criteria of a PGx test based on SNPs in DPYD can 
never reach 100%, because not all DPD deficiencies and toxicity can be explained by variants in 
DPYD 120. It must also be said that the high specificity (≥ 99%) and high NPV (84% - 86%.) in this 
setting are most crucial, when the goal is to treat all patients with a variant (including false-
positives). The consequence of a false positive result is a relatively low-risk dose reduction for the 
first of many cycles, which can be adjusted in safe conditions in the second cycle and onwards if no 
toxicity occurs. The consequence of a false negative result may be much larger since it could result 
in a too high systemic drug exposure that subsequently leads to severe, potentially lethal toxicity, 
which is associated with long-lasting hospital and/or intensive care unit admissions. 
It should also be stressed out that a treatment adjustment based on combined three DPYD test 
could avoid not only grade ≥3 toxicities but also moderate chronic toxicities (grade ≤2) that could, 
anyway, put at risk the success of the treatment and the compliance. In fact, in our study seven 
out of eighteen patients (38.9%) carrying a variant allele for at least one of the three SNPs did not 
develop grade ≥3 toxicity. However, four out of the seven heterozygous patients (57%) had to 
delay the treatment or reduce the FL dose for toxicity-related reasons (i.e. chronic grade 2 
diarrhea, leucopenia, stomatitis, or rectal bleeding).  
 
Despite the high specificity of the DPYD markers test, the sensitivity of the test was relatively low 
even when considering the combined analysis of the three DPYD markers (12%). In an attempt to 
increase this value, we tested also some additional promising DPYD SNPs (DPYD-rs1801158, DPYD-
rs1801159, DPYD-rs2297595, DPYD-rs17376848, and DPYD-rs1801160). In our study, none of these 
DPYD variants resulted significantly related to the patients’ toxicity outcome. As expected, the 
sensitivity of the test including also these five SNPs notably increased (from 12% to 64%) but the 
strong decrement of both specificity (from 100% to 63%) and PPV (from 61% to 26%), and the lack 
of association with any kind of severe toxicity, do not support the introduction of any of these five 
polymorphisms in a pre-treatment PGx test. Consistently with these findings, during the execution 
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of the present work, the CPIC consortium downgraded three of these SNPs (DPYD-rs1801158, 
DPYD-rs1801159, DPYD-rs1801160) to “still functional” and related to a normal activity of DPD 
enzyme (http://www.pharmgkb.org/guideline/PA166122686). 
Our study provides a further advancement in the DPYD testing validation. Previously published 
studies on the clinical effect of DPYD polymorphisms are based on highly selected patient groups, 
mostly derived by clinical studies, with strict inclusion criteria, and this could represent a limit for a 
generalized application of the test in the current practice to unselected patients, as highlighted by 
Lee and colleagues 45. We have been able to confirm the DPYD SNPs and toxicity association in the 
largest independent study with heterogeneous treatments, FL dosages, combination therapy, and 
primary tumor site. Another criticism of some of the previous reports on the association between 
DPYD variants and FL-related toxicity occurrence could be that they did not consider previous FL 
treatments, making it difficult to interpret the validity of an upfront DPYD analysis. The patients 
experiencing severe toxicity in our study had never been exposed to FL before, and only toxicities 
developed during the first three cycles of therapy have been considered. This allowed to avoid the 
bias related to previous treatment and cumulative toxicities. 
We believe that our data, supported by the previously published papers, clearly demonstrate the 
clinical validity of testing DPYD-rs3918290, DPYD-rs67376798, and DPYD-rs55886062 to predict FL 
related severe toxicity. 
Moreover, as a natural continuation of this study, the Experimental and Clinical Pharmacology Unit 
of CRO (Aviano) has set up a clinical PGx service accessible to Medical and Radiotherapy Oncology 
Units to assess also the clinical utility of the DPYD PGx tests. 
Up to date, 239 cancer patients candidate to a therapy with FL were referred to this service prior 
to treatment. Accordingly to genotype data for DPYD-rs3918290, DPYD-rs55886062, DPYD-
rs67376798 a starting dose adjustment was suggested for 5 patients. 
This kind of studies moved in the right direction in order to finally come to an end on the DPYD 
testing clinical utility. 
In addition, in January 2016, the results of a prospective multicenter study conducted in 
Netherlands was published in which 2038 patients were screened for DPYD-rs3918290 prior to 
start with FL treatment 121. 
That study aimed to determine the feasibility, safety and costs of DPYD-rs3918290 genotype-
guided dosing. For this reason, variant allele carriers received an initial dose reduction of ≥ 50% 
followed by dose tritation based on tolerance. The data obtained about toxicities and costs were 
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compared with historical controls (i.e. DPYD-rs3918290 variant alleles carriers receiving standard 
dose described in literature). 
Toxicity results showed that the risk of Grade ≥3 toxicity was significant reduced to 28% compared 
to 73% in historical controls (p < 0.001) and the FL-induced death was reduced from 10% to 0%. 
Beyond these convincing results about the safety of the pre-treatment genotyping test, this study 
shown also the feasibility of this approach in the clinical practice. Indeed, establishing the 
genotyping costs at €75 per test, the average total treatment cost per patient was slightly lower 
for screening (€2772) than for non-screening (€2817), outweighing screening costs. 
Probably, the results of these study could be ameliorated if they will considered also other critical 
DPYD SNPs such as DPYD-rs67376798, and DPYD-rs55886062 and if we bear in mind that 
genotyping technology is developing fast and prices continue to decline. 
 
In conclusion, our results highlighted the high clinical validity and specificity of genotyping the 
three polymorphisms DPYD-rs3918290, DPYD-rs67376798 and DPYD-rs55886062 in predicting the 
occurrence of severe toxicity to FL in the everyday clinical practice. 
Therefore, in our institute the DPYD screening has already became a routinely test for all the 
cancer patients candidate to a FL-based therapy.  
Considering that, worldwide, hundreds of thousands of patients receive FL-based chemotherapy 
each year, genotype based dose adaptation could seriously prevent thousands of patients from 
developing FL-induced severe and potentially lethal toxicity.  
6.2. SUNITINIB PROJECT 
Currently, there are 45 FDA-approved targeted cancer therapies, 26 of which are kinase inhibitors 
and 19 monoclonal antibodies.  
The huge interest of pharmaceutical and biotechnology companies for these drugs was highlighted 
also by the data about the US sales of chemotherapies and target therapies. In 2009, US sales of 
targeted anticancer therapies reached $10.4 billion and the small molecules drugs, such as the 
tyrosine kinase inhibitors, constituted the 23% of the total US sales of targeted therapies 122. 
Although this new class of drugs dramatically changed the chemotherapy strategies and, in some 
cases, strongly improved the outcome of the patients, it has become apparent that the targeted 
cancer therapy action is not without adverse effects or complications. There is a misconception 
that target therapies create fewer classic toxicities, such as diarrhoea, nausea, vomiting, alopecia 
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or neutropenia, and that the toxicities experienced with target therapies are less severe than 
conventional chemotherapy agents. Instead, patients could developed off-target toxicities related 
to cross-reactivity between the target in cancer and in healthy cells 26. 
Some recent meta-analyses confirmed, indeed, that the addition of kinase inhibitors to 
chemotherapy significantly increases the risk of fatal adverse events, treatment discontinuations 
and non-hematological toxicities. 123,124 
It is increasingly appreciated that the variability observed in response to newer targeted drugs is 
influenced not only by the genetic heterogeneity of drug targets (determining tumor sensitivity), 
but also by the PGx background of the patient (e.g. cytochrome P450 and ABC drug transporter 
polymorphisms), the patient adherence to treatment, and environmental factors that influence 
the PK 125. 
Standard dosage regimens rarely result in comparable circulating concentrations of the active drug 
in all patients, possibly favoring the selection of resistant cellular clones (in case of sub-therapeutic 
drug exposure) or the development of undesirable toxicities (in case of overexposure) 10. In this 
respect, the vast majority of targeted drugs are characterized by a wide spread of plasma 
concentrations observed following standard dosage regimens, with inter-individual variability at 
the end of the dosage interval (trough concentrations) of up to 23-fold 126. 
Sunitinib is an oral multi-targeted tyrosine kinase inhibitor with antiangiogenic and antitumor 
activities attributable to the inhibition of several related tyrosine kinase receptors, including 
vascular endothelial growth factor receptors (VEGFRs) types 1 and 2 (FLT1 and FLK1/KDR), 
platelet-derived growth factor receptors (PDGFR- α and PDGFR-β), stem cell factor receptor (c-
KIT), and FMS-related tyrosine kinase 3 (FLT-3), which are implicated in tumor proliferation, 
angiogenesis, and metastasis 7,127. 
Sunitinib has a pKa-value of 8.95 and is metabolized by the P450 enzyme CYP3A4 to N-desethyl 
sunitinib, which is equipotent to the parent compound and has an exposure that is between 23% 
and 37% of the total one. Protein binding of sunitinib and N-desethyl sunitinib are 95% and 90%, 
respectively. AUC and Cmax increase proportionally with the dose increment within a range of 25–
100 mg and are not affected by food. 
This positive dose-efficacy relationship for sunitinib treatment indicates that it should be the aim 
to treat patients with the higher possible dose. Target total plasma concentrations of sunitinib plus 
active metabolite (N-desethyl sunitinib) are in the range of 50-100 ng/mL, as deduced from PK/PD 
preclinical data 128. Total trough concentrations below 50 ng/mL have been associated with 
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decreased therapeutic efficacy, whereas concentrations above 100 ng/mL have been associated 
with an increased risk for toxicity. Taking into account the low therapeutic index, the large 
interindividual varability in the systemic exposure, and the positive exposure-efficacy relationship 
of sunitinib, there is a strong rationale for TDM of this drug. 
In the literature, previously published LC-MS/MS methods were developed for the detection of 
sunitinib alone or with its active metabolite. The main characteristics of these methods are 
reported in Table 32.  
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Year Authors Sunitinib and metabolites 
analized 
Other analytes 
analized 
Sample 
Volume 
(mL) 
Extraction 
Method 
LLOQ       
(ng/mL) 
Linearity Range 
(ng/mL) 
Runtime 
2008 Minkin et al Sunitinib   0.2 LLE  0.2  0.2-500  3 min 
2009 Haouala et al Sunitinib  Imatinib, nilotinib, 
dasatinib, 
sorafenib, lapatinib 
0.1 PP 1  1-500  20 min 
2010 De Bruijin et al Sunitinib, N-desethyl sunitinib  0.1 LLE  0.2  0.2-50  4 min 
2010 Zhou et al Sunitinib   0.01 PP 1.37  1.37-1000  3.2 min 
2010 Honeywell et al Sunitinib  Erlotinib, sorafenib, 
gefitinib 
0.02 PP 5  1-4000  <4 min 
2011 Rodamer et al Sunitinib, N-desethyl sunitinib  0.1 PP 0.06  0.06-100  4 min 
2012 Lankheet et al Sunitinib   Dasatinib, erlotinib 
gefitinib, imatinib, 
lapatinib, nilotinib, 
sorafenib 
0.05 PP 5  5-2500  10 min 
2012 Rais et al Sunitinib, N-desethyl sunitinib 
        
 0.05 LLE  0.1 sunitinib,      
0.2 N-desethyl 
sunitinib 
0.1-100 sunitinib,                 
0.2-200 N-desethyl 
sunitinib 
5 min
2012 Qiu et al Sunitinib,  N-desethyl sunitinib,  
N,N didesethyl  
 0.05 PP 0.1  0.1-100  4 min 
2012 Gotze et al Sunitinib  Erlotinib, imatinib, 
lapatinib, nilotinib, 
sorafenib 
0.1 PP 10  10-1000  12 min 
2013 Andriamanana et 
al 
Sunitinib  Bortezomib 
dasatinib erlotinib 
imatinib lapatinib 
nilotinib sorafenib 
vandetanib 
0.05 PP 2  2-250  10 
2013 Lankheet et al Sunitinib, N-desethyl sunitinib  0.5 PP 2.5  2.5-500  10 min 
2014 Musijowski et al Sunitinib , N-desethyl sunitinib 
  
 0.5 LLE  0.1  0.1-150  6 min 
Table 32 Principal characteristics of the published method for the quantification of sunitinib and its main metabolites. 
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Only six published methods considered the quantification of both sunitinib and N-desethyl 
sunitinib and, except for the method developed by Qiu et al 129, they used a deuterated internal 
standard. 
One of the pivotal characteristics of a good method to be applicable to the clinical routine is the 
use of limited quantity of biological samples. The published methods considered a quantity of 
plasma that ranges from 50 μL 129,130 to 500 μL 131. Our method requires only 30 μL of plasma, 
strongly simplifying the collection of the samples and the compliance of the patients to the TDM 
procedure. 
Another crucial point to consider in the set-up of a TDM method is surely the ease and the rapidity 
of the processing procedure. Three published methods use protein precipitation (PP), whereas the 
other three require a more complex liquid-liquid extraction (LLE). Our processing method consists 
of an easy protein precipitation (PP) with 150 μL of methanol. 
The additional heating step of 5 min in the heated bath little extends the processing time, 
however strongly facilitates the handling of the samples avoiding the necessity of sodium or UV-
light 132 and the setting of suitable dark rooms. 
In fact, the major part of the methods aims to avoid the light exposure in any step, from the 
collection to the analysis of the sample. This is a clear limit in the perspective of the applicability of 
the method to the clinical practice. 
Some authors 133 found a quite elegant way to bypass the light protection: as the two isomers 
showed equal mass spectrometry response, to process the data, the sum of single reaction 
monitoring responses of both separated isomers of each analyte was used. Consequently, 
protection from light during shipment, handling and processing of samples was not necessary. 
However, in order to apply this method, quantifiable peak of both the isomers are necessary in 
any analytical run. This consideration could expain the quite LLOQ (2.5 ng/mL). 
In our method, the LLOQ is 25 fold lower for both the anaytes and the calibration range was 0.1-
500 ng/mL for sunitinib and 0.1-250 ng/mL for N-desethyl sunitinib. 
Considering that the trough plasma concentration during the sunitinib therapy is typically in a 
range from 10 to 200 ng/mL for sunitinib and from 5 to 100 ng/mL for N-desethyl sunitinib, our 
method generously covered the clinical range and could be feasible also for PK studies in which 
really low concentrations should be detected in order to very accurately determine parameters as 
half-life. 
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Finally, regarding the chromatographic conditions of our method, the retention time of the 
analytes results 2.61 and 2.55 min for sunitinib and N-desethyl sunitinib, respectively and the total 
analytical run, including the recondition time, lasts only 7 min. 
 
In conclusion, our method described an innovative approach to overtake the troublesome step of 
the light protection and a rapid and easy preparation process consistent with our aim of 
introducing the TDM of sunitinib in the clinical laboratory routine. 
 
6.3. IRINOTECAN PROJECT 
FOLFIRI is a frequently used chemotherapy regimen for the first-line treatment of mCRC. Results of 
the phase III CRYSTAL trial showed that the addition in this setting of the EGFR antibody cetuximab 
improves the clinical outcome in patients whose tumors did not have mutations at K-RAS codons 
12 and 13. This clinical trial, that compared FOLFIRI alone with FOLFIRI plus cetuximab, showed, 
indeed, improved progression-free survival and, in patients without K-RAS mutations, a 
particularly significant increase in response- (59.3%) and metastasis resection (7.0% vs 3.7%) rate 
117. Some other striking results were observed by Heinemann and colleagues 134, in an open-label, 
randomized phase III clinical trial with the first aim of comparing the efficacy of cetuximab or 
bevacizumab in FOLFIRI first-line treatment of mCRC. Although the interpretation of the results is 
quite controversial 135, it seemed that a statistically significant overall survival advantage was 
reported in favor of cetuximab (median duration 28.7 months [95% CI 24.0–36.6] vs 25.0 months 
[22.7–27.6]; HR 0.77 [95% CI 0.62–0.96]; p=0.017) and this was further increased in the subgroup 
of patients with tumors that were wild-type at all RAS loci (exon 2–4 K-RAS and N-RAS; 33.1 
months vs 25.6 months; HR 0・70 [95% CI 0.53–0.92]; p=0.011).  
Currently, the dose of CPT-11 in FOLFIRI schedule is 180 mg/m2. However, our group 
demonstrated that a higher dose of CPT-11 is tolerated in UGT1A1 *1/*1 and UGT1A1 *1/*28 
patients than UGT1A1 *28/*28 also if the regimen is combined with bevacizumab (Eudract 2009-
012227-28; Protocol code CRO-2009-25, NCT01183494). 
However, at our knowledge, no data have been generated to demonstrate if these higher doses 
are tolerated when cetuximab is added. 
Having regards to the intriguing results obtained from the previous genotype-guided phase Ib 
studies and the information in the literature that assessed the regimen FOLFIRI plus cetuximab as 
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a promising treatment, there was a strong rationale to begin the phase Ib study entitled: “A 
genotype-guided phase I study of irinotecan administered in combination with 5-
fluorouracil/leucovorin (FOLFIRI) and cetuximab as first-line therapy in metastatic colorectal cancer 
patients” in order to assess whether the addition of cetuximab has an impact on CPT-11 PK and, in 
turn, in its dosage, as already demonstrated for bevacizumab. 
At the moment, due to the relative high frequencies of RAS mutations in CRC patients and to the 
additional step of the UGT1A1*28 screening, just one patient resulted eligible and was enrolled in 
this new clinical study. 
A proper statistical analysis of the PK data obtained during this clinical study will be done when the 
patient’s enrollment will be concluded and the total plasma concentrations of CPT-11 and its three 
metabolites will be obtained. In fact, only at the end of the clinical study, the evaluation of the 
effect of cetuximab on the CPT-11 PK could have a statistical significance. 
Anyway, it can be interesting to compare the PK parameters obtained for the first patient enrolled 
with the mean values of those obtained from the patients treated at the same CPT-11 dosage (260 
mg/m2) during the previous phase I clinical trial of CPT-11 in combination with bevacizumab. In 
order that the comparison is homogeneous, only patients with the same UGT1A1*28 genotype 
(UGT1A1*1/*1) will be considered in the calculation of the mean values. As this clinical study is a 
phase Ib, that is a dose escalation study, for this preliminary analysis only Cmax and AUClast have 
been taken in consideration. CPT-11 Cmax (2599.96 and 1933.13 ng/mL for the I and the II 
administration, respectively) and AUClast (16968.01 and 14420.32 hr*ng/mL for the I and the II 
administration, respectively) obtained were in good agreement with the mean Cmax and AUClast 
obtained in the previous study during both the I and the II administrations (Cmax: 2354.46±958.98 
and 1967.14±479.73 ng/mL for the I and the II administration, respectively; AUClast: 
15587.97±6996.21 and 13706.79±3824.02 hr*ng/mL for the I and the II administration, 
respectively). On the contrary, SN-38 Cmax (8.20 and 10.93 ng/mL for the I and the II 
administration, respectively) and AUClast (164.16 and 198.31 hr*ng/mL for the I and the II 
administration, respectively) were overall lower than the mean values previously obtained during 
both the I and II administrations (Cmax: 22.51±14.15 and 15.90±4.92 ng/mL for the I and the II 
administration, respectively; AUClast: 252.01±63.67 and 221.06±60.40 hr*ng/mL for the I and the II 
administration, respectively). The same observation could be done for SN-38G. In fact, SN-38G 
Cmax (33.97 and 22.18 ng/mL for the I and the II administration, respectively) and AUClast (767.06 
and 521.74 hr*ng/mL for the I and the II administration, respectively) resulted lower than the 
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mean values previously obtained during both the I and the II administrations (Cmax: 94.56±40.78 
and 82.95±35.72 ng/mL for the I and the II administration, respectively; AUClast: 1326.29±499.24 
and 1182.49±423.10 hr*ng/mL for the I and the II administration, respectively). Finally, also APC 
showed different results respect to the previous data. In fact, APC Cmax (507.14 and 304.92 ng/mL 
for the I and the II administration, respectively) and AUClast (6576.38 and 3644.86 hr*ng/mL for the 
I and the II administration, respectively) resulted higher than the mean values observed during the 
phase I of CPT-11 in combination with bevacizumab (Cmax: 244.44±191.57 and 143.34±49.78 ng/mL 
for the I and the II administration, respectively; AUClast: 2981.55±1859.81 and 1993.59±954.82 
hr*ng/mL for the I and the II administration, respectively). 
The formation of the two metabolites (SN-38 and APC), follows two different pathways (Figure 8). 
Therefore, the decrease of SN-38 and SN-38G concentrations and the parallel increase of APC 
plasma level, in comparison with the data concerning the previous clinical study, could probably 
be explained by a different activity of the enzymes involved in the metabolism. 
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